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BACKGROUND: An exploratory mixed methods study, with the philosophical basis of 
pragmatism and interpretive description, was used to develop, implement, and evaluate 
an intervention called the Cardiovascular Assessment Screening Program (CASP) to 
address the underutilization of clinical practice guidelines for cardiovascular screening. 
The Knowledge-to-Action (KTA) Framework with guideline adaptation was used to 
guide the study.  
METHODS: In phase 1, the qualitative study, ten interviews and five focus groups were 
conducted with healthcare providers (HCPs), managers, and the public to gain different 
perspectives to inform the development of CASP. In phase 2, the quantitative study, 
CASP was tested in a randomized controlled trial (RCT) with eight nurse practitioners 
(NPs) and 167 patients aged 40-74 years without previously diagnosed cardiovascular 
disease (CVD). The intervention group implemented CASP while the control group 
provided usual care. Phase 3 integration examined the results from phases 1 and 2.  
RESULTS: From the focus groups and interviews conducted in the qualitative phase, 
themes emerged related to the barriers to, facilitators of, and strategies for CVD 
screening in the local context. The Theoretical Domains Framework (TDF) was applied 
to the themes to identify relevant behaviour change techniques and modes of delivery, 
from which specific intervention components for CASP were developed. Findings from 
Phase 2, the RCT, showed a statistically and clinically significant difference between the 
NP intervention group compared to the control group in terms of comprehensiveness of 
screening, RR = 43.9, 95% CI [13.4, 144.2], p < .0001. The NPs in the intervention group 
were able to identify multiple risk factors; determine their patients’ level of CVD risk; 
identify NPs’ and patients’ priorities for action; and encourage individualized goal-setting 
with patients for heart health. In Phase 3, the integration of results from phases 1 and 2 
confirmed and refined strategies for knowledge translation. The mixed methods study 
results are reported in Manuscript 1, while Manuscript 2 focuses primarily on Phase 2, 
the results from the RCT. Manuscript 3 discusses strategies to address recruitment issues 
of HCPs such as nurses and NPs, as participants in research studies. 
CONCLUSION: CASP was effective and can be used by HCPs and patients for CVD 
screening and management utilizing current guidelines to identify risk factors and 
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CHAPTER 1 Introduction 
 
Chapter 1 summarizes the comprehensive literature review conducted on the topic of 
cardiovascular disease screening of risk factors, the issues of inconsistent use of clinical 
practice guidelines for screening by healthcare providers, and the barriers of and 
facilitators to cardiovascular disease screening. Chapter 1 also provides evidence of 
various interventions that can increase healthcare provider adherence to clinical practice 
guidelines and the role of nurse practitioners in cardiovascular screening and 
management. An overview of the mixed methods research study is provided along with a 













Cardiovascular disease (CVD) causes significant mortality and morbidity and 
contributes to substantial economic, social, and personal burden in our society today 
(World Health Organization [WHO], 2017). CVD is the number one cause of death 
globally (WHO, 2018). In both Canada and Newfoundland and Labrador (NL), CVD 
accounts for approximately 30% of the total deaths (Statistics Canada, 2016). The 
provision of care for people with CVD and other chronic diseases must continue, 
however, there needs to be a shift in focus away from treatment-oriented strategies to 
prevention and health promotion strategies through earlier screening and management to 
curtail the development of CVD risk factors and conditions. Screening for CVD is 
suboptimal and it is not clear what interventions are most effective to promote CVD 
screening based on current recommendations (Unverzagt, Oemler, Braun, & Klement, 
2014). A mixed methods study, with the philosophical basis of pragmatism and 
interpretive description, was conducted to develop a contextually relevant intervention 
and to test its effectiveness in comparison to usual practice. The purpose of this research 
was to answer the overall research question about finding effective strategies to increase 
the uptake of clinical practice guidelines, specifically through the development, 
implementation, and evaluation of this novel screening program for nurse practitioners 
(NPs) and patients, the Cardiovascular Assessment Screening Program (CASP). The 
specific populations of interest were NPs, and their patients, aged 40-74 years, without a 
previous diagnosis of CVD residing in communities across NL. 
This dissertation reports on the exploratory sequential mixed methods study that 




relevant CASP intervention and then tests this intervention with NPs and patients. 
Chapter 1 provides the context for the study by summarizing important literature and an 
overview of the mixed methods study. Chapters 2-4 consists of manuscripts related to this 
research and chapter 5 summarizes this dissertation and provides recommendations for 
future practice and research. Further details of the manuscripts and chapters are 
summarized at the end of chapter 1. 
This chapter summarizes key background information and introduces the mixed 
methods study. First, the chapter will define CVD and then describe what is known about 
CVD screening and the gaps that were found in the literature. Then, CVD screening is 
defined for this research study followed by a discussion of the appropriateness of 
screening and how CVD meets accepted criteria for initiating a new screening program. 
Differences in CPGs for CVD screening and management from developed countries are 
briefly discussed as is the importance of adopting the current Canadian guideline, the 
Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) for 
our research study (Tobe et al., 2018). Issues related to the use of current CPGs for CVD 
screening will be discussed including the barriers and facilitators at the individual, 
healthcare provider, organizational and systems levels. The evidence linked with the 
intervention strategies for healthcare provider adherence to CPGs in daily practice will be 
reviewed. NPs are highlighted as members of the interprofessional team to play a key 
role in CVD screening and management (Farrell & Keeping-Burke, 2014). The 
implications for our research will be summarized as relevant. The philosophical and 




for this research study (Thorne, 2016). The research questions that have arisen from the 
gaps identified in the literature along with the mixed methods study design will be 
outlined. This chapter therefore shows evidence to support the development, 
implementation, and evaluation of a unique screening intervention based on current CPGs 
for the NL context to be used to promote cardiovascular health in the population. 
1.1 Background 
Chronic diseases such as CVD represent considerable burden in our population 
and important challenges for the healthcare system. Treatment for people with chronic 
diseases must continue, but a focus on prevention and health promotion strategies can 
potentially reduce this burden in the future. Screening for CVD is critical to identify risk 
factors early so that treatment and secondary prevention can begin (Tobe et al., 2018; 
Piepoli et al., 2016; Goff et al., 2014). Evidence-based CPGs are available with specific 
recommendations for screening, diagnosis, and management of CVD and related 
contributing factors and conditions. The problem that has been identified from the 
literature is that there is inconsistent utilization of cardiovascular screening CPGs by 
healthcare professionals (Unverzagt, Oemler, Braun, & Klement, 2014). Many strategies 
to increase utilization of CPGs have been identified in the literature, but the Knowledge 
to Action (KTA) Framework (Graham et al, 2006), with guideline adaption (Harrison et 
al., 2013) states that interventions must be context driven. Theoretical frameworks and a 




1.11 Use of frameworks to guide the research. The KTA Framework was used 
as a theoretical framework to guide this mixed methods study. The focus of this 
framework is on knowledge translation specifically, getting expert evidence into daily 
clinical practice. The KTA framework has several phases: a) identifying the expert 
knowledge, b) developing a contextually relevant intervention, and c) evaluating the 
implementation of the intervention and sustainability of knowledge use. The KTA 
Framework, with guideline adaption, can be found in Appendix A.  
The KTA Framework was utilized to guide this dissertation research to determine 
effective strategies for knowledge translation of the C-CHANGE guideline into daily 
clinical practice in NL. The first phase of the KTA Framework involved identifying the 
C-CHANGE guideline as the expert knowledge, the second phase required identifying 
the barriers and facilitators to knowledge use and tailoring an intervention to be relevant 
to the NL context. Identification of the barriers and facilitators for CVD screening as well 
as intervention strategies to address screening and appropriate management based on 
current CPGs are relevant to NL; this province has the highest rates of hypertension, 
obesity, diabetes, and cardiovascular disease in Canada and the fastest aging population 
projected for 2024 (Government of NL, 2014). The third phase of the KTA Framework 
completed during this research study was evaluating the implementation process of the 
CASP intervention with NPs across NL. The final phase of the KTA Framework 
concerns the sustainability of knowledge use through the evaluation of patient outcomes, 
practice, and system, but due to limitations of dissertation research this will be the focus 




The Theoretical Domains Framework (TDF) was used in this research to 
specifically guide the development of the CASP intervention by focusing on the 
behaviour change of individuals as well as assessing implementation problems (Michie et 
al, 2013). There is evidence from other research studies of successful use of the TDF for 
intervention development aimed at improving implementation of CPGs by HCPs (French 
et al., 2012). In this research study, the TDF provided a comprehensive approach to 
determine the main factors influencing clinician behaviour according to selected 
domains; the techniques to be used encouraged change at the individual and 
organizational level; and, the methods to facilitate change along with relevant 
components of the CASP intervention (Atkins et al., 2017, Michie, 2015). 
For this literature review, the databases searched were CINAHL, PubMed, and 
Embase from inception until 2019. This timeframe was chosen to capture relevant 
literature on CVD, CPGs, and the population-based screening initiatives that have arisen 
over the past decades. Database searches used both controlled vocabulary such as 
CINAHL Headings and Medical Subject Headings, as well as keyword terms. Major 
concept groups were used in a variety of combinations. The following keywords were 
used in the search: cardiovascular disease, screening, risk assessment, clinical practice 
guidelines, healthcare providers, community settings, interventions, and nurse 
practitioners. Studies published in English and French were considered for inclusion in 
this review. The reference lists of articles were searched for additional articles. Grey 
literature sources were also searched using the following websites: ProQuest 




cardiovascular screening programs, and heart associations. Quantitative studies included 
in the background were critically appraised using the Public Health Agency of Canada 
(PHAC) Critical Appraisal Toolkit (PHAC, 2014). Qualitative studies included in this 
review were critically appraised using the Joanna Briggs Institute (JBI) Critical Appraisal 
Tools (JBI, 2017). 
1.2 Cardiovascular Disease 
CVD includes diseases of the heart, vascular diseases of the brain, and diseases of 
blood vessels. Because of atherogenesis and other mediating factors, individuals can 
suffer from various conditions such as coronary heart disease, ischemic heart disease, 
myocardial infarctions, heart failure, transient ischemic attacks, cerebrovascular 
accidents, and peripheral vascular disease (PHAC, 2016). CVD is associated with 
multiple risk factors and comorbidities. The development of CVD is the result of multiple 
interacting genetic, social, and environmental factors occurring from conception onward 
throughout the lifespan and increasingly prevalent with an aging population (WHO, 
2016).  
1.3 CVD Screening 
For the purposes of this research study, CVD screening is defined as looking for 
the presence of risk factors, comorbidities, and socioenvironmental conditions that can 
lead to the development of CVD. Screening for CVD is far more complex than simply 
screening for a single disease because of the multitude of factors, comorbidities, 




factors such as family history of premature coronary heart disease, dyslipidemia, 
smoking, inactivity, unhealthy diet, excess alcohol, obesity, and psychological stress are 
considered important to screen (PHAC, 2018; Leiter et al., 2011). Comorbidities such as 
diabetes and hypertension further contribute to the development of CVD. However, other 
risk factors and socioenvironmental conditions for CVD may be screened for depending 
on the context. Social circumstances, social support, income level, education, literacy 
level, and living and working conditions can have an impact on the ability or motivation 
of individuals to make healthy choices, achieve food security, and access health and 
social services that can influence health outcomes (Garg, Boynton-Jarrett, & Dworkin, 
2016). In this dissertation, comprehensive CVD screening involved consideration of these 
many factors that can influence the development of CVD. Specifically, comprehensive 
screening was defined as systematic screening of adults aged 40-74 years for the 
following risk components: age, family history of premature coronary artery disease, 
Framingham Risk Score, smoking status, body mass index, waist circumference, blood 
pressure, lipid profile, A1C, and stress. 
1.4 Appropriateness of CVD Screening 
According to WHO, screening for CVD risk factors is important since CVD is 
well defined, is of public health importance, and has a known prevalence in the 
population worldwide with effective, affordable, and acceptable treatment available to all 
those who require it (Mendis, Puska, & Norrving, 2013). Criteria to determine the 
appropriateness of any screening initiative were outlined originally and published in a 




United Kingdom (UK) has since outlined criteria based on the original WHO report that 
should be met before screening for a disease or condition (UK National Screening 
Committee, 2015). According to the UK model, criteria for appraising the viability, 
effectiveness, and appropriateness of a screening program are the following: a) the 
condition as must be an important public health problem, b) the nature of the screening 
test(s) must be simple and valid, c) the treatment for the condition must be effective, and 
d) there must be evidence that screening for the condition can reduce morbidity and 
mortality. Each specific set of criteria is discussed in more detail in this section. 
1.4.1 CVD is an important public health problem. CVD causes significant 
mortality, morbidity, and accelerating healthcare costs. As previously stated, CVD is the 
number one cause of death globally (WHO, 2018). In both Canada and NL, CVD 
accounts for approximately 30% of the total deaths (Statistics Canada, 2016). Morbidity 
resulting from myocardial infarctions and strokes has potential devastating impact on 
individuals, families, and communities. In Canada, costs have escalated beyond $20.9 
billion annually in terms of healthcare expenditures and lost productivity (Heart Research 
Institute, 2019). Morbidity costs for CVD are related to high rates of hospitalization, 
disability, drug utilization, and the use of specialized cardiovascular (CV) diagnostic and 
therapeutic invasive procedures as well as decreased quality of life for many individuals 
and families (PHAC, 2017). 
CVD prevalence increases with advancing age, so although the age-standardized 
incidence of ischemic heart disease, heart failure, and all-cause mortality have declined 




because of our aging population, population growth, and improved survival of those 
affected by CVD in Canada (PHAC, 2018). Older adults are predicted to comprise 25% 
of the Canadian population by 2036 (Statistics Canada, 2016). The province of NL has 
one of the highest rates of CVD in Canada as well as the fastest aging population 
(Government of Canada, 2018).  
In Canada and the province of NL, the potential burden of CVD in the future will 
be significant based on the risk factor prevalence. In 2018, approximately nine in ten 
Canadians (24 million people) had at least one risk factor for heart disease and stroke and 
indigenous people are 1.5 to 2 times more likely to develop heart disease (Heart Research 
Institute, 2019; Heart & Stroke Foundation, 2019). In NL specifically, about 25% of 
people have hypertension, 9% have diabetes, about 23% of individuals are current 
smokers, 26% report heavy drinking, and 70% of individuals are overweight or obese 
(Statistics Canada, 2017). Sustained efforts to prevent development of cardiac risk factors 
through early detection and treatment are needed since the high prevalence of risk factors 
and comorbidities put the aging population at a higher risk of developing CVD in the 
future (PHAC, 2018; Kohli et al., 2014).  
1.4.2 Screening tests and tools are applicable. The second set of criteria that 
should be met before a CVD screening program is initiated is related to the screening 
tests as well as the screening tools used by healthcare providers (HCPs). The screening 
tests used should be simple, safe, precise, validated, and acceptable to the population (UK 
National Screening Committee, 2014). Screening for hypertension is one example that 




diagnosis of elevated blood pressure (BP) or hypertension requires use of an electronic, 
calibrated, blood pressure monitor over several consecutive visits by a primary care 
provider (Gelfer, Dawes, Kaczorowski, Padwal, & Cloutier, 2015). According to 
Hypertension Canada Guidelines, the BP measurement can be easily interpreted as low, 
normal, or elevated (2019). Like BP monitoring for hypertension, valid and reliable tests 
are also available for other risk factors such as diabetes, dyslipidemia, and obesity, and 
meet the requirements of a simple, safe, and precise measurement.  
Because screening for CVD is so complex, measuring risk factors singly is not 
enough; it is more important to consider total or global CV risk to communicate with the 
patient. There are several valid and reliable global risk assessment tools that have been 
developed in countries around the world that are available to use (Willis, Davies, Yates, 
& Khunti, 2012; Grover et al., 2011, Collins & Altman, 2010). Risk assessment tools 
have been validated in specific populations so may or may not be accurate for individuals 
in other populations. The estimates of absolute risk may show variations between 
different populations because of geographical, cultural, social, behavioural, or genetic 
differences found in the population. Common risk assessment tools found in the literature 
are the following: Framingham Risk Score, Systematic Cerebrovascular and cOronary 
Risk Evaluation (SCORE), SCORE-Canada, Reynold’s Risk Score for Women and 
Reynold’s Risk Score for Men, and the Healthy Heart Score, QRISK®2 (Chiuve et al., 
2014; Fornasini et al., 2006; Horgan, Blenkinsopp, & McManus 2010; Collins & Altman, 
2010; Stamatelopoulos et al., 2008; Ulmer, Kollerits, Kelleher, Diem, & Concin, 2005). 




individual’s 10-year risk of having a CV event. Predicting whether an individual is at low 
(<10%), moderate (<10-19%), or high (>20%) risk of having a CV event (angina, 
myocardial infarction and CV death) is important to assist in clinical decision making 
about treatment and to avoid under or over-treatment. Choosing a relevant tool is 
dependent upon the population being researched or treated.  
The Framingham Risk Score, originating from the Framingham Heart prospective 
cohort study, is the most commonly used online risk assessment tool in Canada to 
estimate absolute global cardiovascular risk. The following information can be inserted 
into the FRS calculator to determine an individual risk score: age, gender, total 
cholesterol, smoking status, diabetes, and blood pressure. Based on the risk calculator the 
individual’s overall 10-year risk of development of CV event can be determined. The 
Framingham model works well if it is calibrated to mortality data and other data for 
specific populations, however, the FRS may not accurately predict risk in populations 
that were not involved in the original study, for example, Chinese, Hispanic, South Asian, 
or Indigenous populations (Health Canada, 2017; D'Agostino et al., 2008).  
There are limitations to consider related to using the FRS in the Canadian 
population. Interpretation of risk is determined by the individual clinician’s knowledge 
and experience with using the FRS tool, so results may vary. Further training in the use of 
risk estimation and interpretation may be helpful to ensure interrater reliability. Also, the 
assessment of anxiety and depression is generally not included in risk evaluation tools 
(Health Canada, 2017; Manzoni, Castelnuovo, & Proietti, 2011). Stress is a known risk 




tool, therefore the FRS may not accurately predict risk if an individual has stress. Finally, 
the social determinants of health are generally not considered in evaluating risk for 
individuals or for making recommendations. The social determinants such as income, 
education, social support and employment can all independently and in combination 
increase or decrease level of risk for CVD (Kreatsoulas & Anand, 2010). Despite these 
limitations, the FRS tool is currently recommended to be used in the Canadian population 
(Anderson et al., 2013). 
1.4.3 Effectiveness of treatment of CVD. The third set of criteria that should be 
met before a CVD screening program is initiated relates to the value of early detection 
and thereby the effectiveness of early treatment. There must be evidence that treating the 
condition earlier leads to better outcomes than later treatment so that earlier detection 
through screening is warranted (UK National Screening Program, 2014). There are 
effective treatments available for each modifiable risk factor for CVD. For example, there 
is evidence that glycemic control and appropriate therapeutic management is critical to 
reduce the risk of vascular events for an individual with Type 2 diabetes (Zinman et al., 
2015; Hirakawa et al., 2014).  
1.4.4 Effectiveness of the CVD screening. The fourth set of criteria is that there 
must be evidence from high quality studies that a screening program for CVD reduces 
morbidity and mortality (UK National Screening Committee, 2015). A systematic review 
of systematic reviews has provided evidence of a reduction in morbidity and mortality 
associated with screening for individual risk factors for CVD (Alvarez-Bueno et al., 




participants were screened and followed for five years showed significantly lower rates of 
CVD, higher detection of CVD-related health conditions, and lower healthcare utilization 
and costs (Lee et al., 2015).  
1.5 CPGs for CVD Screening 
There are many guidelines available worldwide with regards to screening for 
CVD or identifying individual CV risk factors and comorbidities. Most countries and 
jurisdictions develop and implement CPGs based on consensus of the best available 
research evidence. The CPGs are frequently updated as new research is reported and are 
based on different levels of evidence. The best available research is evaluated according 
to the type of evidence available using the GRADE criteria to grade quality (or certainty) 
of evidence and strength of recommendations. Randomized Controlled Trials (RCTs) and 
meta-analyses are considered to be the highest level of evidence on which to base 
recommendations. Less valuable evidence is based on consensus of expert opinion or 
retrospective studies that are interpreted and graded differently by professionals as a basis 
for recommendations. Also, regions develop guidelines in accordance with their 
healthcare systems, organizational structures, healthcare costs, and feasibility. 
Guidelines from three different regions of Canada, Europe and the USA can be 
compared to illustrate some of the differences. In Canada, the (C-CHANGE) guideline is 
recommended for HCPs to use as previously mentioned (Tobe et al., 2018). The 
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice is 




Guideline on the Primary Prevention of Cardiovascular Disease is used (Goff et al., 
2014).  
The aforementioned guidelines differ in the timing to screen asymptomatic 
people, the use of global risk assessment tools, and the focus on dominant risk factors or 
comorbid conditions. The target age to begin screening asymptomatic adults varies in the 
three regions: 40 years of age in Canada, adult males over 40 years and females over 50 
years according to European guidelines and adults 20-79 years in the USA (Tobe et al., 
2018; Piepoli et al., 2016; Goff et al., 2014). In Canada, CVD screening may begin 
earlier if there are one or more risk factors already present such as smoking, 
hypertension, diabetes, a family history of premature CVD, or if there are symptoms 
suggestive of CVD (Tobe et al., 2018).  
The use of global risk assessment tools to estimate the 10-year risk of an 
individual having a CV event varies by region. As previously discussed, the Framingham 
Risk Score has been used most frequently in Canada and is recommended to be done 
every 3-5 years (Tobe et al., 2018). The SCORE risk assessment tool is used in countries 
throughout Europe to estimate risk (Piepoli et al., 2016). The Pooled Cohort Equations 
have been used in the USA to determine risk estimates for having a CV event in the next 
10 years (Goff et al., 2014).  
The three regions differ regarding specific risk factors that should be assessed 
such as dyslipidemia, C-reactive protein (CRP), and screening for type 2 diabetes 




guidelines have similar targets for different components, however, the USA has discarded 
the use of lipid targets to guide clinical decisions. For CRP, an inflammatory marker 
detected by a blood test, recommendations differ for all three regions. The Canadian 
guidelines do not include CRP screening and the European guideline indicates that 
including CRP may be premature; the USA, however, states that the CRP test can be 
useful for men 50 years and women 60 years and younger for CV risk assessment. 
Screening for type 2 diabetes mellitus in Canada is recommended every three years 
starting with individuals > 40 years or earlier with either a fasting blood glucose, an A1C, 
or a 2-hour postprandial glucose. The USA recommends measuring A1C in asymptomatic 
adults without diagnosis of diabetes but does not specify age.  
The current C-CHANGE guideline is a consensus document developed for HCPs 
in Canada to potentially integrate the best available evidence into practice, to reduce 
inconsistencies, and to facilitate interprofessional collaboration among team members to 
improve the quality of patient care (Tobe et al., 2018). This guideline was developed by 
experts from the following organizations in Canada: Canadian Action Network for the 
Advancement, Dissemination and Adoption of Practice-informed Tobacco Treatment; 
Canadian Association of Cardiac Rehabilitation; Canadian Cardiovascular Society; 
Diabetes Canada; Hypertension Canada; Canadian Society for Exercise Physiology; 
Heart and Stroke Foundation, Canadian Stroke Best Practice Recommendations; and 
Obesity Canada. The C-CHANGE Guideline Panel updates its harmonized guideline 




a sufficient number of guideline groups have updated their recommendations (Tobe et al., 
2018).  
1.6 Is CVD Screening Utilizing CPGs Currently Being Done? 
Although the C-CHANGE guideline is available and there is evidence that CVD 
screening is effective (Alvarez-Bueno et al., 2015), we have no national database to 
determine screening rates for CV risk factors in Canada for primary or secondary 
prevention. In Canada, there is no surveillance for screening rates of CVD risk factors 
like there is for chronic disease rates, hospitalization rates, or mortality data (PHAC, 
2018). National and provincial survey data is often based on self-reports, hospitalization 
rates, or government documents not on actual screening at the provider level. Statistics 
Canada, Canadian Institute for Health Information (CIHI), and the NL Centre for Health 
Information (NLCHI) may collect data on individual risk factors in the population but 
there is no context for the data. For example, HCPs will document CVD screening results 
but if it is not recorded in a standardized way into a provincial or national databases, the 
screening rate is not accessible.  
Progress is being made with the implementation of electronic health records, but a 
standardized documentation system for screening rates of CVD risk factors is lacking. 
Screening for CVD risk factors in Canada is not required through legislation, so records 
are not generally available or accessible for routine screening practices. Screening that 
occurs in the hospital setting may be recorded in provincial databases that are not 




records have improved over the past decade, but is they are not always readily accessible 
in all provinces and territories and may vary depending on the region of the country 
(CHHS, 2009). In contrast, electronic databases in the UK contain specific information 
on rates of smoking, diabetes, hypertension, and other risk factors by region through 
accessible databases to the government, organizations, HCPs, and the public (National 
Health Service [NHS] Health Check, 2018). 
This review of the literature found that documentation of screening rates for CVD 
risk factors in Canada and NL is suboptimal due to lack of specific information about the 
surveillance of risk factors or prevalence studies as just described. The surveillance of 
specific risk factors that can lead to the development of chronic diseases are not 
consistently recorded in accessible databases nationally, provincially, or regionally.  
Although there are no prevalence studies assessing screening rates, baseline rates 
reported in of intervention studies suggest screening is low. For example, in the UK, a 
recent quasi-experimental trial had an outcome measure of participation in the NHS 
Health Check Program. Researchers reported that attendance in the Health Check 
Program was low, but with a slight increase in participation from 12% to 30% between 
the years 2011-2015 (Kennedy, Su, Pears, Walmsley & Roderick, 2019). Similarly, a 
meta-analysis of studies from a recent systematic review by Unverzagt, Oemler, Braun, 
& Klement (2014), indicates that uptake of different CVD guidelines in primary care was 
lower prior to interventions, but these studies evaluated treatment for CVD care rather 
than CVD screening. Uptake of the C-CHANGE guideline by HCPs is similarly a 




communication, October 12, 2017). We also have evidence from a retrospective cohort 
analysis of 5688 patients admitted to hospitals with their first MI in Canada on 
suboptimal screening for diabetes and dyslipidemia (Lugomirski et al., 2013). 
Researchers found that opportunities for the prevention of coronary artery disease were 
being missed, and more emphasis needed to be on identifying CVD risk factors before 
the development of acute coronary artery disease (Lugomirski et al., 2013).  
1.7 Major CVD Screening Initiatives 
Since screening for CVD risk factors or risk assessment is important for reducing 
CVD through appropriate management, it is important to review successful initiatives 
that are currently ongoing. In the UK, there is a NHS Health Check program that targets 
adults aged 40-74 years without previously diagnosed CVD. This Health Check program 
mandates HCPs to identify risk factors and to use appropriate management aimed to 
reduce CVD risk for patients (NHS Health Check Program, 2015). The USA has a 
population level program that promotes assertively screening for CVD and other chronic 
conditions called the Million Hearts Initiative (MHI). This federally funded initiative that 
focused on primary and secondary CVD prevention has recently ended and claims to 
have prevented half a million MIs and CVAs over five years from 2011-2017 (Centers 
for Disease Control [CDC], 2012). Based on these positive results, the MHI was extended 
to 2022 (CDC, 2019). There is support for the role of nurses, and specifically NPs, with a 
workforce of 2.8 million to take the lead in promoting CV health through the MHI 
(Melnyk et al., 2016). In Canada, there is no national CVD screening initiative despite the 




that was developed with extensive input by national experts in cardiovascular health. 
Unfortunately, this national initiative in Canada was never implemented (Smith, 2009). 
Although there is no national program in Canada, a provincial initiative in Ontario 
for adults 65 years and over, the Cardiovascular Health Awareness Program (CHAP), is a 
community-based initiative that is mainly focused on blood pressure assessment by 
trained volunteers. It also gathers information about other key risk factors such as 
smoking and dietary habits through a screening questionnaire. CHAP volunteers then 
communicate abnormal findings to primary care providers. The CHAP initiative was 
successfully evaluated using a cluster RCT comparing the year before and the year after 
implementation of CHAP. The researchers Kaczorowski et al. (2011) found that CHAP 
was associated with a 9% relative reduction in the composite end point (rate ratio 0.91, 
95% CI [0.86 to 0.97], (p = .002) and there were 3.02 fewer annual hospital admissions 
for cardiovascular disease per 1000 people aged 65 years and over. CHAP has been 
implemented in other Canadian provinces such as Quebec, and continues to expand in 
other areas. However, CHAP is limited in its scope and does not take a comprehensive 
approach to CVD screening and management. The target population for CHAP is 
individuals over 65 years and is limited to individuals obtaining prescriptions from local 
pharmacies rather than targeting younger people to identify and manage risk factors. The 
organizational infrastructure necessary for a CVD program similar to CHAP is not likely 
realistic in NL. In our province, there have been successful heart health initiatives with 
community-based programming and strategic partnerships implemented in the past such 




Wellness Coalitions in the province. However, interventions that can be implemented at 
the level of individual HCPs such as NPs and family physicians do not exist. There are no 
provincial screening programs that use an upstream approach to identify risk factors 
earlier for primary or secondary prevention of CVD and other chronic diseases.  
1.8 Summary of Background and Implications for Current Research 
 Screening for CVD meets the criteria as an appropriate condition for screening 
since CVD is an important health problem with applicable tests and effective treatments. 
The C-CHANGE guideline recommends screening for asymptomatic adults beginning at 
the age 40 or earlier if warranted by the presence of risk factors. The FRS is the most 
acceptable tool to assess global risk and on which to base recommendations for 
management of risk factors for specified populations. 
 There is good evidence from systematic reviews that adherence to guidelines can 
reduce morbidity and mortality so systematic CVD screening is justified. 
Recommendations on the use of current CPGs for appropriate testing and treatments is 
key. Even though little is known about screening rates, limited evidence indicates it can 
be increased. The UK has implemented the NHS Health Check Program, but no such 
national initiative exists in Canada, even though one was recommended (Smith, 2009). 
The implementation of a comprehensive CVD screening program is warranted. 
Reviewing the literature as well as existing initiatives and programs was 
important to determine the successful components to be incorporated into a CVD 




implementation by HCPs on a provincial level should target asymptomatic high risk 
individuals aged 40-74 years with at least one risk factor for CVD. The literature supports 
implementation of an intervention to promote screening by HCPs with specific guidelines 
for screening and management available in the C-CHANGE guideline. The utilization of 
global risk assessment tools, physiological measurements, and online programs with 
consistent documentation of risk factors into an electronic database would be integrated 
into the screening program for NL. The CVD screening program planned for NL would 
integrate the social, behavioural, and environmental determinants of health. Before 
decisions can be made about an intervention that can be implemented, it is important to 
consider the factors that can impact screening and to discuss the barriers and facilitators 
associated with screening that have been published in the literature.  
1.9 Factors That Can Impact Screening 
Screening for the multitude of comorbid conditions and CVD risk factors is 
complex. Each risk factor or comorbid condition for CVD has different clinical 
guidelines on “best practice”, and this can be overwhelming and make it difficult for 
clinicians to stay abreast of the most current research available. Screening and treatment 
of individual risk factors, such as diabetes, hypertension, or dyslipidemia, for example, 
are more likely to occur than assessment of multiple risk factors simultaneously (Hopper, 
Billah, Skiba, & Krum, 2011; Kumar et al., 2009; Wright, Romboli, DiTulio, Wogen, & 
Belletti, 2011). HCPs find it challenging to follow the most evidenced-informed practice 
guidelines and make appropriate clinical decisions to provide the best individualized care 




Screening for risk factors for the prevention of CVD generally occurs 
opportunistically rather than systematically for several reasons such as the complexity of 
CVD screening, limited time available, and alternative priorities of organizations. 
Opportunistic screening by HCPs often occurs when individuals present with another 
health issue or following an acute CV event. Busy health professionals with limited time 
for patient encounters may screen for single risk conditions rather than comprehensive 
screening for all relevant risk factors for CVD during a single visit (Dyakova et al., 
2016). Organizational priorities focus on the treatment of established disease rather than 
comprehensive screening for CVD or systematic documentation of CVD risk factors.  
1.9.1 Barriers and facilitators to CVD screening. There are barriers and 
facilitators to the uptake of CVD screening practices by individual patients, HCPs, and 
the organizational or health systems level described in the literature (Khatib, et al., 2014). 
Improved awareness of global risk scoring (Hobbs, Jukema, Da Silva, McCormack, & 
Catapano, 2010) and other components of comprehensive screening such as obtaining 
physiological measurements, ordering specific laboratory tests, and following up with 
patients individually, may be achieved through increased awareness by the public, HCPs, 
and organizations. Emphasizing the significance of identification of individuals at high 
risk for developing CVD in the future is critical. The barriers and facilitators relevant to 
screening for CVD at each level are discussed in this section. 
1.9.1.1 Individual patient level. At the individual level, healthy people may feel 
reluctant to be screened since they are asymptomatic and may not feel that it is relevant. 




excessive stress, or unhealthy eating may not be motivated to be screened related to fear 
of identification of problems requiring behavior change (Ford, Zhao, Tsai, & Li, 2011). 
Individuals may not be interested in taking or adhering to new medication regimes 
(Benito et al., 2018) Also, those individuals living in low socioeconomic conditions, and 
poor housing may have no or poor accessibility to health services, screening, and 
recommended treatments (Wools, Dapper, & de Leeuw, 2016). Another issue could be 
related to the amount of time and effort required for some procedures and then associated 
wait times (Leinonen et al., 2017). Finally, some people may lack knowledge of the 
importance of screening for certain health conditions and, therefore, would not seek 
screening opportunities (Fritzell, Stake Nilsson, Jervaeus, Hultcrantz, & Wengstrom, 
2017). 
Facilitators at the individual level may increase participation in the screening 
process. Individuals who are motivated to stay healthy and strive to engage in screening 
can communicate with providers through online programs, social media, or apps that link 
directly to clinics (Hobbs et al., 2010). Capitalizing on opportunities to encourage self-
motivation and assess the level of self-efficacy in individuals can facilitate screening. 
Other people may be fearful of being unhealthy so this may encourage them to continue 
to be screened so that they know that they are in good health. Some individuals who have 
had the experience of a close relative diagnosed with a terminal disease may be prompted 
to undergo investigations and screening (Benito et al., 2018). Awareness campaigns, 
including social media, can increase knowledge about the importance of getting screened 




making the screening process more convenient for people may encourage them to 
participate in a screening program (Ragas et al., 2014). 
1.9.1.2 Healthcare provider level barriers. At the healthcare provider level, 
accessibility, capability, and intention barriers can exist. Screening initiatives for younger 
adults are problematic to implement because it is often difficult to access this population 
unless they present to the primary care provider for another reason. Other individuals in 
the target population may be employed during the daytime and may not be able to attend 
clinic visits due to designated office hours that are not convenient. The process of 
screening individuals does not consider the determinants of health such as income, 
employment, education, social support, and housing. Often, the segments of the 
population that would truly benefit from screening interventions and appropriate 
treatment recommendations are difficult to access, diagnose, and treat. HCPs must 
consider the inability of patients to afford medications, their lack of understanding of the 
benefits of treatments, and inadequate support for behaviour change that may limit the 
effectiveness of some health promotion strategies. It is therefore important to tailor risk 
assessment programs to the specific needs of the population being treated (Harkins et al., 
2010), and to individualize care for unique circumstances. 
HCPs may also experience capability barriers such as lack of knowledge and 
skills to complete and communicate risk assessments. There can be a lack of 
understanding about nutrition, physical exercise, giving practical advice, and 




unfamiliarity with using risk tools, poor computer software support, and difficulty in 
communicating risk to patients (Wan, Harris, Zwar, Vagholkar, & Campbell, 2010). 
There may also be intention barriers for HCPs which can be considered to be lack 
of motivation, priority setting, social influences or personal stress, anxiety, or depression 
(Khatib et al., 2014; Hobbs, Jukema, Da Silva, McCormack, & Catapano, 2010). Some 
providers may have lack of trust in the evidence that supports guideline development and 
implementation due to inconsistencies in the methods used to grade evidence and make 
recommendations (Andrews et al., 2013). Another reason for non-adherence to CPGs 
could be that providers use the patient’s wishes and other acceptable norms in the 
healthcare system to influence treatment decisions (Hobbs et al., 2010). Psychological 
stress and other psychiatric illnesses experienced by HCPs can inhibit their motivation to 
engage patients in prevention activities (Goldberg, Cho, & Lin, 2019).  
In addition to barriers, there are also facilitators to CVD screening at the provider 
level that are related to accessibility and capability. Accessibility to target populations 
can be improved by increasing the convenience to patients by changing office hours to 
evenings and weekends if practitioners were available. Also, offering interventions at the 
workplace during the daytime may increases accessibility for younger adults that may not 
otherwise be able to leave their place of employment for outside appointments (Boorman, 
2019; Schliemann & Woodside, 2019). Offering clinics in community centres or areas 
with low-income housing reduces barriers associated with transportation and aging and 




Facilitators for screening at the provider level can occur by enhancing the 
capability of clinicians during patient encounters through the convenience of interactive 
tools, enhanced communication with patients, and accessibility of current guidelines for 
clinical decision-making (Karlsson et al., 2018; Ranta et al., 2017; Sheibani, Sheibani,  
Heidari-Bakavoli, Abu-Hanna, & Eslami 2017). Screening for risk factors can be 
enhanced through the use of global risk screening tools, the ability to do clinical 
measurements with the reliable devices at point-of-care, and the opportunity to document 
CV risk factors in electronic databases (Willis, Davies, Yates, & Khunti, 2012). Often 
healthcare practitioners such as family physicians and NPs have access to global CV risk 
screening tools to determine 10-year risk of having a CV event, but improved education 
would help implementation. Community pharmacies have opportunities to access the 
population to be able to perform screening risk assessment when combined with retail 
services (Horgan, Blenkinsopp, & McManus, 2010). Providers and patients who are 
confident utilizing telehealth, texting, email, or other social media can further enhance 
communication and follow-up opportunities related to risk factor management using this 
technology. Making current CPGs accessible can enhance provider adherence to current 
research and empower clinicians to make effective decisions for patient care (Njie et al., 
2015). 
1.9.1.3 Organizational and health systems level barriers. Barriers at the 
organizational or health systems level that influence screening and adherence to 
guidelines also exist. Government or organizational policies are predominantly focused 




procedures and interventions. Organizations may not be supportive of providing ample 
time for screening and risk assessment during patient-practitioner encounters despite the 
complex nature of patients with multiple comorbidities (Unverzagt, Oemler, Braun, & 
Klement, 2014; Hobbs, Jukema, Da Silva, McCormack, & Catapano, 2010). There may 
be a lack of computer software support or other useful tools to effectively implement 
screening initiatives and ongoing management and follow-up. Lack of support in terms of 
financial incentives for providers may negatively influence adherence to guidelines for 
screening and other prevention strategies (Scott et al., 2011). 
At the organizational and governmental level, population-wide strategies that 
address behaviour risk factors through integrated risk assessment and management 
approaches can facilitate screening and prove to be cost-effective (Mendis, Puska, & 
Norrving, 2011). The NHS Health Check Program in the UK is a program that is focused 
on risk factor identification and management in asymptomatic patients and has 
demonstrated cost-effectiveness. The NHS program has mandated that the population-
based prevention screening program be implemented and economic modelling suggests it 
is cost effective with estimated savings to the NHS budget of about ₤57 million per year 
after four years and rising to ₤176 million per year after a fifteen-year period (Waterall, 
Smith, Keogh, & Daykin, 2013). The use of statin therapy for primary prevention 
according to the ACC/AHA cholesterol treatment guidelines showed an acceptable cost-
effectiveness profile in a microsimulation model of US adults aged 45 to 75 years with 




1.9.2 Summary and implications for current research. For this dissertation 
research, exploration of the specific barriers and facilitators to CVD screening that are 
relevant to individual patients, providers, and administrators in the NL context provided 
insight into the development of an intervention that was based on current evidence such 
as the C-CHANGE guideline. Focusing on strategies at the individual patient and the 
healthcare provider level is important since much of health care occurs during the 
interaction between the provider and the individual patient which ultimately influences 
the quality of care provided (French et al., 2012). Finding innovative ways to address the 
complexity of CVD screening in an intervention that could be used by HCPs in a timely 
manner in clinical practice was critical. It was identified that having organizational 
support and buy-in into implementation of the intervention at the provider level would 
improve acceptability. Determining the strategies that would be relevant and cost-
effective for the NL context to enhance the uptake and delivery of current evidence in 
daily clinical practice was important and are reviewed in the next section.  
1.10 Intervention Strategies to Enhance HCP Guideline Adherence for Screening 
Intervention strategies that enhance the utilization of current CVD screening and 
management guidelines by HCPs have been found in the literature. There is evidence of 
effectiveness of different interventions that improve HCP guideline adherence in clinical 
practice such as educational interventions, clinical decision support systems (CDSSs), 
audit and feedback, provider reminders, and multifaceted strategies. Intervention 




1.10.1 Educational intervention strategies. Educational interventions such as 
educational meetings, educational materials, interactive educational media, and 
educational outreach are strategies for implementation of CPGs that have been shown to 
be effective for guideline adherence by HCPs. Educational intervention strategies in 
CVD-specific systematic reviews, systematic reviews of non-CVD related studies, and 
other levels of evidence are described below. 
1.10.1.1 Systematic reviews on effectiveness of educational interventions. There 
were three well conducted systematic reviews that examined looked at educational 
interventions related to healthcare provider adherence to CVD guidelines (Shanbhag et 
al., 2018; Jeffrey et al., 2015; Unverzagt, Oemler, Braun, & Klement, 2014). Most of the 
studies in these systematic reviews compared the educational intervention with usual 
practice. There were a variety of educational strategies utilized that targeted different 
providers, resulting in considerable heterogeneity. Two systematic reviews Unverzagt et 
al. (2014) and Jeffrey et al. (2015) reported on guideline adherence based on self-reports, 
appropriate prescriptions, and chart reviews. Unverzagt et al. (2014) that analyzed 17 
RCTs with 32 756 patients and 5935 HCPs found that guideline adherence was higher in 
the provider education group compared to the usual practice group OR=1.69, 95% CI 
[1.23, 2.32]. Examples of educational interventions reported in some of the RCTs and 
cRCTs were the following: training in information management, academic detailing, 
training programs on prescribing beta-blocker treatments, specific education programs on 




Jeffrey et al. (2015) built on the work of Unverzagt et al. (2014) and conducted a 
meta-analysis of 17 studies, (2306 patient participants). Researchers did not report the 
number of HCPs involved in the selected studies. Results showed that educational 
interventions were favoured over usual practice or another strategy in the short-term at 3-
6 months OR = 2.11, 95% CI [-90, 4.97] and in the long-term at 7 months or longer OR = 
1.05, 95% CI [0.82, 1.34] to improve clinical practice guideline adherence by HCPs. 
Interventions that focused on provider education demonstrated statistically significant 
improvements. The educational interventions used in the studies were the following: 
academic detailing individually or group to increase diuretic use in HTN patients; 
continuous medical education sessions (CMEs); small group face-to-face sessions; 
dissemination of guidelines; nurse-led guideline based software; office visits and 
educational materials; educational module for physicians for the management of CHF; 
adult-based education to reduce BP; recommendations of specific textbooks; and clinical 
decision algorithms. 
A third systematic review Shanbhag et al. (2018) reported specifically on the 
treatment of heart failure with prescribing ACE inhibitors and beta blockers with an 
educational intervention in a hospitalized inpatient setting. Researchers reported on only 
two studies that had conflicting results. One study was a cluster RCT (Thilly, Briançon, 
Juillière, Dufay, & Zannad, 2003) with 370 patients and the other study was a controlled 
before-after with 489 patients (Asch et al., 2005). Both studies found that the 
prescriptions of ACE inhibitors increased significantly post intervention, p < .003. The 




blockers at target doses but found no difference. Examples of the educational 
interventions reported in these studies were the following: distribution of educational 
materials, focused educational sessions, and education outreach visits. 
One other systematic review Pedersen et al. (2018) focused on guideline 
adherence for the treatment of depression using diverse educational interventions, such as 
distributing guidelines, education and training, or combining education with other 
components. This systematic review reported on 10 RCTs (3158 patient participants) that 
focused on the effectiveness of educational interventions compared to usual practice. 
Only one of the 10 RCTs, a cluster RCT with 444 patients, reported findings with a 
statistically significant difference. In this RCT, the intervention group received tailored 
provider implementation strategies to improve guideline adherence IRR = 0.85, 95% CI 
[0.43, 1.69] compared to provider training alone. In the other nine RCT studies conducted 
in the USA, Canada, and Iran there was heterogeneity in the type of educational 
intervention in combination with other interventions with variations in the timing of 
follow-up and the primary outcomes. For the other nine studies, the differences were not 
statistically significant for overall adherence, however, the majority of the RCTs reported 
results in favour of educational intervention effectiveness on prescribing 
pharmacotherapy for depression referral to mental health services or referral to 
psychiatrists. 
1.10.1.2 Other evidence for the effectiveness of educational interventions. There 
were other studies not included in the systematic reviews related to the effects of 




positive effects on provider guideline adherence. For example, Suman et al. (2018) 
compared the effects of a multifaceted educational intervention on HCP adherence to low 
back pain guidelines. The results suggested that, with one exception, there were no 
improvements. They did find statistically significant improvements, p < .01 in the 
frequency of inappropriate referrals to neurologists in the intervention group compared to 
the usual practice group. However, the authors concluded that the implementation 
strategy did not result in improved guideline adherence, stating that inappropriate 
referrals or requests for diagnostic tests were already low at baseline, leaving little room 
for improvement.  
1.10.2 Summary of educational interventions and implications for research. 
Despite some contradictory findings, there is evidence from aforementioned systematic 
reviews that educational interventions can improve provider adherence to CPGs, despite 
considerable heterogeneity associated with the many RCTs that examined different 
outcomes, targeted different providers, and took place in various settings. There are 
implications for further research that is focused on utilizing educational interventions 
strategies for HCPs to use in daily practice. It would be helpful for interventions to focus 
not only on measuring adherence to guidelines, but also on targeted outcomes and 
performance indicators such as assessing referral rates, appropriate prescribing of CV 
medications, identifying those at high risk for developing premature CVD, as well as 
providing supportive counselling to patients on risk factor management according to the 
C-CHANGE guideline (Tobe et al., 2018). Our research is focused on the effect of a 




process outcomes such as adherence to CPGs and tracking improvements in performance 
indicators. However, due to time constraints of dissertation research, the focus was on 
CVD screening behaviours and management rather than patient outcomes.  
1.10.3 Clinical decision support systems. Clinical Decision Support Systems 
(CDSSs) can be algorithms or prompts from computer-based electronic information 
systems designed to assist HCPs in critical thinking and decision-making to enhance 
optimal clinical judgement during patient encounters (Holsteige, Mathes, & Pieper, 
2015). The next sections will discuss the evidence related to CVD-related and non-CVD 
related guidelines separately. CDSSs for adherence to CPGs have been shown to be 
effective for guideline adherence by HCPs in CVD-specific systematic reviews, 
systematic reviews of non-CVD reviews, and individual RCTs and other well-conducted 
analytical studies.  
1.10.3.1 CVD systematic reviews for effectiveness of CDSSs. One systematic 
review by Njie et al. (2015) with 45 studies reported on the effect of CDSSs on both 
primary and secondary outcomes. Primary outcomes were quality of care outcomes 
measuring provider adherence to guidelines for CV risk factor screening, preventative 
care, and treatments. Secondary outcomes were the effect of CDSSs on the clinicians’ 
focus on patient health behaviours such as smoking cessation, dietary changes, and 
increased physical activity (Njie et al., 2015). Seventeen of the 45 studies evaluated 
CDSSs on quality of care outcomes for screening and other preventative care services 
related to CPGs with an overall median effect estimate increase of 3.8% Interquartile 




compared to usual practice. Seven out of 45 studies reported an increase (median 4% 
points) IQI [0.7, 7.0] in the proportion of guideline-based clinical tests completed or 
ordered by clinicians when prompted by CDSSs, compared with usual practice. Most 
recorded outcome measures (such as screening for hypertension, diabetes, dyslipidemia 
and prescribing medications and counselling on healthy diet and physical activity) 
showed a statistically significant improvement with provider use of CDSSs compared to 
usual care, p < .05.  
1.10.3.2 Other CVD-specific evidence for using CDSSs. Since the systematic 
review by Njie et al. (2015), three more recent CVD-related studies two RCTs Karlsson 
et al. (2018) and Ranta et al. (2017) and one well-conducted interrupted time series study 
Sheibani, Sheibani, Heidari-Bakavoli, Abu-Hanna, & Eslami, (2017) reported on the 
effectiveness of CDSSs on adherence to current CPGs. One cluster RCT, Karlsson et al. 
(2018) with 13 379 patients reported on physician prescribing of anticoagulant 
medications for atrial fibrillation for patients at risk for stroke, with and without the 
assistance of CDSSs. This cluster RCT found a significant increase of 73%, 95% CI 
[64.6%, 81.4%] in guideline adherence after 12 months in the intervention group that 
used CDSSs versus an improvement of 71%, 95% CI [60.8%, 81.6%] in the control 
group that did not use CDSSs (p = 0.013). Researchers reported a treatment effect 
estimate of 0.016, 95% CI [0.003, 0.028] (Karlsson et al., 2018).  
In comparison, two studies did find significant differences but were related to 
different guidelines and measured different outcomes. Ranta et al. (2017) conducted an 




had experienced transient ischemic attacks (TIAs) with the use of electronic decision 
support or CDSSs compared to usual practice. There was a higher degree of appropriate 
ultrasounds orders with a cluster adjusted OR = 1.41, 95% CI [0.44, 4.49], p = .56 and 
CT scans OR = 13.8, 95% CI [1.7, 110.7], p < .001 in the intervention group compared to 
the control group. The researchers reported that this study was a post-hoc analysis of a 
secondary outcome variable and therefore was vulnerable to Type I error rate inflation, so 
statistically significant results should be interpreted with caution. The second study by 
Sheibani et al. (2017) was a well-conducted interrupted time series study. Researchers 
found that mean adherence to anticoagulant guidelines for the treatment of atrial 
fibrillation by cardiologists significantly increased from 48% to 65.5% (p < .0001) and 
that the trend of adherence to the guidelines was stable in the post-intervention phase. 
1.10.3.3 Systematic reviews of non-CVD studies on effectiveness of CDSSs. 
CDSSs have also been examined in non-CVD guideline adherence. Two systematic 
reviews evaluated the effect of CDSSs for appropriate prescribing and other health care 
processes (Holstiege Mathes, & Pieper, 2015; Bright et al., 2012). In the systematic 
review by Holstiege et al. (2015) five trials were reviewed and all showed significant 
effects in improvement of antibiotic prescribing behaviour with computer-aided CDSSs 
compared to usual practice. For example, one study by Christakis et al. (2001) showed 
that, relative to baseline, physicians and NPs in the intervention group were significantly 
more likely than those in the control group to prescribe antibiotics appropriately to treat 
acute otitis media. In another trial, Forrest et al. (2013) found increases from the baseline 




effusion and acute otitis media compared to the usual care arm. Also, amoxicillin, as a 
first line treatment, was more likely to be prescribed in the intervention group compared 
to the control group with no CDSSs. The risk of bias of the included studies was unclear. 
The second systematic review Bright et al. (2012) examined 128 RCTs that 
evaluated the effectiveness of CDSSs on the improvement of health care processes such 
as performance of recommended preventative care services, ordering clinical studies, and 
prescribing appropriate therapies for treatment of a variety of health conditions. In a 
meta-analysis of 43 studies, the researchers reported favorable outcomes OR = 1.42, 95% 
CI [1.27, 1.58] on provider performance of preventative care services using CDSSs 
compared to usual practice with no CDSSs. In this review, another meta-analysis was 
completed on 20 studies related to ordering clinical studies for diagnosis, 
pharmacotherapy, chronic disease management, laboratory testing and initiating 
conversations with patients with the assistance of CDSSs and found a positive result OR 
= 1.72, 95% CI [1.47, 2.00] compared to usual practice. Finally, one other meta-analysis 
of 67 studies evaluated the effect of CDSSs on the prescribing of appropriate treatment 
compared to usual care and found favorable results OR = 1.57, 95% CI [1.35, 1.82]. The 
level of evidence was rated high by the researchers with good quality studies even though 
it had a high level of bias since most settings had well-established information 
technology infrastructure already in place (Bright et al., 2012). 
1.10.4 Audit and feedback interventions. There is evidence that interventions to 
increase adherence to guidelines as a result of audit and feedback in clinical practice can 




on audit interventions that were carried out to review current practice using various 
methods and with feedback given through written reports, individual face-to-face 
meetings, or group feedback sessions. 
1.10.4.1 Effectiveness of audit and feedback interventions. There have been 
numerous studies and recent systematic reviews on the effectiveness of audit and 
feedback interventions to increase guideline adherence. Unverzagt et al. (2014) included 
two relevant studies in their systematic review of interventions to promote guideline 
adherence. In one study, Korgan, Reynolds, and Shea (2003) provided feedback to HCPs 
using a report card and found no difference in physician guideline adherence; that study 
had an unknown risk of bias. In contrast, in the other trial Fiscella et al. (2010) there was 
a low risk of bias, and a statistically significant improvement in adherence OR = 3.72, 
95% CI [1.86, 7.41] when peer review visits were used as a method to provide feedback 
to clinicians compared to usual care.  Jeffrey et al. (2015) conducted a meta-analysis to 
determine the most effective intervention to improve implementation of CVD- related 
CPGs by HCPs in RCTs. They included six studies (2983 participants) that examined the 
effect of audit and feedback with an education component, with different comparison 
groups, but most frequently usual care. The researchers did not specify the nature of the 
feedback, but excluded academic detailing. They found no significant differences 
between groups OR = 1.39, 95% CI [0.88, 2.21] and reported that risk of bias was high or 
unclear in the majority of studies. 
Since the meta-analysis by Jeffrey et al. (2015), five other studies showed 




CPGs. Two studies evaluated audit with group feedback, and both found a positive effect. 
One of the studies Rawlins et al. (2017) used a cohort design that provided group 
feedback during rounds and reported that referrals for advice from prospective audit and 
feedback rounds were significantly more likely (p < .0001) to come from physicians on 
the rehabilitation service (61.9%) compared with the acute hospital (16.3%). Non-
adherence with antimicrobial advice was more frequent in the acute hospital setting 
(13.8%) compared with the rehabilitation service (7.6%), p < .0001 (Rawlins et al., 
2017). Another study, a well-conducted interrupted time series, showed an improvement 
in the appropriate prescribing of antibiotics at six months following an audit and 
feedback intervention (Hogli, Garcia, Skjold, Skogen, & Smabrekke, 2016).    
Two studies examined individualized feedback rather than group feedback and 
found improved adherence to CPGs. Raval, Kwan, Travers, and Heiss, (2018) used a 
cohort study to provide individual feedback using email and personalized verbal 
communication with providers post intervention, which resulted in increased CPG 
compliance from pre-intervention (7%) to post-intervention (23%). Early postoperative 
ambulation improved significantly (p < .001) for patients post appendicitis from pre-
intervention (47%) to post-intervention (84%) (Raval et al., 2018). The other study was a 
cluster RCT with a stepped-wedge design. Physicians were randomly assigned to one of 
six clusters that began in the control group and crossed over to the intervention group 
until all physicians received the intervention. The intervention consisted of monthly audit 
and feedback with blinded peer comparison on guideline adherence for treatment of 




adherence significantly from 52% without feedback to 65% after feedback. In subgroup 
analysis of patient diagnosis, CPG adherence remained statistically significant for the 
feedback group who had for patients with pneumonia, but not for physicians of patients 
with sepsis. After adjusting for several variables such as time, physician clustering, and 
patient and physician variables, individualized feedback compared to group feedback 
remained significantly associated with guideline adherence for pneumonia and sepsis 
management in the emergency department adjusted OR = 1.8, 95% CI [1.01, 3.2] (Trent, 
Havranek, Ginde, & Haukoos, 2018).  
Finally, in a cluster RCT, peer review with audit and feedback was used to 
evaluate guideline adherence for ordering tests and prescribing behaviour of clinicians. 
Feedback was provided to each physician in an individualized report of prescribing and 
test ordering behaviour from the pharmacist and laboratory specialist. Results showed 
that this feedback strategy did not show any differences between the intervention and 
control groups for the volume of tests ordered or the medications prescribed (Trietsch et 
al., 2017).  
1.10.5 Provider reminders. Clinical reminders in practice settings can cue HCPs 
to recall specific information through verbal, paper-based, or electronic format (Chan et 
al., 2017). There is evidence from the literature that clinical reminders are effective for 
improving provider adherence to guidelines. Evidence on effectiveness has been found in 




1.10.5.1 Effectiveness of reminders in CVD-specific systematic reviews. There 
were two CVD-specific systematic reviews of studies that showed effectiveness of 
clinical reminders as interventions for promoting provider adherence to guidelines 
compared to usual care. In one systematic review Unverzagt, Oemler, Braun, & Klement, 
2014, with 15 RCTs, 184 132 patients and more than 1625 HCPs, a meta-analysis 
conducted showed that providers who received clinical reminders were 1.3 times (95% 
CI [1.17, 1.45]) more likely to adhere to guidelines than those who did not receive such 
reminders. Results across studies were consistent with moderate heterogeneity (I2  = 34%) 
and only one trial found no benefit of provider reminder systems compared with usual 
care. There was no evidence of publication bias. 
In the other more recent systematic review, five studies [one RCT and four 
controlled before-after studies (CBA)] not included in the previous review reported 
process outcomes in the use of provider reminders to improve adherence to heart failure 
guidelines (Shanbhag et al., 2018). The RCT and two CBAs evaluated prescription of 
medications. In two CBAs by Qian et al. (2011) and Braun et al. (2011) that looked 
specifically at antihypertensive drugs, there was a statistically significant improvement in 
provider prescribing of both ACE inhibitors 9.2%, p = .04, and target beta-blockers 
12.3%, p = .03. In contrast, the RCT Ansari et al. (2003), did not show statistically 
significant results compared to usual care in prescribing when the providers were given a 
list of heart failure patients who would benefit from the addition of beta-blockers to their 
medication regimes. One of the five studies, Gravelin et al. (2011) evaluated the use of 




fractions for implantable defibrillators. One site using clinical reminders reported 
improved referral rates for ICDs by 40%, p = .02 compared to usual care with no 
intervention. The other site reported a statistically significant difference, p < .001 with an 
improved referral rate of 47% compared to usual care. Lastly, one study Butler et al. 
(2006) showed statistically significant results in provider use of disease-specific prompts 
in a computer order entry program compared to usual care +53%, p < .001.  
1.10.5.2 Effectiveness of reminders from other non-CVD studies. Two cluster 
RCTs and one controlled before-after study that were non-CVD studies have shown 
effectiveness of provider reminders for HCP guideline adherence from different health 
conditions in a variety of settings. One stepped-wedge cluster RCT evaluated the effect of 
reminders on concordance with recommendations to decrease unnecessary ordering of 
tests according to Choosing Wisely Campaign in the USA. The researchers reported 
statistically significant decreases in the percentages of visits in compliance with the 
Choosing Wisely Campaign (indicating a decrease in the ordering of unnecessary tests). 
An overall decrease of 1.8%, 95% CI [−2.9%, −0.7%], p = .001); for headaches −0.7%, 
95% CI [−1.3%, −0.2%], p = .006); and for acute sinusitis −3.2%, 95% CI [−5.1%, 
−1.3%], p = .001 (Kullgren et al., 2018). In contrast, the authors of the other cluster RCT 
did not report statistically significant differences with the use of electronic clinical 
reminders to nurses in decreasing complications associated with peripheral venous 
catheters. However, the researchers concluded that the clinical reminder strategy may 




reasons for removal of catheters, inspection of IV sites, and providing more regular 
feedback to RNs (Forberg et al., 2016).   
The controlled before-after study did not evaluate the same type of reminder as 
the two cluster RCTs, but instead tested the effect of requesting a reason for non-
adherence to a CPG that focused on prophylaxis of post-operative nausea and vomiting 
with specific medications. The researchers reported a statistically significant difference, p 
< .0001, in prescribing according to guidelines between two different intervention groups 
(89% and 90%) and a historical control group (82%) (Kooij, Klok, Preckel, Hollmann, & 
Kal, 2017).  
1.10.6 Multifaceted interventions. Interventions that are multifaceted are 
considered by many to have greater evidence of effectiveness than single interventions 
strategies for guideline adherence (Chan et al., 2017). However, other researchers claim 
that there is inconclusive evidence for single or multimodal interventions to promote 
guideline adherence or behaviour change of clinicians (Squires, Sullivan, Eccles, 
Worswick, & Grimshaw, 2014). Evidence about effectiveness of multifaceted 
interventions to improve provider adherence were identified from CVD-specific 
systematic reviews, RCTs, cohort, as well as other well-conducted interrupted time series 
studies.  
1.10.6.1 CVD-specific systematic reviews of multifaceted interventions. One 
recent systematic review of six studies, reported statistically significant differences 




receiving usual practice in the prescribing of medications for heart failure patients 
(Shanbhag et al., 2018). All six studies that employed multimodal interventions used 
some form of audit and/or feedback strategy for the clinicians to promote adherence to 
guidelines. Four of the six studies used a combination of both audit and/or feedback and 
educational strategies to promote adherence. In the intervention groups of these studies, 
providers received a combination of other strategies to enhance guideline adherence such 
as: CDSSs with a toolkit, provider reminders, electronic prompts on medication 
prescribing, financial bonuses for quality compliance, and discharge referral summaries. 
Statistically significant differences between the intervention groups and control groups 
were reported for prescribing of ACE inhibitors (+6.7 to 15.7%, range p < .001 to .04) 
and beta-blockers (+7.4% to 15.2%, range p < .0001 to .01), and for referring patients for 
ICDs (+30.3%, p < .001).  
In 2012, a Joanna Briggs Institute (JBI) systematic review was published on the 
effectiveness of interventions on health providers’ compliance with CPGs on venous 
thromboembolism risk assessment and prophylaxis. The authors critically appraised 20 
studies (experimental, observational, and qualitative studies) using JBI tools. The studies 
included in the systematic reviews used single or a combination of interventions such as: 
face-to-face education sessions, computer reminders, risk assessment tools, pre-printed 
order forms, regular feedback on facility audits, and newsletters. The interventions that 
increased awareness of guidelines and clinical reminder prompts for HCPs led to short-
term improvements in compliance from approximately 5% to 50% (Gaston, White, & 




interventions, the outcomes measured, and the quality of the studies, there was 
insufficient evidence to support using single versus multifaceted interventions.  
1.10.6.2 Non-CVD studies of effectiveness of multifaceted interventions. Two 
RCTs reported contrasting evidence of guideline adherence for multifaceted 
interventions. The first multicentre cluster RCT (4183 patients) investigated whether the 
patient survival was improved by a reduction in the time that antibiotics were 
administered by HCPs according to sepsis guidelines (Bloos et al., 2017). The 
intervention group received input from quality improvement teams, educational outreach, 
provider reminders, as well as audit and feedback compared to a control group that 
received conventional continuous medical education (CME) opportunities. The 
multifaceted intervention was not effective to change the time to antimicrobial therapy in 
this setting and did not affect survival.  
In contrast, the second RCT (902 patients) by Vellinga et al. (2016) used 
multimodal interventions that were shown to be effective. This RCT investigated the 
improvement in antimicrobial prescribing for urinary tract infections (UTIs) in general 
practice utilizing two intervention arms (A and B) that received multifaceted 
interventions compared to one control arm.  All arms had baseline training on coding a 
consultation as a UTI or not.  In both intervention arms, whenever a consultation was 
coded as a UTI, the physicians got a reminder outlining the guidelines. Physicians in arm 
B also got a reminder to encourage them to consider delaying prescription for UTI. The 
primary outcome measure was the proportion of prescriptions that was consistent with 




prescribing from baseline to the intervention period showed improved prescribing for 
both the intervention arm A (45.4% baseline to 68.2% post-intervention) and the 
intervention arm B (49.8% baseline to 66.5% post-intervention), but not for the control 
arm. The effect of the intervention was calculated as an OR in a logistic generalized 
estimating equation model. Physicians in the intervention arms were 2.3 times more 
likely with 95% CI [1.7 to 3.2], to prescribe antibiotics appropriately for UTIs compared 
to the control arm.  
Three well-conducted interrupted time series studies have shown evidence of 
effectiveness of adherence to guidelines as a result of multifaceted interventions. One ITS 
showed improved guideline adherence following interventions from a newly constructed 
best practice guideline. The results showed that guideline adherence improved from 47% 
to 69% (Riney et al., 2018). The second well-conducted ITS assessed the ordering of CT 
scans according to the Canadian CT Head Rule and found a minimal difference of 2% 
monthly OR = 0.98, 95% CI [0.96, 0.99] for the seven post-intervention months. There 
was also an increase of 2.3%, 95% CI [1.5%, 3.1%] in appropriate head injury diagnoses 
(Sharp et al., 2018). The third ITS investigated changes in the identification of risk of 
falls, which is a key recommendation for guidelines for physical therapists. Following a 
multifaceted intervention, the researchers found an improvement in identification of falls 
from 6.3% pre-intervention to 94.8% post-intervention, p < .001 (Thomas & Mackintosh, 
2016). 
1.10.7 Overall summary of interventions. From the review of the literature, 




identified that can be used at the provider level to enhance the adherence to current 
CPGs. There is evidence to support the use of educational, CDSSs, audit and feedback, 
provider reminders as well as multifaceted interventions. Appropriate strategies for an 
intervention to improve screening would include the following: using educational 
interventions such as webinars with facilitators; online educational modules to provide 
background information on the implementation of the screening intervention; and an 
interactive website with an algorithm to assist in HCP decision-making. The educational 
strategies chosen for our research were supported in the literature as effective evidence to 
improving utilization of CPGs by HCPs. Strategies for educational interventions that 
were used in our research study were relevant to the NL context and selected with 
consideration for feasibility given the geographic barriers that exist in the province. 
Educational interventions or strategies used in our research study were incorporated into 
the CASP intervention to improve the uptake of the C-CHANGE guideline by NPs in our 
province. A clinical database that was easily accessible at point of care was used by NPs 
across NL for the diagnosis, and management of patients, and documentation of CVD 
risk factors for individuals at high risk for CVD in NL. 
1.11 NPs and Screening for CVD 
Health professionals, primarily family physicians and more recently pharmacists 
and nurses working within the interprofessional team, are able to promote CVD screening 
and management in the community. However, NP numbers are growing, and these 
providers are positioned to play a key role in CVD screening and management and to 




the required core competencies and it is within their mandate to order the necessary 
investigations, diagnose health conditions, and prescribe therapeutic management 
according to the most current CPGs and recommendations (ARNNL, 2016). NPs also 
involve individuals in goal-setting, use a patient-centred approach, embrace a population 
health perspective, and advocate for healthy public policy and programs that are informed 
by the determinants of health (College of Registered Nurses of Newfoundland and 
Labrador [CRNNL], 2019; WHO 2005). NPs have access to the population in urban, 
rural, and remote community settings in NL for routine care and follow-up thereby 
improving the accessibility to individuals and communities to support positive health 
outcomes (Government of NL, 2015).  
1.12 The Research Problem 
Even though CPGs are available in Canada and throughout the world to guide 
CVD screening and follow-up actions, one of the main issues that has arisen in recent 
years is the inconsistent implementation of CPGs by HCPs (Unverzagt, Oemler, Braun, 
& Klement, 2014). One of the key reasons for inconsistent use of guidelines for CVD is 
that each risk factor or condition has different clinical guidelines based on “best 
practice”; this can be overwhelming and difficult for clinicians to apply in daily practice. 
This means that screening for individual risk conditions is more likely to occur than 
screening for multiple risk factors or conditions comprehensively (Hopper Billah, Skiba 
& Krum, 2011; Wright Romboli, DiTulio, Wogen, & Belletti, 2011; Kumar et al., 2009). 
To address the complexity issue related to CVD screening and management, the C-




currency. Even though the C-CHANGE guideline is available, there is a gap in the 
implementation of this comprehensive guideline (Hua et al., 2011).  
The methodological philosophy and qualitative approach of interpretive 
description (Thorne, 2016) was embraced as the foundation for this research study to 
derive new nursing knowledge and to better understand this real-life issue from the 
clinical context (Thorne, 2016). The research problem identified is how best to get HCPs 
to utilize current CPGs in clinical practice, otherwise referred to as knowledge translation 
of evidence into practice. According to Thorne, the methodological approach of 
interpretive description enables researchers of various disciplines the opportunity to 
utilize applied qualitative research in a pragmatic way to address real-life issues or 
problems identified in the field and to find solutions that could be useful in the practice 
setting (2016).  
There were effective interventions for guideline adherence found in the literature, 
but it was not clear what interventions would work best or if these intervention should be 
implemented alone or in combination. The intervention components chosen would need 
to be realistic and feasible for the local NL context to improve adherence to guidelines. 
Furthermore, the interventions or strategies to be used had to be relevant to the NL 
context according to the Knowledge to Action (KTA) Framework with guideline 
adaption (Harrison et al., 2013; Graham et al., 2006).  
The KTA Framework was selected for this mixed methods research study because 




The first phase of the KTA Framework is the choice of guidelines or evidence, and the 
evidence chosen for translation is the C-CHANGE guideline. The second phase is about 
contextualizing the program or intervention, so in this research study a strategy to obtain 
input from key stakeholders to was planned to ensure that the intervention was relevant to 
the local context. The third phase of the framework is the evaluation of the intervention 
implementation process and the sustainability of knowledge use over time. For this 
research study, the focus was on the evaluation of the implementation process of the 
intervention. An intervention could have just been developed and evaluated to promote 
screening and application of the C-CHANGE guideline based on the literature, but to 
ensure that the intervention was relevant to and sustainable in the province of NL, a 
multiphase mixed methods study was conducted. 
1.13 Overview of the Exploratory Sequential Mixed Methods Study 
A multiphase exploratory sequential mixed methods design was used in this 
research study with an underlying philosophical basis of pragmatism and interpretive 
description. Utilizing a variety of methods and frameworks is consistent with pragmatism 
as we focused on finding a solution to the research problem that was a clinical practice 
issue. The overall purpose of the mixed methods study was to determine successful 
strategies for implementation of CPGs through the development, implementation, and 
evaluation of a cardiovascular screening intervention called CASP. There were three 
distinct phases in this mixed methods study, a qualitative phase, a quantitative phase, and 




The target groups for the qualitative study (phase 1) were HCPs, managers, and 
public to gather a variety of perspectives from key stakeholders to inform the 
development of the CASP intervention. Phase 2 had two target participant groups, the 
NPs working in community settings in NL and their patients. Inclusion criteria for the 
NPs were to have access to and be able to follow-up with patients in the community 
setting. The patients involved in the study had to be asymptomatic adults aged 40-74 
years in NL without established CVD.  
1.13.1 Research questions. The overall research question that was addressed in 
this mixed methods study was the following: “What strategies are effective to enhance 
HCPs’ use of evidenced-based CPGs for CVD screening and management in NL?” The 
research questions that were answered through the research process were the following: 
Phase 1 questions (qualitative phase): 
1. What are the facilitators and barriers associated with screening at-risk 
individuals aged 40-74 years in NL? 
2. What tools and strategies do healthcare providers, health administrators, and 
members of the public recommend to increase comprehensive CVD screening 
in NL? 
Phase 2 questions (quantitative phase) 
3. What is the effect of implementing CASP on comprehensiveness of screening 




4. What is the effect of implementing CASP on the identification of multiple risk 
factors for individuals and determining the level of CVD risk for patients in 
the NP practice? 
5. What is the effect of implementing CASP on the identification of NPs’ and 
patients’ priorities for heart health in NL? 
6. What are the patients’ and NPs’ experiences with the CASP intervention in 
NL? 
Phase 3 question (integration phase): 
1. What strategies are effective to enhance healthcare providers’ use of 
evidenced-based CPGs for CVD screening and management in NL? 
 
1.13.2 Research study design. An exploratory sequential mixed methods study 
design was appropriate to answer the stated research questions. Figure 1.1 shows the 
sequence of the phases for this mixed methods study. Phase 1, a qualitative study, led to 
the development of CASP. The original logic model for the CASP intervention was based 
on a review of the literature and was comprised of the components that were thought to 
be important for implementation success. The original logic model can be found in 
Appendix B. Phase 2 was a larger quantitative study that tested the implementation of the 
CASP intervention with NPs and their patients. Phase 3, the integration phase, provided 
an opportunity to analyze the results of both phase 1 and 2 to generate new knowledge 
about strategies that can enhance provider adherence to current guidelines relevant to the 




logic model for the CASP intervention that was created following the completion of the 
mixed methods study. The final logic model for the CASP intervention can be found in 
Appendix B. The focus of an exploratory design is to obtain input from key sources to 
ensure that the intervention developed is contextually relevant. An overview of each 
phase is presented in this section. Details of each phase and of CASP can be found in 
subsequent chapters. Research ethics approval was obtained for phase 1 and then phases 
2 and 3 of this mixed methods study. The Health Research Ethics Board Approvals for 
this mixed methods study can be found in Appendix C. Approval was also obtained from 
the regional program approvals committees across NL. 
            
Figure 1.1 Exploratory Sequential Mixed Methods Study 
 
1.13.2.1 Phase 1. The aim of the first phase of the mixed methods study was to 
explore the perspectives of various health professionals and members of the public to 
inform the development and implementation strategies of the screening program, CASP. 
We conducted five focus groups and 10 individual interviews with HCPs, health 
managers, and members of the public, between October 2016 and May 2017 in both 
urban and rural settings in NL. The focus was to explore the barriers and facilitators to 
Exploratory sequential mixed methods study











cardiovascular screening by HCPs with patients in NL. Appendix D contains the research 
documents for phase 1. 
Interpretive description encourages the use of diverse methods to analyze data 
rather than using rigid techniques that are specific to one philosophical stance, for 
example, phenomenology or grounded theory (Thorne, 2016). Data analysis of the focus 
groups used specific methods on focus group analysis from Kruger and Casey (2015). 
The TDF was used to inform the researchers and provide insights into the development of 
CASP. Themes derived from the interview and focus group analysis were categorized 
into specific domains of the TDF and then behaviour change techniques were matched to 
those domains. The modes of delivery for the CASP intervention components that were 
selected were relevant to the NL context.  
To ensure credibility of the results from the data analysis, the researcher has 
declared epistemological integrity of pragmatism and encouraged representativeness of 
the data from a variety of perspectives in the development of the intervention consistent 
with interpretive description. As well, an audit trail was created and independent 
researchers verified the analysis of numerous transcripts. Having disciplinary knowledge 
also gives credibility to interpretation of the data while being cognizant of the knowledge 
gained. Taking the time to participate in reflective journaling following the interviews 
and focus group sessions, also lends credibility to the findings (Thorne, 2016). 
The CASP intervention content consisted of four main components: a) an 




CVD database. The CASP intervention components with examples can be found in 
Appendix E. Both the knowledge user and patient partners on our research team were 
able to review CASP and provide important suggestions for improvement prior to 
finalizing these components. Details of the four components of the CASP intervention are 
described in below: 
1) Educational resources-The educational module consisted of an online module 
to enhance CVD knowledge and CVD screening with CVD assessment tools and devices. 
Providing educational resources to all NPs was important to ensure a consistent 
standardized approach during the implementation phase. 
2) CASP interactive website-The second component was a CDSS, an interactive 
website that housed a new algorithm and the C-CHANGE guideline to assist practitioners 
in clinical decision-making. The website also contained a separate section for patient use 
to access various provincial resources and contacts. 
3) Health providers’ toolkit-The third component of the CASP intervention was 
the HCPs’ toolkit that contained devices and tools for risk assessment such as the 
following: an automated BP monitor (if the current office did not have one available); a 
digital weigh scale; a standard measuring tape; and handouts and brochures for patient 
counselling. 
4) CVD database-The fourth component was a CVD database that was created by 
researchers with technical assistance from NLCHI. This database was used to document 




factors; prescribed medications; calculated FRS and heart age score; and diagnostic and 
laboratory findings. The NPs’ priorities for patient management, the patients’ priorities 
for heart health, and the patients’ individualized goals documented on the My Heart 
Healthy Plan forms were summarized in the CVD database.   
1.13.2.2 Phase 2. The purpose of the quantitative phase 2, an RCT, was to 
evaluate the effectiveness of CASP in clinical practice compared to usual practice to 
determine whether the intervention would increase comprehensiveness of screening, 
identification of patients’ level of CVD risk, and individualized goal-setting. The primary 
outcome of phase 2 was the comprehensiveness of CVD screening. The null hypothesis 
for phase 2 was stated as follows: There will be no difference in comprehensiveness of 
screening between the intervention group and the control group.  
The NPs in the intervention group implemented CASP and participated in 
educational webinars from their workplaces and received information on using specific 
tools to identify, screen, and follow-up with patients. The NPs received instructions on 
recruiting patients, obtaining consent, and on data collection methods using the CVD 
database that was developed by researchers with technical assistance from NLCHI 
specifically for this research study. The CVD database was an online database that had 
specific items that had to be filled in by the NPs during the assessment and management 
of patients in the intervention group during the study implementation. Tools to assist the 
NPs and additional resources for the patients were available on the CASP website that 
was developed with technical expertise from Memorial University of Newfoundland as 




the components included the following: a website, an educational module, interactive 
tools, clinical reminders, and CDSSs. These CASP components were used to promote 
adherence to guidelines and to facilitate comprehensive screening and follow-up actions 
with patients in the community. Following completion of data collection, the NPs 
transferred the CVD database containing the patients’ data by secure transfer to NLCHI. 
Descriptive statistics were used to compare differences between the intervention and the 
control group outcomes. The relative risk was calculated for the primary outcome using 
generalized linear modelling to control for the effect of the NP. 
The NPs in the control group participated in webinar education sessions different 
from the webinars held with the intervention group NP participants, and were instructed 
to follow usual practice to screen patients for CVD. They were given instructions on 
recruiting patients and obtaining consent. The researchers conducted retrospective chart 
reviews in the NPs’ practice settings who had consented to participate in this study. Data 
were collected about NP screening practices and follow-up care that occurred when the 
patients were recruited to the study, and any subsequent screening related visits. The 
specific CVD screening tools provided to the NPs in the intervention group were made 
available to NPs in the control group following the completion of data collection for 
phase 2 of the study. All NPs and patients were given feedback questionnaires to 
complete at the end of the data collection period in order for researchers to obtain 
valuable feedback on the participants’ experiences in the RCT. The research documents 




1.13.2.3 Phase 3. Phase 3 involved the integration of the results of phases 1 and 2 
so that effective strategies to increase uptake of evidence-informed CVD screening and 
management in NL were identified to enhance knowledge translation in clinical practice. 
During the integration phase, researchers evaluated whether the CASP intervention 
components addressed the barriers and facilitators identified in phase 1 by evaluating the 
completed NP and patient feedback questionnaires. Researchers confirmed the CASP 
intervention components that were effective strategies to change provider behaviour and 
to increase uptake of CVD screening (according to C-CHANGE). The feedback 
questionnaires from NPs and patients at the end of phase 2 were used to evaluate whether 
the BCTs, methods of delivery, and intervention content were effective in changing the 
behaviour of the clinician and increasing comprehensive CVD screening. We evaluated 
the results to determine whether there was confirmation, congruence, or discordance of 
the findings to further refine the components of the CASP intervention.  
1.14 Organization of Dissertation 
This three-manuscript dissertation contains a total of five chapters. Chapter 1 
provides the comprehensive literature review that identified a gap in the research that 
needed to be addressed and that stimulated the intervention design. The underlying 
philosophy of pragmatism and interpretive description is described as the foundation for 
this research (Thorne, 2016). 
Chapter 2 contains the mixed methods manuscript. The results of the qualitative 




intervention development using a five-step process (French et al., 2014; Backman et al., 
2015). The behaviour change techniques (BCTs) taxonomy was used to select relevant 
BCTs with specific modes of delivery (Michie et al., 2013). The results of phase 2 are 
briefly presented in a table to illustrate how specific barrier, facilitator and strategy 
themes from phase 1 were addressed during the implementation of the intervention in 
phase 2. The integration phase 3 describes how the quantitative results further explain 
how the theory-informed intervention developed in phase 1 is culturally and contextually 
relevant. Phase 3 also presents effective strategies that can be used in clinical practice to 
enhance the utilization of CPGs by HCPs at the present time, and in the future.  
The manuscript in Chapter 3 reports on the results of testing the theory (TDF) 
informed intervention CASP, in an RCT, and provides evidence for the effectiveness of 
utilizing a comprehensive CVD screening intervention in clinical practice.   
The manuscript in Chapter 4 contains the literature review on the methodology of 
the recruitment of healthcare professionals to research studies. This review was 
conducted because of the difficulty experienced by the research team in the recruitment 
of busy HCPs for this research study. Details on the methodology of recruitment was 
chosen to inform novice, and even experienced researchers, about effective strategies to 
streamline efforts for recruitment of HCPs and address any issues early in the research 
process.  
Finally, Chapter 5 summarizes the dissertation journey and describes future 




can be adapted to be used with different patient populations. Details of how the 
intervention could be specifically tailored to meet the unique needs of vulnerable 
populations and used in practice to address health inequities that can exist during patient-
provider interactions.  
1.15 Conclusion 
To address the economic, social, and personal burden associated with developing 
cardiovascular disease, there needs to be a shift in focus away from treatment-oriented 
strategies to prevention and health promotion through earlier screening and management 
of CVD risk factors and conditions. CVD is an important public health problem with 
acceptable screening tests, and treatments, and CPGs to guide health professionals using 
the latest research evidence to prevent or delay the development of CVD and 
complications. Even though there are relevant guidelines available for CVD screening 
and management, there remains a gap in their implementation. The mixed methods study 
was warranted and the results of this study will add to the nursing and knowledge 
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CHAPTER 2 Development and Refinement of the Cardiovascular Assessment 




The manuscript in Chapter 2 focuses on the development of the CASP intervention based 
on the results of phase 1 and the integration phase 3 of the mixed methods study. 
The target audience is health professionals, administrators, government officials, and the 
university research community. 
 
JB conceptualized the study, collected the data, performed data analysis, interpreted the 
results, and wrote the manuscript. DM contributed to the conceptualization of the study, 
research design, and interpretation of data. KP contributed to the data analysis, data 
interpretation, and conceptualizing results. DM, KP, and CD contributed to the 













BACKGROUND: There is inconsistent utilization of clinical practice guidelines (CPGs) 
for cardiovascular disease (CVD) screening and management by healthcare professionals 
to identify CVD risk factors early and to intervene using current recommendations. This 
manuscript reports on the development of the Cardiovascular Assessment Screening 
Program (CASP) and focuses on the qualitative phase of the exploratory mixed methods 
study. METHODS: Focus groups were held with nurse practitioners (three groups) and 
the public (two groups) in both rural and urban settings. Ten individual interviews were 
conducted with target health professional groups, the public, and health managers in 
community settings in phase 1 of the study. The Theoretical Domains Framework (TDF) 
was applied to the themes that emerged from the focus groups and interviews. Behaviour 
change techniques (BCTs), modes of delivery, and intervention components were 
selected for the development of the CASP. The CASP intervention was tested in phase 2 
and refined in phase 3 of the mixed methods study. RESULTS: Themes identified 
included lack of knowledge about comprehensive screening, ambiguity around 
responsibility for screening, lack of time and commitment to screening. These themes 
lead to the development of a website, education module, decision tools, and a toolkit as 
part of CASP. Feedback obtained from participants at the end of phase 2 confirmed the 
relevance of the CASP components. CONCLUSION: Following focus groups and 
interviews with health professionals, managers, and the public; the barrier, facilitator, and 




CASP intervention was developed. Keywords: clinical practice guidelines, Theoretical 
Domains Framework, cardiovascular, screening, intervention development 
2.2 Background and Overview 
 
Cardiovascular disease (CVD) is the leading cause of death globally and accounts 
for approximately 31% of all deaths (World Health Organization [WHO], 2017). In 
Canada and Newfoundland and Labrador (NL), CVD accounts for 30% of all deaths 
(Public Health Agency of Canada [PHAC], 2018) while also resulting in lost years of life, 
reduced productivity, and decreased quality of life for individuals (Heart and Stroke 
Foundation, 2019). CVDs include diseases of the heart, vascular diseases of the brain, 
and diseases of the blood vessels that can progress to myocardial infarctions and 
cerebrovascular accidents leading to increased morbidity and mortality (PHAC, 2016). 
CVD develops as a result of a combination of genetic, social, and environmental 
influences over a number of years with CVD incidence increasing with advancing age 
(WHO, 2017). With consideration of many unique genetic and socioenvironmental 
influences on an individual's behaviour, traditional risk factors such as smoking, physical 
inactivity, and poor dietary intake can lead to chronic conditions such as hypertension, 
obesity, and diabetes; all of which contributes to the development of CVD. Control of 
risk factors is therefore critical to the prevention of CVD. 
There is evidence that screening to identify cardiovascular risk factors and 
conditions early, with attention to the socioenvironmental influences that impact daily life 




reduce morbidity and premature mortality related to CVD (Alvarez-Bueno et al., 2015; 
Lee et al., 2015). CVD screening for the multitude of comorbid conditions and risk 
factors is complex. The fact that each risk factor or condition has different clinical 
practice guidelines (CPGs) can be overwhelming, making it difficult for clinicians to stay 
abreast of the most current research.  
Current recommendations supporting CVD screening and management in Canada 
can be found in a set of coordinated CPGs by the Canadian Cardiovascular Harmonized 
National Guidelines Endeavour known as C-CHANGE (Tobe et al., 2018). The C-
CHANGE guideline is comprehensive in the depth of information for CVD screening and 
management. As well, this guideline is multifaceted addressing many different risk 
factors and conditions. Many HCPs are not aware of the existence of these harmonized 
guidelines. Even though the C-CHANGE guideline is published in an online journal, the 
daily application of the guideline is difficult for clinicians because the screening and the 
management recommendations for many chronic conditions are presented together, 
making the guideline burdensome with respect to deciding appropriate actions during 
patient encounters. As a result of these and other barriers, there are inconsistencies in the 
utilization of cardiovascular CPGs by healthcare providers (HCPs) such as family 
physicians and nurse practitioners (NPs) (Graham, Xiao, Taylor, & Boehm, 2017; 
Unverzagt, Oemler, Braun, & Klement, 2014). 
To address this clinical practice issue and increase utilization of the C-CHANGE 
guideline, a multiphase sequential mixed methods exploratory study was conducted to 




guidelines. Through the development, implementation, and evaluation of a cardiovascular 
screening intervention. The use of a qualitative study as the first phase was important for 
ensuring that the intervention would be contextually and culturally relevant, which is a 
key aspect of the Knowledge to Action (KTA) Framework, with guideline adaption 
(Harrison et al., 2013; Graham et al., 2006). 
Our aim in phase 1 of the mixed methods study was to develop a theory-informed 
intervention named the Cardiovascular Assessment Screening Program (CASP). This 
intervention made the C-CHANGE guideline more user-friendly for HCPs to screen 
comprehensively in daily practice. We followed a process similar to others who 
developed interventions to promote adherence to guidelines utilizing the Theoretical 
Domains Framework (TDF) (Backman et al., 2015; French et al., 2014). 
There were five steps in the process of developing the theory-informed 
intervention (summarized in Table 2.1). In brief, from the literature, the identified target 
behaviour was consistent use of the C-CHANGE guideline to promote comprehensive 
CVD screening and management of patients. Findings from a review of the literature also 
showed that in order for guideline adherence (behaviour change) to occur, the HCP 
required awareness and access to the guidelines congruent with the organizational 
environment (Michie et al., 2013). The next step involved conducting interviews and 
focus groups to explore the barriers of, and facilitators to, achieving the target behaviour 
change and finding strategies within the local context to increase uptake of the C-




feedback was obtained on the provisional CASP with knowledge users and patient 
partners prior to its implementation and evaluation.  
The TDF was originally developed by a number of behavioural scientists and 
implementation researchers to provide a comprehensive approach to determining the 
main factors influencing clinician behaviour, to assess the implementation research, and 
to support intervention design along with other uses (Atkins et al., 2017; Michie et al., 
2013; French et al., 2012). The TDF was developed by identifying theories relevant to 
implementation research and grouping the constructs from these theories into domains 
(Atkins et al, 2017). The specific definitions and constructs underlying the domains of the 
TDF have been validated for assessing professional or other health related behaviours as 
well as implementation problems as a basis for the development of interventions (Atkins 
et al., 2017; Cane, O'Connor, & Michie, 2012). 
This paper presents the results of the mixed methods study. The results of phase 1, 
the qualitative study leading to the development of the intervention, are summarized in 
Table 2.1 (Steps 1-5) and are described in more detail in this manuscript. There is a brief 
discussion on the results of phase 2, a randomized controlled trial (RCT) that was 
conducted to test the intervention. Phase 3, the integration phase, reports on how the 






Table 2. 1 Overview of the Process for the Development of a Theory-informed 
Intervention, CASP. 
Steps Sources and Methods 
 
1. Identify the target behaviour: HCP 
consistent use of CPGs in daily 
clinical practice for comprehensive 
CVD screening and management. 
 
 
2. Explore the barriers and facilitators 
related to CVD screening and 
identify possible strategies within 
the local context to improve uptake 
of the C-CHANGE guideline. 
 
 
3. Match barriers and facilitators with 





4. Integrate the behaviour change 
techniques with the modes of 









1. Performed a literature review to identify the 
target behaviour and to find effective 
interventions to promote HCP adherence to 
the C-CHANGE guideline.  
  
 
2. Conducted focus groups and individual 
interviews using evidence-informed 
interview guides with HCPs, managers, and 
the public during qualitative phase 1 of the 
mixed methods study; research team 
consensus. 
 
3. Identified barriers and facilitators from 
research findings to: a) match with the 
theoretical domains of the TDF, and b) 
choose relevant behaviour change 
techniques; research team discussion. 
 
4. Selected the modes of delivery congruent 
with the local context; researchers and 
technical support available at the local 
university and agencies to support the 
intervention components. 
 
5. Obtained feedback on CASP from 
knowledge users and patient partners; 




The philosophy and qualitative methodological approach of interpretive 
description (Thorne, 2016) was embraced as the foundation for this research study to 
derive new nursing knowledge and to better understand the real-life issue from the 
clinical context (Thorne, 2016). The problem or issue identified is how best to get HCPs 
to utilize current CPGs in clinical practice, otherwise referred to as knowledge translation 




interpretive description enables researchers of various disciplines the opportunity to 
utilize applied qualitative research in a pragmatic way to address real-life issues or 
problems identified in the field and to find solutions that could be useful in the practice 
setting (2016). Using the interpretive description approach, new nursing knowledge 
subjectively constructed that is relevant and contextually meaningful could be applied in 
the clinical practice setting (Thorne, 2016).  
2.3 Exploration of Barriers and Facilitators: Methods 
To explore barriers, facilitators and strategies, we sought to answer two research 
questions:  
1. What are the facilitators and barriers associated with screening at-risk 
individuals aged 40-74 years in NL? 
2. What are the tools and strategies that various healthcare providers, health 
administrators, and members of the general public recommend to increase comprehensive 
CVD screening in NL?  
2.3.1 Participants and sampling. The target groups for this study were NPs, 
nurses, family physicians, dietitians and pharmacists, healthcare managers, and the 
general public. A convenience sample representing various members of the 
interprofessional team, healthcare managers, and the general public was recruited from 
both urban and rural areas in the province of NL. It was important to conduct interviews 
with a variety of participants for several reasons. Individuals representing different 




dietician, and pharmacist) would have varied experiences with CVD screening and 
management and their different perspectives could provide unique contributions to 
inform the development of the intervention. The NPs were of particular interest to the 
researchers since this professional group comprised the knowledge users who would be 
participating in the second phase of the mixed methods study. Having buy-in from 
management was important to determine the feasibility of implementation of such an 
intervention into the local context.  Finally, engaging knowledge users and patient 
partners who would be collaborators in a patient-centred care approach for the 
intervention during the design phase of interventions ensured that the end program or 
intervention was relevant to the context and potentially sustainable (Brett et al., 2014). 
This is consistent with the interpretive description philosophy of encouraging input from 
a variety of perspectives to address the healthcare issue or problem (Thorne, 2016). 
There were 30 participants involved in phase 1 of this study. This number was 
thought to be a sufficient sample by the research team and was consistent with 
interpretive description methodology (Thorne, 2016). Obtaining a variety of perspectives 
to answer the semi-structured questions contained in the interview guides used during the 
focus groups and interviews was important to inform the development of an intervention 
that was contextually and culturally relevant. The participant sample was recruited from 
both rural and urban settings utilizing different strategies such as putting up wall posters 
in community health clinics, setting up an information table, in workplaces, attending 




2.3.2 Data collection. Focus groups and individual interviews were conducted for 
this research study. There were five focus groups held with 3-6 participants each. Three 
focus groups were held with NPs, and two focus groups with members of the general 
public in both rural and urban settings. The focus groups with the NPs took place at 
Memorial University and in Grand Falls-Winsor, NL. The focus groups with the public 
took place in a government building in St. John’s and in the small town of Harbour 
Grace, NL. Ten individual interviews were conducted in various locations in the province 
by phone and in St. John’s and the surrounding area with a number of different HCPs: a 
family physician, a pharmacist, a public health nurse, a nurse practitioner, two dieticians 
working in community health settings, and a member of the public. Three managers from 
different locations within the eastern Regional Health Authority were also interviewed. 
We developed three different semi-structured interview guides, informed by the 
literature, that were used with the different participant groups (HCPs, healthcare 
managers and the general public). These interview guides were used for the focus groups 
and the individual interviews. Appendix D contains the interview guide documents 
entitled the Focus Group/Individual Interview Questions for Health Professionals, and the 
Focus Group/Individual Interview Questions for the Public.  
Each focus group lasted 60-90 minutes and the individual interviews were 
approximately 60 minutes in length. We initially pre-tested the interview guide for the 
HCP group with four NP colleagues of the primary researcher since this HCP group 




guide for the general public was also tested prior to use in the focus groups with members 
of the public in both rural and urban settings.  
At the beginning of each focus group and individual interview, participants were 
given an information letter that explained their role and were invited to ask questions. 
Verbal consent was obtained from all participants. The primary researcher conducted all 
of the focus groups and recorded the sessions using a digital audio recorder. Field notes 
were taken during and following the focus groups and were recorded as personal 
responses to what had been learned or observed during the focus groups sessions. All 
focus groups were transcribed verbatim and field notes further guided the content and 
interpretation of the data. The individual interviews were conducted, recorded, and 
transcribed in a similar manner. 
Focus groups were used to derive benefit from group dynamics that enriched the 
responses given by participants during the sessions (Thorne, 2016). Responding to 
questions that are relevant to members of the same professional group created the 
circumstances or dynamics that allowed further reflection and expression of ideas by the 
individual members that may not otherwise be revealed in an individual interview. The 
questions in the semi-structured guide that were posed to the focus group members 
contained a subject matter that was non-threatening in nature which further encouraged 
the expression of ideas (Kruger & Casey, 2015). Using the interview guide questions, 
face-to-face or telephone individual interviews, were conducted by researchers for 
individuals who were unable to participate in a focus group in order to gain the 




interview was conducted, modifications to the original guides occurred to ensure that the 
data obtained were addressing the stated research questions. 
2.3.3 Data analysis. The focus group and interview data were analyzed using 
constant comparative strategy as described by Kruger and Casey (2015). All transcribed 
focus group sessions and individual interviews were uploaded into NVIVO software for 
data management and coding (Pro, 2016). All transcripts were coded line by line and 
were further organized into nodes in NVIVO according to the semi-structured interview 
guide questions. Transcripts were coded and verified by two researchers. Then, categories 
were analyzed, and patterns were arranged in relationship to one another. The patterns 
were then compared between and across the three NP groups to construct the main ideas 
that evolved (Kruger & Casey, 2015). Relationships and patterns evolved from the public 
participant groups in both rural and urban settings. From the analyses of the individual 
interviews, some common findings as well as unique ideas emerged across the different 
professional groups.  
Interpretive description encourages the use of diverse methodologies to analyze 
data rather than using rigid techniques that are specific to one philosophical stance, for 
example, phenomenology or grounded theory (Thorne, 2016). In keeping with 
interpretive description, patterns were transformed during the analysis of the focus 
groups, according to Kruger & Casey (2015), and during the analysis of the individual 
interviews with health professionals, healthcare managers, and the general public. These 




findings to inform the development of relevant themes, and implementation strategies for 
CASP.  
To ensure credibility of the results from the data analysis, the researcher has 
declared epistemological integrity of pragmatism and encouraged representativeness of 
the data from a variety of perspectives in the development of the intervention consistent 
with interpretive description. As well, an audit trail was created and independent 
researchers verified the analysis of numerous transcripts. Having disciplinary knowledge 
also gives credibility to interpretation of the data while being cognizant of the knowledge 
gained. Taking the time to participate in reflective journaling following the interviews 
and focus group sessions, also lends credibility to the findings (Thorne, 2016). 
2.4 Exploration of Barriers and Facilitators: Results 
The analysis of the focus group and interview data revealed various perspectives 
about the barriers and facilitators for CVD screening and management in the province of 
NL.  
2.4.1 Barriers to CVD screening. Several themes associated with the barriers to 
CVD screening emerged from the data analysis of the focus groups and the individual 
interviews with health providers, managers, and the public. The main barrier themes that 
emerged were the following: ambiguity and uncertainty around responsibility for CVD 
screening; lack of knowledge and skills for comprehensive CVD screening using the C-
CHANGE guideline; questioning the necessity of screening in light of the Choosing 




resources and organizational supports for CVD screening; changing behaviour is 
difficult for patients; and lack of access to services. Each theme will be discussed with 
supportive evidence from the data. 
Ambiguity and uncertainty around the responsibility for CVD screening emerged 
from the NP focus groups. NPs recognized that comprehensive screening for CVD was 
important but were uncertain about whether they were fully responsible. Some NPs 
thought that family physicians were responsible; however, NPs recognized that they too 
had a role along with other providers such as dieticians, public health nurses, community 
health nurses, and diabetes educators. One NP commented: “Yeah. Totally I think it 
should always be in the back of our minds – health screening, screening 
everything….they do have family doctors and visit them regularly not that I’m putting it 
back on the family doctor but I mean we do, do screening tests.” Another NP stated: “The 
family physician is probably an obvious answer. But you know some people are 
connected with diabetic teams of dieticians and diabetic RNs….people are sometimes 
identified through that avenue. I know they come across my desk sometimes from teams 
like that.” One NP commented: “I think it depends on what type of screening you’re 
talking about too because if it’s labs then only the NPs and the physicians can do that but 
if you’re talking about sort of risk factors of obesity and smoking…then someone else 
can initiate screening.” 
The interviews with the public health nurse and two dietitians suggested that they 




behaviour, but these health professionals agreed that screening was not part of their 
mandate and the major responsibility should fall to physicians primarily, and NPs. 
A second theme that emerged from data analysis was the lack of knowledge and 
skills for comprehensive CVD screening using the C-CHANGE guideline. NPs often 
screen for individual CVD risk factors but were unfamiliar with the C-CHANGE 
guideline. As was stated earlier, many HCPs including NPs may not be familiar with or 
understand the purpose of the guidelines as they may not be widely disseminated in 
clinical practice. When NPs were questioned about their knowledge of the C-CHANGE 
guideline, they had not heard of them. One NP commented: "No I have never heard of 
them (C-CHANGE guideline)." Another NP responded: "….so they really just put it all 
together from all the guidelines that are out there?" Other health professionals and 
managers were also not familiar with the existence of the C-CHANGE guideline when 
questioned during individual interviews. 
Another theme was questioning the necessity of CVD screening in light of the 
Choosing Wisely Campaign that discourages family physicians and other practitioners 
from ordering unnecessary tests and procedures. Because of this campaign NPs have 
begun to question whether certain screening tests, including CVD screening, should be 
done at all. One NP said, "…and provincially you're getting into the whole financial 
discussion now of the Choose Wisely Campaign about unnecessary diagnostic testing and 
everything so it's a delicate balance. It's a very individual decision as a practitioner I find 
you know." Another NP commented: “…are we going to do anything with it (screening 




Another theme emerged around the lack of time and commitment for CVD 
screening in the current provincial health care climate of fiscal restraints. NPs in the 
community setting are very busy managing patients in clinical practice. NPs recognized 
that implementing a new CVD screening initiative would take extra time in their daily 
routine. Getting extra resources such as staff to assist in this screening process was very 
unlikely because of the present climate of decreased resources. One frustrated NP 
commented: “…from an organization’s perspective, if you’re doing all the work well fine 
and dandy, go and do it. I think that’s what we find with that. As for putting in extra 
resources like giving everybody an LPN or something to do all the screening, that’s not 
happening. If we’re going to do the work ourselves and get the patient back and 
everything, yeah (it will happen).” 
 Similarly, one pharmacist and one physician who were interviewed were aware of 
the time and commitment required for implementing a comprehensive CVD screening 
program in the current fee-for-service system in this province. Reluctance about 
participating in a CVD screening program was based on a lack of financial compensation 
and lack of dedicated time for implementation of such a program.  
Likewise, lack of dedicated resources and organizational supports for CVD 
screening was a similar theme that emerged through the interviews with the healthcare 
managers. There was no organizational priority for prevention nor resources allocated for 
implementation of a CVD intervention focused on prevention. The health managers were 




comprehensive CVD screening program. Also, there was a question about the 
sustainability of such a program in light of the associated costs and necessary resources.  
 Another theme was changing behaviour is difficult for patients. The NPs were 
frustrated due to lack of interest by many patients to change unhealthy behaviours. NPs 
questioned the value and the purpose of screening when the patients are reluctant to 
participate in the screening process and change their behaviour. One NP commented: 
“What if the patient doesn’t want to take meds, doesn’t want to make changes you know 
before we actually do the screening. We should, well we do, we ask them you know 
we’re going to do this test. It’s going to tell us your cholesterol level and if it’s elevated 
you may need to do a, b, c, or d but if they already don’t want to do anything….why do 
it, put them through it? So, the risk associated with pricking them and then the cost of it 
and if they’re not going to change things?” Another NP stated: “People are resistant to 
change, just generally speaking, not just about cardiac but I mean diabetes, 
everything…(it’s) the same thing.” 
Dietitians also spoke about the fact that behaviour change is difficult. The 
dietitians explained that eating patterns are formed at a young age and are often resistant 
to change in later years. Changing behaviours associated with eating is difficult based on 
their experience with counselling patients with diabetes mellitus. One dietitian stated: 
“And part of the issue is…that patients don’t engage for the follow-up piece. They 
believe that it is a quick fix. They believe that you’re going to tell them what to do.” One 
dietitian reported that patients often say, “Tell me what to eat…they find it hard to get 




focus groups with the public the following comment was made about the reality of not 
being able to successfully change behaviour: “I think sometimes doctors…asking 
someone to change their diet, change their cholesterol level is not really effective. I think 
that’s the bottom line.” 
In their encounters with patients, NPs identified a lack of access to services. In the 
province of NL, there are many people who live in rural and remote areas who often lack 
access to services. NPs stated the following: “I just think access (for some people) you 
know. How are you going to get it out there? If you don’t have the patients coming 
forward or someone saying it to them, I think access is huge…” Another NP suggested 
that if people do not actually come to the clinic, then how would any program make a 
difference. One NP stated “..Yeah, but it (the CVD screening program) only catches the 
ones who come to the clinic." Therefore, the people who would truly benefit from the 
program are not accessing preventative services. 
For participants from both the rural and urban general public focus groups, lack of 
access to care was an important theme in terms of the number of primary care providers 
available, mainly physicians, in the rural setting. For the urban group, wait times and lack 
of time given by family practice physicians to individualized care was brought forward. 
“And it's not only that, people say oh go to my family doctor and that's a two-hour wait. I 
can't get in to see him for a month. How does that work?" Another commented: "Yeah, 
and then of course, you forget about it because I can't see my family doctor for two 




the public in both urban and rural areas, there were complaints about the lack of 
opportunity for a focus on CVD risk factors.  
2.4.2 Facilitators for CVD screening. There were two themes related to 
facilitators for CVD screening; the first theme was knowing who to screen for CVD was 
obvious, but the timing of screening was not clear, and the second theme was components 
and tools identified from other successful provincial screening initiatives were important 
to consider to determine successful strategies for the CASP implementation. Both themes 
will be discussed with supportive evidence from the analysis of the data. 
One theme was knowing who to screen for CVD was obvious, but the timing of 
screening was less clear. There was a realization by NPs that there is a major problem 
with CVD risk factors in the province of NL. They recognized that NL has the highest 
prevalence of many CVD risk factors in Canada such as family history, obesity, 
hypertension, and dyslipidemia. Global risk assessment is used to determine risk 
categories and to identify those at highest risk, but this was not always consistently 
carried out in routine daily practice. NPs in the focus groups presented a variety of 
responses such as the following: “age and co-morbidities”; “family history”; “their 
lifestyles – if they’re smokers or inactive”; and “Aboriginal descent- they are considered 
high risk… so we begin screening (earlier).” One NP commented: “…there are a lot of 
the young people who came in with heart failure related to IV drug use (so they) are at an 
increased risk of cardiovascular disease...” Another NP stated: “…I guess like race. You 




Another NP proclaimed: “I think just being a Newfoundlander is a risk factor!” The other 
health professional groups and managers recognized that there is a high prevalence of 
many CVD risk factors and conditions, so they believed CVD screening was obviously 
very important for all the people in NL. 
NPs recognized that the ideal time for CVD screening for patients needed to be 
individualized since there are many different factors that have to be taken into 
consideration. NPs agreed that early screening is best especially for people in NL with a 
significant family history and given the fact that the province has the highest rates of 
CVD in Canada. One of the NPs commented: “I know there was a lot of obesity in a 
kindergarten class of one of my kids.” Another NP stated: "… I think one standard age 
would be appropriate.” An NP explained the following: "…It depends – sometimes you 
get people on medication like in their 30s." Still another NP stated: "I think everybody at 
some point should be screened. I think age is a big precursor I guess but again, you can’t 
put everyone out there (to be screened).”  The reality about the costs associated with 
screening was stated by another NP: “I mean you’re not going to start screening everyone 
at 18…It’s expensive too, right.” 
The second theme was components and tools identified from other successful 
provincial screening initiatives could provide successful strategies for implementing 
CASP. In NL, the provincial cervical screening program and the Diabetes Strategy 
Initiative provide good examples of successful screening in the NL context. NPs 
concurred that considering the tools used for successful NL screening initiatives would be 




the cervical screening initiative that was a huge thing in the province, and I think it’s 
worked quite well. You know something like that…” Another NP commented about tools 
being used during implementation of the Diabetes Strategy Initiative: “…. (using) the 
quick sheets like you got for diabetes… like I know with my diabetic patients I kind of 
just flip to the sheet…about what you do every 3 months, what you do every year. Like 
something like that – a quick sort of guideline thing.”  
 2.4.3 Strategies for CVD screening. There were two themes identified for 
potential strategies that could be utilized for CVD screening. One theme was the 
importance of training of healthcare providers such as NPs for the implementation of the 
CASP intervention to reduce the stress of fitting this program into daily clinical practice, 
and allaying fears of not knowing or understanding correct screening process according 
to the C-CHANGE guideline. Managers and the other health professionals agreed that 
training in comprehensive CVD screening was integral to success of the program. One 
HCP stated: “The important part here is they are quite familiar with the current guidelines 
and …they have to have a very good working knowledge of the tools like the 
Framingham, the heart score and whatever tools are available.” Having standardized 
training could ensure the consistent implementation of the intervention by HCPs. 
 The other strategy that emerged as a theme from the focus groups and interviews 
with patients, HCPs, and managers was the importance of making the public aware of the 
importance of CVD screening so to address the challenge of patient engagement and 
participation in the CASP intervention. The need for a public awareness campaign and a 




and sustainability of CASP. One NP stated: “…you could have the faces of different 
people on the side of the Metrobus to bring awareness of the importance of screening”. 
Another healthcare provider said: “you need to get this out into the public to let the 
people know-you need a champion.” One member of the public stated, and others in the 
group agreed, with the following: “…why not have a screening clinic just like we have 
flu clinics…that will get our attention.” 
2.5 Development of CASP 
 The CASP intervention was developed by selecting the TDF domains (described 
in the next section) to match the barriers and facilitators themes from the interviews, and 
focus groups, then choosing behaviour change techniques (BCTs) from a valid taxonomy, 
and confirming the modes of delivery and content. A summary of the barriers, 
facilitators, and strategy themes from our qualitative study, the theoretical domains 
selected from the TDF and the intervention components including the modes of delivery 
used can be found in Table 2.2 Application of the Theoretical Domains Framework for 
the Development of the Cardiovascular Assessment Screening Program (CASP). One 
example from Table 2.2 is used in this section to illustrate how the TDF and the BCT 
taxonomy were applied and the modes of delivery and content were selected in the 
process CASP development.  
2.6 Using the Theoretical Domains Framework 
The TDF was used as a framework to inform the development and 




framework, was important to ensure that the CASP intervention was informed by proven 
domains to enhance clinician behaviour change and our implementation research study 
(Cane, O’Conner, & Michie, 2012). The TDF was applied to the themes that were already 
derived from the qualitative data analysis of the focus groups and interviews based on the 
stated research questions for our study. The TDF did not inform the interview guides as 
such or data analysis in keeping with the interpretive description. The interpretive 
description methodological approach encourages the researcher to immerse themselves in 
the data to construct themes based on the stated research question(s), rather than 
following prescriptive interview guides according to rigid frameworks.  
The TDF contains a set of 14 domains covering the main factors influencing 
practitioner clinical behaviour: professional role and identity; knowledge; skills; 
motivation and goals; emotions; memory, attention and decision processes; beliefs about 
capability; beliefs about consequences; optimism; reinforcement; intentions; behavioural 
regulation; social influences; environmental context and resources (Cane et al., 2012; 
French et al., 2012; Michie et al., 2005). In our research, eight of the 14 theoretical 
domains of the TDF were relevant to the themes from the qualitative study and were 
deemed important by researchers to the development of the CASP screening intervention. 
The eight domains selected to enhance clinician behaviour change were the following: 
professional role and identity; knowledge; skills; motivation and goals; emotions; beliefs 
about capability; beliefs about consequences; social influences; and environmental 
context. Table 2.2 summarizes the application of the TDF for the development of CASP 




shown in the first column of Table 2.2 was lack of knowledge and skills for 
comprehensive screening using C-CHANGE guideline. This barrier operates within the 
two theoretical domains of Knowledge and Skills as shown in the second column of 
Table 2.2. 
2.7 Behaviour Change Techniques 
BCTs were developed and organized into an extensive taxonomy of techniques 
for use in behavioural change interventions following an international consensus of 93 
distinct BCTs organized into 16 clusters (Michie et al., 2013). BCTs are reproducible, 
observable actions used alone or in combination to explain the process used to change 
professional behaviour (or changes within organizations) during implementation of the 
intervention. Following the identification of the TDF domains associated with the 
identified barriers and facilitators, the next step was to select the BCTs for our research. 
The structural taxonomy of BCTs by Michie et al. (2013) was used during this study as 
similarly described for other behaviour change interventions found in the literature 
(Backman et al, 2015; French et al, 2012). The BCTs were not prioritized in any specific 
order, but are listed in Table 2.2 according to the themes and the identified domains. In 
the example from Table 2.2, column three shows the change technique that was selected 
from the BCT taxonomy that was “shaping knowledge, instructions on how to perform a 
behaviour” (within the Knowledge and Skills domains) to overcome the barrier of lack of 
NP knowledge and to provide a pathway to changing behaviour. For example, shaping 
NP cognitive knowledge occurred through access to information on performing 




waist circumference accurately using a colourful illustration provided the instructions on 
performing this specific behaviour in the online education module. 
2.8 Modes of Delivery and Content 
The modes of delivery for the intervention were determined by the researchers 
based on the literature review of effective interventions, focus groups and interviews with 
key stakeholders, and available resources in terms of the feasibility and practicality, 
within the NL context. The methods or modes of delivery as described by Michie et al. 
(2013) are procedures for the delivery of the content of the intervention. Modes of 
delivery such as webinars, websites, and online resources can provide information that 
could potentially encourage change in the behaviour of the clinician. Following the above 
example, column 3 in Table 2.2 shows the modes of delivery for the intervention content 
to enhance NP knowledge and skills. They were the following: a webinar, an online 
education module, the CASP website, and other online resources. 
Column 3 of Table 2.2 also provides examples of the content of the CASP 
intervention to be delivered. Following the example from above, the content covered to 
enhance the knowledge and skills of the NPs included background information on CVD 
screening and access to an interactive decision algorithm based on the C-CHANGE 
guideline. Other content contained in CASP was a HCP Toolkit and other resources for 
NPs to use during the screening process. This intervention content addressed the 




Table 2. 2 Application of the Theoretical Domains Framework for the Development 































BCT: Shaping knowledge; 
instruction on how to 
perform a behaviour 
 
Mode: Webinar, Online 
education module, CASP 
Website with tools, 
resources, and the 
interactive C-CHANGE 
guideline algorithm. CVD 




information on CVD 
screening, and access to 
clinical practice guidelines 
(C-CHANGE). NP Toolkit 
(Provided resources and 
materials for NP behaviour 
change related to the 




▪ NPs believed that it 
was easy to identify 
patients to screen and 
to access C-CHANGE 
in CASP. 
▪ Communication of 
screening test results 
with patients and 
individualized goal-
setting was considered 
important for the NPs. 
▪ 90% of the patients in 
the intervention group 
had 9-10 risk factors 
documented vs only 2% 
of patients’ charts had 
documented risk factors 
in the control group. 
▪ CASP was effective in 
promoting 
comprehensiveness of 
screening by NPs 
compared to usual care 
RR = 43.9, 95% CI 












BCT: Goals and planning-
discrepancy between 
current behaviour and 
standard of practice 
 
Mode: Webinar; One-on-
one facilitator support; 
Online education module  
 
Content: NP role in CVD 
screening, health 
promotion, adherence to 
clinical practice guidelines, 
and access to relevant 
nursing research. ARNNL 
NP Standards of Practice 
▪ All NPs agreed that 
CVD screening of 
adults was important, 
however, at baseline, 
most NPs (75%) 
believed that doing 
CVD screening in 




CASP, NPs in the 
intervention group 
believed that CVD 














state the role of NPs to 
integrate health promotion 
at the individual and 
community level in clinical 
practice and research. 
do in daily clinical 
practice and all NPs 
(100%) believed that it 
was easy to access 
CPGs for following up 
on results of screening 
for CVD.  
 
Questioning 
the necessity of 
CVD screening 







BCT: Goals and planning-




questionnaires given to 
NPs. 
 
Content: CASP contained 
information that was in 
congruent with the 
Choosing Wisely 
recommendations.  
▪ Post intervention NP 
questionnaires 
indicated that screening 
according to the 
Choosing Wisely 
Campaign was more 
important in the NP 
intervention group 
(100%) compared to 
the NP control group 
(66%). 


























BCT: Commitment; Social 
support. 
  
MODE: Email and phone 
calls; Webinar; Online 
access to facilitator and 








online resources for easy 
access and to reduce time 
and costs associated with 
NP participation in 
screening process. Ongoing 
support from designated 
CASP facilitator and 
technical support during 
intervention 
implementation. 
▪ NPs in the intervention 
group initially felt that 
the organization did not 
consider CVD 
screening a priority. 
Post intervention NPs 
indicated that they felt 
support from the health 
organization for 
participating in CASP.  
 
▪ At baseline, all NPs 
(100%) thought it was 
difficult to find time to 
screen patients. Post 
intervention, only half 
of the NPs (50%) 
believed it was difficult 
























restructuring the physical 
environment 
 
MODE: Online CASP 
website accessible to HCPs 
and separate access for 
members of the public. 
 
Content: The CASP 
intervention and other 
resources for NPs and 
patients in urban and rural 
remote areas of NL. 
Resources to promote heart 
health for screening and 
management and self-
management. 
▪ All NPs (100%) in the 
intervention group were 
able to access the 
CASP website, HCPs’ 
toolkit, and other CASP 
resources. Most 
patients (69%) who 
responded to the post 
questionnaires utilized 
the CASP website. 
▪ All NPs (100%) in the 
intervention group 
utilized the online 
CASP resources and 
HCP Toolkit provided 
to screen and follow-up 
with patients in various 
locations across NL to 
provide better access to 
screening and 














MODE: Online educational 
module containing 
PowerPoint presentation. 
Content: Focused on 
behaviour change of NPs 
and behaviour change of 
patients. Focused on the 
application of the Trans 
Theoretical Model and 
motivational interviewing 
techniques for NP 
behaviour change. 
Assessing the patient’s self-
efficacy would be 
important to determine 
motivation to change 
behaviour. Access to My 
Heart Healthy Plan that is 
focused on a patient-
▪ All NPs (100%) in the 
intervention group 
versus a few in the 
control group 
documented priorities 
for CVD prevention. 
▪ Patients were able to 
identify priorities for 
action using My Heart 
Healthy Plan.  
▪ There was 94% 
congruence between 
NP and patient 
priorities for action to 














centred approach where the 
onus is on patient self-
management and patient 
control of decision-making 
and goals for behaviour 
change to assist the NP. 
Knowing who 
to screen for 
CVD was 








BCT: Action planning 
(including implementation 
intentions); Shaping 
knowledge (instruction on 
how to perform a 
behaviour). 
 
MODE: Access to CASP 
resources for 
implementation of the 
intervention, CASP 




Content: Access to the C-
CHANGE guideline using 
interactive algorithm to 
assist in determining who 
and when to screen for 
CVD. Access to the CVD 
database that outlines what 
data needed to be collected 
for comprehensive 
screening and when that 
data needed to be collected 
by NPs. The Access 
Database also provided a 
place to document findings 
of CVD screening and 
management. 
▪ In the NP practices, the 
Heart Health 
Assessment Pamphlet 
was used for the initial 
CVD screening and 
96% of patients thought 
it was easy to complete.  
▪ All NPs (100%) could 
determine eligibility of 
who and when to 
screen individual 
patients by utilizing the 
Eligibility to Screen 
Forms A and B 
provided in CASP.  
▪ The CVD database was 
used by NPs (100%) to 
document findings 
related to CVD 
screening, NP and 
patient priorities, 



















BCT: Goals and planning-
problem-solving 
 
MODE: Access to 
resources for providers and 
patients through the NP 
Toolkit and CASP Website, 
▪ Results in the post-
questionnaires indicate 
that NPs utilized 
resources available in 
the CASP intervention. 
NPs used the CASP 


















online links to other 
resources.  
 
Content: Use of the CASP 
resources such as Heart 
Health Pamphlet, patient 
education materials and 
screening tools for NPs to 
use in daily practice. 
health providers’ 




























instruction on how to 
perform a behaviour; 







Support from researchers 
through various means. 
Online support from CASP 
Website, online support 
through Educational 
Resource, online CVD 
database. 
 
Content: Introduction of 
the educational module and 




contained videos on correct 
technique on how to do 
skills correctly according to 
CPGs. Support available to 
NPs participating in by 
CASP facilitator through 
email, phone, or in-person 
during CASP study 
implementation and 
availability of online 
resources. 
▪ All NPs (100%) 
participated in training, 
webinars, utilized the 
educational resource to 
gain the necessary 
knowledge and skills 
for successful 
implementation of the 




























restructuring the physical 
environment, changing 
exposure to the cues for the 
behaviour 
 
MODE: NP Toolkit, Send 
materials to various RHAs, 
posters, pamphlets, media 
campaigns. 
 
Content: Distribution of 
Heart Healthy Posters in a 
regional health authorities, 
grocery stores, community 
centres, etc. across the 
province of NL. NPs 
advertising specific days 
for CVD screening clinics. 
 
▪ Providing access to the 
CASP study across NL, 
patients were informed 
about the importance of 
heart health screening 
and encouraged to 
identify priorities and 
decide on goals for 
action to improve heart 
health. 
*The CASP intervention components contain the following: the BCT: behaviour change technique, 
MODE: how the technique was delivered, and Content: what specific information was delivered (Michie et 
al., 2013). The BCT, MODE, and Content selected address the modifiable barriers and facilitators to 
promote behaviour change of the healthcare provider. 
 
2.9 The CASP Intervention 
The researchers developed an original logic model for the CVD screening 
program based on the literature and this original model was further refined following the 
completion of the mixed methods research study. The original model provided a way for 
our researchers to represent or conceptualize the components of a successful CVD 
screening program. At the centre of this model was depicted the screening program and 
strategies were needed for identifying patients, screening patients, and actions for 




support; provider education and training; and continuous patient collaboration, in order 
for the program to lead to increased comprehensive screening in our province. Appendix 
B contains the original logic model.  
Figure 2.1 shows the refined logic model for CASP, which was developed based 
on the original model; evidence and analysis from phase 1 then further refined following 
implementation of the intervention in phase 2 and the integration of the results in phase 3. 
The revised screening program has several interrelated elements with processes and 
resources for identifying, screening, and following up with patients by HCPs taking 
appropriate actions. Overall, in the environmental context of organizational support, 
implementation of the screening process by the NPs who will receive appropriate 
education and training, in collaboration with patients throughout the screening process, 
should lead to increased comprehensive CVD screening by NPs and enhanced 
individualized patient goal setting.  
 





2.9.1 The screening program. Central to the program is the implementation of 
the CASP screening process with patients that has three steps as described in this section.  
 2.9.1.1 Step 1. The first step in the screening program involves the identification 
of patients aged 40-74 years that come into NP practice for care. Age-eligible patients are 
then given a Heart Health Assessment (HHA) pamphlet with the Heart Disease and 
Stroke Risk Profile questions to complete (risk assessment profile questions adapted from 
the Cardiovascular Health Assessment Program with permission). To determine whether 
patients are appropriate to be screened, the NPs uses the HHA risk profile, the Eligibility 
for Heart Health Screening Form A and the Decision to Screen Form B. Appendix F 
contains the HHA pamphlet, Eligibility for Heart Health Screening Form A, and the 
Decision to Screen Form B.  
2.9.1.2 Step 2. The second step involves screening by the NPs once the patients 
have been identified as eligible. The NPs use an interactive website and an online 
decision tool created by our researchers to simplify the screening process according to 
current CPGs. The NPs complete the specific components of screening checklist for each 
eligible patient and enter the data into the CVD database designed for CASP.  
2.9.1.3 Step 3. The last step involves actions by the NPs to follow-up with the 
results of the screening tests. Those patients at CVD risk require appropriate follow-up on 
lifestyle recommendations, medications, referral to interprofessional team members, or 
further diagnostic tests. The NPs’ recommendations are based on the most recent CPGs 




CASP website according to health condition. Counselling on behaviour change utilizing 
motivational interviewing assists NPs and patients to improve individualized goal setting 
utilizing the My Heart Healthy Plan. Appendix E contains My Heart Healthy Plan. 
Resources and external links on motivational interviewing techniques and assessing the 
patient’s readiness to change according to the trans-theoretical model using the readiness 
to change ruler developed by researchers, were available to NPs in the CASP 
intervention. Assessing the patient’s self-efficacy would be important way to determine 
level of motivation for behaviour change (Rollnick, Miller and Butler, 2008). Scheduling 
of regular follow-up appointments assists the patient and NP to achieve individualized 
goals that have been developed. 
2.9.2 CASP intervention components. The logic model in Figure 2.1 shows that 
the CASP intervention is comprised of four components: educational resources, an 
interactive website, healthcare providers’ toolkit and the CVD database. These were 
identified as key modes of delivery for the intervention content to promote a change in 
the screening behaviour of the NPs. These components were used to address the 
educational needs of the NPs, streamline the screening process for efficiency since time 
was a concern, and share key tools and strategies for CVD screening. The CASP 
components were available in an electronic format and this provided feasible access to 
screening services within the community practice settings, even in rural and remote areas 
addressing the identified barrier of lack of access to services. The CASP website 
contained an interactive algorithm that assisted NPs in clinical decision-making and 




into practice. Patients also had a unique code to access information on the CASP website. 
Both the knowledge user and patient partners on our research team were able to review 
CASP, and to provide important suggestions for improvement prior to finalizing these 
components. The development of these CASP components considered adult learning 
principles in terms of the following: a) focusing resource materials at the education level 
of NPs; b) building on prior knowledge and experiences of NPs; c) providing relevant 
information in a time-sensitive manner; and d) offering opportunities to share experiences 
to optimize the CVD screening process (Arghode, Brieger, & McLean, 2017; Hoffman, 
Klein, & Rosenzweig, 2017).  
2.9.3 Patient collaboration. At the centre of the CASP intervention is patient 
collaboration meaning that there must be patient engagement and collaboration in order 
for the CASP screening implementation to be a success. Because changing behaviour was 
identified as being difficult for patients, CASP incorporated a process for patients to 
decide what specific goals were a priority for action by completing My Heart Healthy 
Plan (adapted from the document: Checking in on my plan sheet and used with 
permission from the Centre for Collaboration, Motivation and Innovation, BC Ministry of 
Health). Appendix F contains My Heart Healthy Plan. 
2.9.4 Environmental and cultural context. The outermost section of the logic 
model depicts the environmental context, illustrating the necessity of considering the 
environmental and cultural context in the development of an intervention, which is 
consistent with the KTA Framework with guideline adaption (Harrison et al., 2013; 




2.9.5 Health organizational support and healthcare provider support. Figure 
2.1 also depicts the health organizational support and the healthcare provider support that 
is critical for CASP to be implemented. Gaining the support of key people within 
organizations and the HCPs who implement CASP is instrumental to success. Having a 
facilitator to promote and assist with the implementation of CASP throughout the 
organization is important for sustainability of this program into the future. 
2.9.6 Public awareness campaign. Lastly, for the implementation of CASP to be 
successful, a public awareness campaign that emphasized the importance of CVD 
screening for the public could lead to increased comprehensive screening and 
individualized goal-setting for heart health. There is a need to increase public awareness 
about the NP’s role in CVD screening. For this dissertation research, the public 
awareness campaign was limited to NP offices for recruitment purposes. 
2.10 Evaluation of CASP 
The second phase of the mixed methods study was an RCT that tested the 
effectiveness of the theory-informed screening intervention CASP on comprehensiveness 
of CVD screening by NPs. Ten NPs from across NL were randomized to either the 
intervention group implementing CASP (68 patients), or the control group providing 
usual care (99 patients). In addition to collecting data on comprehensiveness of screening 
and addressing screening results, questionnaires were distributed to both the NP and 
patient participants at the end of the RCT. Details of the phase 2 methods and results are 




In phase 3 of this mixed methods study, the integration of the results from phase 
2, including the feedback obtained from NPs and patients, with the results of phase 1 
were used to further refine CASP. During the integration phase, researchers evaluated 
whether the CASP intervention components addressed the barriers and facilitators 
identified in phase 1 by evaluating the completed NP and patient feedback 
questionnaires. Researchers confirmed the CASP intervention components that were 
effective strategies to change provider behaviour and to increase uptake of CVD 
screening (according to C-CHANGE). The feedback questionnaires from NPs and 
patients at the end of phase 2 were used to evaluate whether the BCTs, methods of 
delivery, and intervention content were effective in changing the behaviour of the 
clinician and increasing comprehensive CVD screening. We evaluated the results to 
determine whether there was confirmation, congruence, or discordance of the findings to 
further refine the components of the CASP intervention.   
Column 4 of Table 2.2 summarizes some key results of the RCT that are relevant 
for each of the themes identified in phase 1 as shown in column 1. Overall, CASP was 
effective in promoting comprehensiveness of screening, but it is the process-oriented 
results that are most relevant to this paper on the development of CASP. For example, all 
of the NPs in the intervention group stated post-intervention that CVD screening was 
easy to do in clinical practice utilizing the interactive algorithm with current CPGs, 
whereas 75% of all participants at baseline said it was difficult. More felt supported by 
their organization and fewer identified time as a constraint post intervention compared to 




provided during the implementation of the intervention. When following up with patients 
after the screening process was complete, the NPs shared the laboratory results, 
physiological findings, and new diagnoses with patients. Priorities for heart health were 
determined by both the NPs and their patients. There was 94% congruence between 
patients and NPs in terms of priorities for action for heart health. Individualized goals, 
documented by the patients, were supported by the NPs to improve heart health in the 
future. The CVD database facilitated documentation of patient data and NPs’ and 
patients’ priorities for action. The NPs appreciated the education and training provided 
early in the research process, and provided feedback that the education content was 
appropriate. Based on these results, few refinements were identified as being necessary to 
the processes and tools of CASP. Further implementation of CASP will however focus on 
promoting organizational support, securing a facilitator, and assessing needs for 
additional educational or other resources. Details of the results of the RCT conducted in 
phase 2 of this mixed methods study are reported elsewhere. 
2.11 Discussion 
This article has summarized the approach used for the development of the CASP 
intervention in phase 1 of a mixed-methods research study. The research problem from 
the clinical setting was addressed by conducting a qualitative research study using focus 
groups and individual interviews to obtain input on strategies and to determine the 
barriers and facilitators associated with intervention implementation and behaviour 
change of the NP in the local context.  The TDF was then applied to the themes that 




The TDF has been applied by researchers to determine barriers and facilitators to 
behaviour change, adherence to national guidelines, and other knowledge translation of 
evidence into practice (Backman et al., 2015; French et al., 2012). Many studies have 
described the barriers and facilitators of recommended practice and have utilized the TDF 
as a guide to develop interventions aimed at translating evidence from clinical guidelines 
into practice (Hofstede et al., 2013). Other studies have described the matching of the 
theoretical domains of the TDF with behaviour change techniques (Atkins et al., 2017; 
Cane, O'Connor, & Michie, 2012). Even fewer studies have described the specific modes 
of delivery for the intervention components that are relevant to clinical practice 
(Backman et al., 2015; French et al., 2012). This study also applied the TDF as a 
framework, used of the behaviour change taxonomy for BCTs and identified modes of 
delivery relevant to the local context for CASP intervention development. This research 
also adds another important element by identifying the importance of having patient buy-
in for intervention success. By engaging patients and knowledge users in the research 
process, further improvements can occur in the design, implementation, and 
dissemination of research evidence into practice. 
Our research adds to the body of knowledge of implementation science. The 
development of an intervention containing current evidence such as C-CHANGE 
guideline that can be applied in daily clinical practice is important to translate evidence 
into practice. The interactive C-CHANGE algorithm was developed as part of the CASP 
intervention to simplify the complex nature of CVD screening and to enhance provider 




can be used to enhance patient care through utilizing current evidence for CVD screening 
and can identify and manage individuals at high risk in a timely manner. Using an 
exploratory sequential mixed methods study with a knowledge translation framework 
enabled researchers to gain the perspectives of participants, and to design an intervention 
that added critical elements necessary for CVD screening that were relevant to the local 
context. Phase 3 integration confirmed that it was important to add these components to 
address the concerns and suggestions identified in phase 1 and to understand the value of 
using this research design. 
This research also adds to the nursing body of evidence by providing useful tools 
and training methods that can be utilized in a supportive environment to incorporate 
screening and management into clinical practice. NPs can add this useful screening tool 
to enhance identification and management of patients in their daily routine. New 
knowledge to enhance patient-centred care may direct more focus on the patient-driven 
priorities for action that could lead to more sustainable behaviour change and improved 
heart health in the future.  
Our study has some limitations. The qualitative research study in phase 1 that 
identified barriers and facilitators was based on a small sample of HCPs, patients, and 
administrative personnel due to the time constraints of dissertation research. The 
intervention was implemented with NPs; however, it is intended to be used by other HCP 
groups so some of the materials would need to be modified to be applicable to all HCPs 




population base, and therefore may not be generalizable to the wider Canadian 
population.  
2.12 Conclusion 
Focus groups and interviews with various key informants identified the main 
barriers and facilitators related to CVD screening and management of CVD risk factors in 
NL and influenced the development of a tailored intervention called CASP for one 
Canadian province. Using interpretive description and pragmatism as the philosophical 
basis was important to answer the clinical practice issue of knowledge translation of 
evidence into practice. The CASP intervention was further guided by the application of 
the TDF to ensure that it contained appropriate theoretical domains, informed by the BCT 
taxonomy for the selected behaviour change techniques, and had realistic modes of 
delivery or strategies for implementation in the local context. Online intervention 
components created during this research enhanced the delivery of provider information to 
promote evidence-informed practice. The use of a mixed methods study with a qualitative 
phase and the TDF helped in the development of a theory-informed intervention CASP. 
Successful testing of CASP with NPs and the integration of findings showed the value of 
the components added to be a contextually relevant intervention, a key aspect of the KTA 
Framework. Addressing the barriers, facilitators, and strategies identified in the local 
context was important for the development of an intervention that can be successfully 
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CHAPTER 3 Evaluating the Effectiveness of the CASP Intervention 
 
 
The Chapter 3 manuscript describes the results of phase 2 of the mixed methods study, the 
RCT. The intended audience is practitioners, researchers, and government officials. 
 
JB conceptualized the study, collected the data, interpreted the results, performed data 
analysis and wrote the manuscript. DM contributed to the conceptualization of the 
research design and study. DM and CD contributed to the data analysis, interpretation, 















BACKGROUND: There is inconsistent utilization of clinical practice guidelines (CPGs) 
for cardiovascular disease (CVD) screening and management by healthcare professionals 
to identify CVD risk factors early and to intervene using current recommendations. A 
mixed methods study was conducted to develop and test a novel intervention called the 
Cardiovascular Assessment Screening Program (CASP) that contained current CPGs, the 
Canadian-Cardiovascular Harmonized and National Guideline Endeavour (C-CHANGE). 
Phase 2 of the mixed methods study tested CASP with nurse practitioners (NPs) across 
one Canadian province, Newfoundland and Labrador (NL). METHODS: Ten NPs were 
recruited and then randomly allocated to either the intervention group testing CASP or 
the control group providing usual care. As a result of attrition, a total of eight NPs 
participated in the RCT. The NPs in the intervention group recruited 68 patients; 
whereas, the NPs in the control group recruited 99 to participate in the RCT. A database 
was used in the intervention group to document screening of risk factors, priorities, and 
actions; control group patients’ charts were reviewed by researchers. RESULTS: 
Comprehensiveness of screening (9 to 10 risk components) increased significantly in the 
NP intervention group using CASP versus the NP control group providing usual care 
after controlling for the effect of the NP with an adjusted RR = 43.9, 95% CI [13.3, 
144.2], p < .0001. Sixty-five percent (65%) of the patients in the intervention group were 
at moderate to high risk for having a CV event in the next 10 years; the level of CVD risk 
was unknown (96%) for control group patients. The recommendations made by 




intervention group patients developed individualized goals for heart health. 
CONCLUSION: CASP, an innovative CVD screening program, was effective to 
identify CVD risk factors early through comprehensive screening, priorities for action, 
and individualized goal-setting for heart health.  
Keywords: Clinical practice guidelines, nurse practitioner, cardiovascular, screening. 
3.2 Introduction 
Although specific guidelines for cardiovascular disease (CVD) screening are 
available in the UK, the USA, Canada, and Australia, there is inconsistent identification, 
management, and documentation of CVD risk factors by healthcare providers (HCPs) 
(Unverzagt, Oemler, Braun, & Klement, 2014). When screening for CVD risk factors, 
often single risk factors or conditions are addressed rather than using a comprehensive 
approach to identify multiple risk factors simultaneously in a systematic manner 
(Dyakova et al., 2016). Comprehensive strategies for identification and improved 
documentation of risk factors can lead to identification of individuals at high CVD risk 
and enhance management and monitoring by HCPs (Kennedy, Su, Pears, Walmsley, & 
Roderick, 2019). Improvements in the communication between providers and patients 
about CVD risk factors can lead to identification of priorities and individualized goal-
setting to improve heart health and to promote healthy aging. 
Although a variety of HCPs are involved in CVD screening, the focus of this 
study was on the role that nurse practitioners (NPs) perform in CVD screening, 




identify risk factors, order specific diagnostic tests, prescribe current therapies, refer 
patients to other team members, and engage in individualized counseling to contribute to 
the reduction of CVD morbidity and improve health outcomes (Farrell & Keeping-Burke, 
2014). NPs work in both urban and rural settings and they are often the only providers in 
very remote areas. Patients in these remote rural areas may otherwise have difficulty 
accessing appropriate CVD risk factor assessment and management. 
Reported elsewhere, the qualitative findings of a mixed methods study were used 
to inform the development of the Cardiovascular Assessment Screening Program 
(CASP). In phase 1 of a mixed methods study, a theory-informed intervention CASP, was 
developed. The methodological philosophy of interpretive description (Thorne, 2016) and 
pragmatism were embraced as the foundation for this mixed methods research study to 
derive new nursing knowledge and to better understand the real-life issue from the 
clinical context (Thorne, 2016). The results of phase 1 are reported elsewhere. This 
article reports on the results of phase 2 of a mixed methods study in which an randomized 
controlled trial (RCT) was conducted to determine whether implementation of CASP by 
NPs resulted in increased comprehensive CVD screening of community dwelling adults 
aged 40-74 years without established vascular disease. 
3.3 Background 
CVD screening and management is critically important since CVD causes 
significant mortality and morbidity worldwide (WHO, 2017). Finding strategies to 




reduce the CVD burden and to promote healthy aging. Criteria outlined and published 
originally by WHO, and later revised by the National Screening Committee (NSC) in the 
UK described principles that should be met before screening for a disease or condition 
(NSC, 2013). According to the UK model, criteria for appraising the viability, 
effectiveness, and appropriateness of a screening program are the following: a) the 
condition must be an important public health problem, b) the screening test(s) must be 
simple and valid, c) the treatment for the condition must be effective, and d) there must 
be evidence that screening for the condition can reduce morbidity and mortality. 
Screening for CVD meets the criteria set out in the UK model for screening based on the 
original WHO Report.  
CVD is an important health problem causing significant mortality and morbidity 
that with effective screening and management of risk factors, can lead to better patient 
outcomes. More people die annually from CVD than from any other cause; CVD is the 
number one cause of death globally (WHO, 2017). The morbidity caused by CVD has a 
significant impact on individuals, families, and communities. Costs are related to high 
rates of hospitalization, disability, drug utilization, and invasive diagnostic procedures; 
CVD also causes significant decrease in the quality of life for many individuals and 
families (Canadian Institute for Health Information, 2014).  
Screening tests used in a timely manner for the identification of CVD risk 
conditions such as dyslipidemia or hypertension can prevent further escalating costs and 
burden to the healthcare system (Anderson et al., 2013; Lindsay et al., 2013; Grover & 




and acceptable to the population. For example, screening for hypertension using a BP 
monitor is a valid and reliable test. Also, screening for other CVD risk factors such as 
diabetes and dyslipidemia meet the requirements of a simple, safe, and precise 
measurement process. Because screening for CVD is so complex, measuring risk factors 
singly is not enough; it is also important to consider total or global CV risk such as the 
Framingham Risk Score (FRS) or other risk assessment scores validated for different 
populations (Willis, Davies, Yates, & Khunti, 2012; Grover & Lowensteyn, 2011).  
Earlier treatment of CVD leads to better outcomes than later treatment, thus 
earlier detection through screening is warranted (National Screening Program, 2014). 
There are effective treatments available for each modifiable risk factor for CVD. For 
example, optimizing insulin dosage for the treatment of Type 2 diabetes can significantly 
reduce morbidity (Zinman et al., 2015). A systematic review of systematic reviews 
provides evidence of a decrease in morbidity and mortality associated with screening and 
management of individual risk factors for CVD (Alvarez-Bueno et al., 2015).  
In summary, CVD is a significant public health problem with validated and 
acceptable screening tests to detect CVD. There are effective treatments available for 
identified risk factors and evidence that screening programs can reduce risk of CVD 







3.4 Current CVD Screening Initiatives 
There are three main examples of CVD screening initiatives at the population 
level, notably those in the UK, the USA, and Australia, that involved screening for CVD 
and other chronic conditions. In the UK, HCPs are mandated to offer the National Health 
Service (NHS) Health Check Program to healthy adults aged 40-74 years who have no 
prior diagnosis of CVD (NHS, 2015). In the USA, the Million Hearts Initiative (MHI), a 
federally funded nation-wide initiative focused on primary and secondary CVD 
prevention was initially aimed to prevent one million MIs and CVAs over five years from 
2011-2017. Centers for Disease Control (CDC) Reports claim that half a million people 
have been saved thus far with this initiative that has recently been extended until 2022 
(CDC, 2019). In Australia, a Health Check Program has recently been launched with the 
intention to detect, treat, and reduce the CVD burden in the population (National Heart 
Foundation of Australia, 2020). However, in Canada, there has been no national 
comprehensive program implemented although there are separate initiatives presently 
occurring at the provincial level.  
These national programs have been shown to be effective for CVD prevention in 
their countries of origin, but they may not be relevant or easily adopted in different 
contexts. There is one provincial initiative ongoing in Canada that has been shown to be 
effective called the Cardiovascular Health Awareness Program (CHAP). This provincial 
initiative began in Ontario about 10 years ago and has a target population of adults aged 
65 years and older. CHAP is a community-based initiative that is limited in scope since it 




information about other key risk factors such as smoking and dietary habits are captured 
through a screening questionnaire. CHAP volunteers then communicate abnormal BP 
findings to primary care providers for follow-up (Kaczorowski et al., 2011). 
Despite having current CPGs available for CVD prevention, screening, and 
management, there is inconsistent implementation of guidelines (Unverzagt, Oemler, 
Braun, & Klement 2014). We do not know specifically about uptake of CVD screening 
guidelines because of a lack of prevalence data on screening rates. There is also concern 
about implementation of the comprehensive C-CHANGE guideline by HCPs in clinical 
practice (S. Tobe, personal communication, October 12, 2017). Finding innovative ways 
to enhance guideline awareness and implementation that is relevant to the context can 
potentially optimize patient outcomes and reduce CVD morbidity and mortality. 
The Knowledge to Action (KTA) Framework (Graham et al., 2006) with 
guideline adaption (Harrison et al., 2013) was used to guide the development, 
implementation, and evaluation of the CASP intervention. The KTA Framework 
emphasizes the importance of the alignment of any intervention based on expert 
knowledge with the local context, practice, and system. In phase 1 of this mixed methods 
study, the qualitative phase, the CASP intervention was developed following the 
exploration of the barriers, facilitators, and strategies related to CVD screening through 
focus groups and interviews with patients, providers, and administrators locally. This 
article is focused on the results of the quantitative phase 2 of the study, an RCT to 




consistent with the final stage of the KTA cycle to monitor the knowledge use and to 
evaluate the implementation process.  
3.5 The CASP Intervention 
The development of the CASP intervention was intended to simplify the complex 
nature of screening for CVD to make it more user-friendly and to enhance provider 
adherence and effective decision-making according to current evidence. CASP is a novel 
intervention utilizing an innovative algorithm based on the Canadian Cardiovascular 
Harmonized National Guidelines Endeavour (C-CHANGE) 2018 to enhance the ability 
of HCPs to identify and manage individuals at CVD risk using current evidence in a 
timelier manner. The logic model for CASP is shown in Figure 3.1 and in Appendix B. 
 
Figure 3.1 Logic model of the Cardiovascular Assessment Screening Program 
(CASP) 
Overall, within the environmental context of organizational support, 
implementation of the screening process by the NPs who receive appropriate education 
and training, including patient collaboration throughout the screening process should lead 




goal setting. Central to the program is the implementation of the CASP screening process 
with patient collaboration.  
Step 1 of the screening process involves the identification of patients aged 40-74 
years that come into NP practice for care. Age-eligible patients are then given a Heart 
Health Assessment (HHA) pamphlet with the Heart Disease and Stroke Risk Profile 
questions to complete (risk assessment profile questions adapted from the Cardiovascular 
Health Assessment Program with permission). To determine whether patients are 
appropriate to be screened, the NPs uses the HHA risk profile, the Eligibility for Heart 
Health Screening Form A, and the Decision to Screen Form B. Appendix F contains the 
HHA pamphlet, the Eligibility for Heart Health Screening Form A, and the Decision to 
Screen Form B.  
Step 2 involves screening by the NPs once the patients had been identified as 
eligible. The NPs use an interactive website and an online decision tool created by our 
researchers to simplify the screening process according to current CPGs. The NPs 
complete the specific components of screening checklist for each eligible patient and 
enter the data into the CVD database designed for CASP.  
Step 3 involves actions by the NPs to follow-up with the results of the screening 
tests. Those patients at CVD risk require appropriate follow-up on lifestyle 
recommendations, medications, referral to interprofessional team members, or further 
diagnostic tests. The NPs’ recommendations are based on the most recent CPGs 




CASP website according to health condition. Counselling on behaviour change utilizing 
motivational interviewing assists NPs and patients to improve individualized goal setting 
utilizing the My Heart Healthy Plan. Appendix E contains My Heart Healthy Plan. 
Scheduling of regular follow-up appointments assists the patient and NP to achieve 
individualized goals that have been developed. 
The CASP intervention consists of four main components: an educational 
resource, an interactive website, a health providers’ toolkit, and a CVD database. The 
educational resource consists of an online module to enhance providers’ knowledge of 
CVD, screening, and the use of assessment tools and devices. Another component is an 
interactive website that houses the C-CHANGE algorithm decision tree to simplify the C-
CHANGE guideline to assist practitioners in clinical decision-making based on the most 
current evidence. The website also contains a separate section for patient use that 
provides access to provincial resources and contact information. The third component of 
CASP intervention is a health providers’ toolkit that contained devices for risk 
assessment such an automated BP monitor (if not already available in the office setting), 
digital weigh scales, measuring tape, handouts, and brochures for patient counselling. 
The fourth component is an electronic CVD database created by researchers with 
technical assistance from the Newfoundland and Labrador Centre for Health Information 
(NLCHI) for this study. This database was used by NPs implementing CASP to record 
patient data electronically, guide them through the key steps of screening, and to transfer 




patient partners on our research team were able to review the CASP and to provide 
important suggestions for improvement prior to finalizing these components. 
CASP provides a comprehensive approach to CVD screening to simplify the 
process of identifying and managing CV risk factors in a timely manner. CASP focuses 
on changing providers’ behaviour and enhancing patient-provider interactions to reduce 
CVD risk with the goal of improving heart health and promoting healthy aging. 
3.6 The RCT Study 
3.6.1 Aims. 
3.6.1.1 Primary aim. Aim 1: To determine whether implementation of CASP 
resulted in increased comprehensiveness of CVD screening. 
Hypothesis (Ho): There will be no difference in comprehensiveness of CVD screening 
between the NP intervention group, compared to the NP control group providing usual 
care. 
3.6.1.2 Secondary aims. Aim 2: To evaluate whether or not implementation of 
CASP led to identifying multiple CVD risk factors and determining the patients’ level of 
CVD risk in comparison to the control group. 
Aim 3: To evaluate NPs’ and patients’ priorities for heart health based on implementation 
of the CASP intervention compared to usual care. 




3.6.2 Design. A two-group, non-blinded, randomized controlled trial design was 
conducted. Block randomization was completed to allocate the NPs from the four 
Regional Health Authorities across NL into either the intervention or the control group. 
Using a random number generator in STATA, NPs (with patient participants) were 
allocated to either the intervention or control group (STATA, 2013). The RCT consisted 
of an eight-month screening and follow-up period with NPs screening and following up 
with patients in community-based settings in the intervention group. Visits to four clinics 
by the principal investigator (PI) were carried out in different community clinics to 
complete reviews on charts of the control group patients.   
3.6.3 Setting and participants. 
3.6.3.1 Community-based clinics. Community-based clinical practices in four 
regional health authorities across Newfoundland and Labrador (NL) participated in this 
trial.  
3.6.3.2 Nurse practitioners. A convenience sample of ten NPs were recruited to 
participate in this study. Inclusion criteria for NPs were that each NP had to be practicing 
in a community clinic setting with access to healthy, asymptomatic patients between the 
ages of 40 and 74 years. NPs had to have the ability to collect the patient data and to be 
able to perform routine follow-up. Prior to the data collection period, two NPs withdrew 
from the study (one from the intervention group and one from the control group) so there 




3.6.3.3 Patients. Patients were recruited by the NPs in community-based 
practices. Inclusion criteria for the patients were the following: a) were between the ages 
of 40-74 years of age, b) had no established CVD or vascular disease, and c) were willing 
to participate in the study.  
3.6.4 Sample size calculation and randomization. The sample size estimation 
for this study was determined using the proportion of eligible patients who were 
comprehensively screened as the outcome measure of interest. A study that considered 
the effectiveness of a national risk assessment program for patients aged 40-74 years 
found that approximately 40% had complete Health Checks and 60% had partial Health 
Checks among high risk patients in the UK National Health Service Health Check 
Program (Artac et al., 2013).  The sample size for this proposed study was calculated 
based on the assumption that 40% of the screening will be comprehensive in the control 
group practices. The research team decided that comprehensive screening of 70% of 
patients seen by the NPs in the intervention group during this study would indicate an 
effective intervention. Using a two-sided alpha of 0.05 and 90% power, the sample size 
was calculated to be 250 patients (125 patients per group). Considering that patients 
would need to provide consent to participate in this study the research team assumed that 
20% of those approached would refuse. This meant that 300 patients with 150 patients 
per group would be required. To be realistic about workload, each NP would need to 
recruit 30 patients. If 10 NPs were recruited, each NP would need to recruit 30 patients. 
The duration of the data collection period varied by NP according to the number of 




recruited, NPs were allocated to either the experimental group or the control group. Since 
it was not possible to randomly allocate patients to groups, NPs were allocated and the 
effect of the NP was controlled for in the analysis. 
3.6.5 Intervention 
3.6.5.1 Intervention group. NPs randomized to the intervention group completed 
CVD screening over two patient visits using the using the CASP intervention. During the 
initial visit, the Heart Health Assessment Form was completed by the patient followed by 
a focused history and physical exam by the NP. During the follow-up visit, the NP shared 
blood work results, FRS, and heart age, and then provided an opportunity for patients to 
identify priorities and goals for a heart health action plan. 
3.6.5.2 Control group. For NPs randomized to the control group (usual care), no 
adjustments were made to the NPs’ daily routine or the usual care provided to patients. 
The NPs in the control group participated in webinar education sessions different from 
the webinar held with the intervention group, and were instructed to follow usual practice 
to screen patients for CVD. The NPs were given instructions on recruiting patients and 
obtaining consent. 
3.6.6 Outcome measures 
3.6.6.1 Primary outcome. Comprehensiveness of CVD screening by NPs was 
assessed following implementation of the CASP intervention at the completion of the 
trial period. The number of risk components screened for was calculated. These 




obtaining blood work results, or computing the FRS in accordance standard instructions 
provided in the CVD database. Comprehensive CVD screening by NPs required nine or 
ten of the following risk components to be documented during study implementation: a) 
patient’s age, b) family history of premature coronary artery disease (CAD), c) FRS, d) 
smoking status, e) body mass index (BMI), f) waist circumference, g) blood pressure 
(BP), h) lipid profile, i) A1C, and j) stress. If six to eight of the risk components were 
documented then this was considered to be a moderate level of screening. If NPs obtained 
only three to five risk components, this was categorized as limited screening. Minimal 
screening was defined as obtaining only one or two risk components.  
3.6.6.2 Secondary outcomes. The secondary outcomes were the following: the 
identification of multiple CVD risk factors and determining the patients’ level of CVD 
risk using the FRS; the identification of NPs’ and patients’ priorities for heart health; and 
gaining the NPs’ and patients’ experiences with the CASP intervention.   
3.6.7 Data collection. The collection of patient data for the RCT was different for 
the NP intervention group compared to the NP control group. For the intervention group, 
NPs documented patient data in the CVD database. At the end of the data collection 
period, the database files on which the NPs documented were securely transferred to 
NLCHI to be de-identification prior to being sent to the researchers for analysis.  
In contrast, for the NPs in the control group the researchers made arrangements 
with the NPs in designated communities to review the charts of those patients who had 




researchers, was used by the researchers to obtain information from the patients’ charts. 
Examples of the type of information extracted from the patients’ charts were the 
following: demographics, history and physical findings, physiological measurements, 
laboratory data, and NP recommendations for patient care during clinical visits. The 
Chart Review Form can be found in Appendix F. 
At the end of data collection period, the NPs in both the intervention group and 
the control group gave each participant a Patient Feedback Questionnaire Form to 
complete and mail back to the researcher in a pre-paid envelope. This questionnaire was 
developed by the researchers and was pre-tested with patient partners for content validity. 
The Patient Feedback Questionnaire Form for the intervention group patients contained 
Likert-type questions and short answer questions related to their experiences participating 
in CASP. The feedback form completed by the control group patients had different 
Likert-type questions about their interest in participating in a CVD screening program in 
the future. The Patient Feedback Questionnaire Forms can be found in Appendix F.   
Feedback was obtained from all the NPs on their experiences in participating in 
the RCT using NP Feedback Questionnaires developed by the researchers. The NP 
participants were sent the feedback questionnaires electronically to be returned 
confidentially to the Nursing Research Unit at Memorial University.  The NP Feedback 
Questionnaires were different for the NPs in the intervention group compared to the 
control group. Both NP questionnaires contained a series of questions that were asked 
previously on the NP Profile Questionnaire (pre-questionnaire). The researchers were 




the NPs’ knowledge, attitudes, and behaviour post-intervention. The remaining questions 
on the questionnaires were related to either the NPs’ experiences being involved in the 
intervention or the control arm of the RCT. The questionnaires contained both Likert-
type questions and short answer questions. Appendix F contains the NP Profile 
Questionnaire and the NP Feedback Questionnaires for the intervention and control 
groups. 
3.6.8 Endpoints. Data collection was completed once the NPs had enrolled and 
screened thirty (30) patient participants each or at the end date of the data collection for 
the study, November 2018. 
3.6.9 Validity, reliability, and rigour. Multiple strategies were used to recruit 
NPs and patients from a variety of locations across the province of NL to ensure that 
study participants were representative of the target population. To minimize selection 
bias, the recruitment process was the same for NP participants in both groups and they 
were assessed and found to have similar baseline characteristics. 
A number of measures were taken to address the threats to internal validity. The 
NPs were not blinded, but trained in data collection and adhered to procedures explained. 
Some of the tools and instruments used were known to be valid and reliable, for example, 
the FRS, patients’ blood tests, and standardized methods to obtain electronic BP 
measurements. Other measures such as the CVD database and data extraction form, used 




To control for confounding, several strategies were used. NPs in the intervention 
and control groups were assessed for similarities at baseline. Block randomization was 
used to allocate NP practices to either the intervention or control group. Appropriate 
statistical testing was used to control for the effect of the NP and the study had adequate 
power to detect statistically significant differences. The rigour of the study was therefore 
enhanced because of the methods used to minimize selection bias and key threats to 
internal validity, control for confounding, and promoting statistical conclusion validity. 
3.6.10 Ethical considerations. Approval was obtained from the Health Research 
Ethics Board (HREB) and the Research Proposal Approval Committees (RPACs) in the 
regional health authorities prior to commencement of the study. Key ethical 
considerations of potential risks and benefits, informed consent, confidentiality, and cost 
considerations were addressed.  
The potential benefits and risks of participating in the study were clearly outlined 
on the NP and patient consent forms. Appendix F contains the consent forms for the NPs 
and patient participants. 
3.6.11 Data analysis. The data collected were analyzed using Stata 13 statistical 
software (STATA, 2013). The relative risk was calculated for the primary outcome using 
generalized linear modelling to control for the effect of the NP.   
Descriptive statistics were used to compare differences between the intervention 
and the control group in terms of the identification of patients at risk for CVD, the 




NPs. Differences between patient baseline characteristics were tested using 2. Content 
analysis was done on the responses to the short answer questions on the NP and patient 
feedback questionnaires to assess the specific components of the screening program and 
to determine the factors that influenced patients’ and NPs’ participation in the screening 
process. 
3.7 Results of the RCT 
3.7.1 Baseline characteristics  
3.7.1.1 NP baseline characteristics. A total of eight NPs participated in the RCT 
study. The NPs in both groups were comparable in age, with most NPs over 45 years. 
Only one NP in the intervention group was in a younger age category 25-34 years. Both 
intervention and control groups were similar in gender representation with each group 
having three female NPs and one male NP. Three of the NPs in the intervention group 
had less than 10 years working as NPs compared to those NPs in the control group who 
all had over 10 years of experience. Almost all NPs were involved in professional 
development and attended conferences at least every three years with the exception of 
one NP in the intervention group that reported rarely attending conferences. Although 
there were some variation in the NPs’ baseline characteristics, these were controlled for 
in the statistical analysis. 
The study was conducted in eight community-based practices in four regional 
health authorities (RHAs) across the province of NL, Canada. The NPs in the 




group, there were three NP participants in Eastern Health (EH) and one NP participant in 
Central Health (CH), with no representatives in either Western Health (WH) or Labrador-
Grenfell Health (LGH). The NP Profile Questionnaire (pre-questionnaire) was given to 
the NPs in the intervention group and the control group after consent was obtained, to 
determine baseline knowledge, attitudes, and behaviour related to CVD screening. At 
baseline, all NPs agreed that screening for CVD was important, but that there was limited 
time to do so in daily clinical practice. The importance of screening according to 
Choosing Wisely Campaign was important to all NPs in the intervention group and 66% 
of those in the control group. Most NPs (75%) in the intervention group disagreed that 
CVD screening was easy to do in daily clinical practice compared to 100% of NPs in the 
control group who thought that screening was easy to do. At baseline, some NPs in the 
intervention group (25%), and control group (33%), thought that accessing current CPGs 
to follow up on the results of CVD screening with patients was difficult to do. 
3.7.1.2 Patient baseline characteristics. There were 167 patient participants in 
total, with 68 patients in the intervention group and 99 patients in the control group. We 
did not obtain the planned number of patients because of the time limitations of 
dissertation research. As shown in Table 3.1, baseline characteristics of patient 
participants in the intervention and control groups were similar with the exception of the 
distribution of patients across NL. In the intervention group, patient participants were 
equally distributed throughout all regional health authorities; the patient participants in 
the control group were from two regional health authorities only, namely Eastern Health 




control group in terms of education, age, and gender. Table 3.1 also shows the results of 
patients’ documented comorbidities for the intervention group compared to the control 
group. There was considerable variation in the proportion of the patients with 
comorbidities in the NP practices. In the intervention group NP practices, there were 
similar proportions of patients with renal dysfunction and dyslipidemia and more 
variation for hypertension and diabetes. The intervention group had a higher proportion 
of comorbidities documented compared to the control group participants. In the control 
group, comorbidities were unknown in 21% to 66% of the patients because of lack of 
documentation in the patients’ charts, compared to fewer than 10% of patients in the 
intervention group having unknown comorbidities, which were documented in the CVD 
database. Between group differences were compared using 2. 
Table 3. 1 Baseline Characteristics of Patient Participants 
Baseline Characteristics 
 




Eastern  14.1% (10) 69.7% (69) 
Central  16.9% (12) 30.3% (30) 
Western  42.2% (30) 0% (0) 
Labrador-Grenfell  26.8% (19) 0% (0) 
     
Education Less than high school  26.7% (19) 46% (6) 
High school  45.1% (32) 38.4% (5) 
Undergraduate   21.1% (15) 15.4% (2) 
Graduate degree  7% (5) 0% (0) 
     
Age Mean  55 years 56 years 
Range  40-74 years 40-74 years 
     
Gender Males  25% (18) 23.2% (23) 
Females  75% (50) 76.8% (76) 
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1 % (N): the percentage and number of patients in each group with the identified characteristic; there were 
68 patients in the intervention group and 99 patients in the control group. 
 
3.7.2 Comprehensiveness of CVD screening by NPs. There was a statistically 
significant difference between intervention group NPs doing comprehensive screening 
(identifying 9-10 components) compared to control group providing usual care. A greater 
proportion of patients received comprehensive screening in the intervention group (90%; 
n=61) versus the control group (2%; n=2) RR = 43.9, 95% CI [13.4, 144.2], p < .0001, 
adjusted for the effect by NP. The patients in the intervention group much more likely (43 
times) to have comprehensive screening compared to the control group patients. The CI 
was wide, but even the lower limit was 13.4 indicates a significant effect of CASP on 
comprehensive screening. As shown in Table 3.2, all of the NPs in the intervention group 
performed moderate or comprehensive screening, as previously defined, compared to the 
control group where the majority of NPs did limited or minimal CVD screening. There 
was variation in the degree of comprehensiveness of screening by NPs in the intervention 




NPs screened comprehensively about 70-80% of the time due to extenuating 
circumstances. As an example, there were seven patients who had a moderate level of 
screening rather than comprehensive because these patients did not return for their 
follow-up appointment. Therefore, the patients did not have the required blood work 
(lipid profile and A1C level) completed or the FRS calculated for comprehensive 
screening.    
Table 3. 2  Degree of Comprehensive Screening Comparison between Groups 










   






   






   








% (N): the percentage and number of patients in each group with the identified characteristic; there were 
68 patients in the intervention group and 99 patients in the control group. 
2 Comprehensive CVD screening was based on the NPs obtaining information from the patients on 9 or 10 
of the following components: age, family history of premature coronary artery disease, Framingham Risk 
Score, smoking status, body mass index, waist circumference, blood pressure, lipid profile, A1C, and 
stress. 
3 Screening was categorized as moderate if 6-8 components were evaluated, as limited if 3-5 components 
were evaluated and minimal if 1-2 components were evaluated. 
 
3.7.3 Identification of multiple risk factors and level of CVD risk. 
3.7.3.1 Multiple CVD risk factors identified. Patients had more risk factors 
documented by NPs in the intervention group compared to the control group. As shown 




factors including premature family history of CVD, smoking, hypertension, diabetes, 
obesity, renal dysfunction, and dyslipidemia for CVD. In the intervention group, over 
70% of patients had four or more risk factors for CVD, with a mean age of 56 years. The 
majority of males (72%) and females (70%) had a high number risk factors (4 to 10 risk 
factors). The majority of the patients in the control group (68%) had up to three risk 
factors documented by NPs. There were no patients in the control group with 7-10 risk 
factors documented in their charts. The mean age of 56 years for females and 54 years for 
males was similar in both groups. 










7-10 18% (12) Female 14% (7) 0% (0) Female 0% (0) 
Male 27% (5) Male 0% (0) 
4-6 53% (36) Female 56% (28) 5% (5) Female 4% (3) 
Male 44% (8) Male 8% (2) 
2-3 23% (16) Female 28% (14) 46% (46) Female 46% (35) 
Male 11%(2) Male 48% (11) 
0-1 3% (2) Female 2% (1) 22% (22) Female 21% (16) 
Male 5% (1) Male 26% (6) 
Unknown 3% (2) Female 0% (0) 26% (26) Female 29% (22) 
Male 11% (2) Male 17% (4) 
1 % (N) the percentage and number of patients in the intervention group; there were 68 participants. 
2 % (N) the percentage and number of participants according to breakdown by sex; there were 50 females 
and 18 males. 
3% (N) the percentage and number of patients in the control group; there were 99 participants. 
4% (N) the percentage and number of participants according to breakdown by sex; there were 76 females 
and 23 males. 
 
 
3.7.3.2 Determining the level of CVD risk. Ninety-one percent (91%) or 62 
patients seen by the NPs in the intervention group had their risk of having a CV event in 
the next 10 years assessed using the FRS available on the CASP website; only 9% of 




for having a CV event was largely unknown for 96% (92 patients) in the control group 
because the FRS was documented on only 7 patients (4%). Due to lack of information in 
the control group, it was not possible to test for significant differences between the 
intervention and control groups. 
Using the FRS available in CASP, 8% of the patients in the intervention group 
were identified as being a high risk for a CV event, while 10% were categorized as 
moderate risk and 72% were categorized as low risk. With the majority of patients in the 
control group not having an FRS recorded, only 2% were identified as high risk, 2% as 
moderate risk, and 3% as low risk.   
Since the majority of the intervention group patients had more than four different 
CVD risk factors identified, researchers were expecting a higher number of patients in the 
high and moderate risk categories using the FRS. Based on data obtained from the CVD 
database, researchers were able to recalculate the FRS utilizing an updated FRS 
calculator for the intervention group patients. The additional factors in the updated FRS 
calculator compared to the original FRS calculator were the diastolic BP and the 
premature family history of coronary heart disease (Canadian Cardiovascular Society 
[CCS], 2019). Table 3.4 shows the revised categorization of risk using the updated 
version of the FRS, with many of the intervention group patients (65%) at high or 
moderate risk of having a CV event in the next 10 years. Seventy-seven percent (77%) of 





Table 3. 4 Recalculated FRS with Intervention Group Patients at High, Moderate, 
or Low CVD Risk 
Framingham Risk Score (FRS) Intervention1 Male2 Female3 
High Risk (>20%) 28% (19) 55% (10) 18% (9) 
Moderate risk (10-20%) 37% (25) 22% (4) 43% (21) 
Low risk (<10%) 27% (18) 5% (1) 34% (17) 
Unknown risk 
 
9% (6) 16.6% (3) 6% (3) 
1 % (N) the percentage and number of all patient participants; there were 68. 
2 % (N) the percentage and number of males; 18 participants 
3 % (N) the percentage and number of females; 50 participants 
 
 
3.7.4 Effectiveness of CASP for the Identification of NP and Patient Priorities 
for Heart Health. The CASP intervention required NPs to identify priorities for patient 
management based on the results obtained from CVD screening and the current CPGs 
and document this in the CVD database. Priorities for patient management were defined 
as identifying specific risk factors to be addressed to improve heart health. Some 
examples of NP priorities were the following: reducing salt intake, losing weight, 
controlling glucose level, or increasing physical exercise. There was variation in the 
proportion of patient priorities identified by each NP in the intervention group. However, 
all NPs identified two to three patient priorities for at least 75% of the patients. Ninety-
four percent (94%) of the priorities for heart health identified by the NPs were the same 
as the priorities identified by the patients. Over three quarters (80%) of the patients 
identified two or more priorities for improving heart health. 
Most of the NPs (93%) documented that they did lifestyle counselling to address 
patients’ identified risk factors. Referrals to interprofessional team members were made 




patients with newly diagnosed risk conditions such as dyslipidemia, hypertension, and 
diabetes to optimize management and to reduce CV risk. 
It was not possible to compare the control group because the NPs did not clearly 
document in the patients’ charts patient identified priorities related to CVD management. 
Generally, the priorities or plans for improving heart health were not clearly recorded in 
the patients’ charts in the control group, rather NP plans were documented related to 
managing single risk factors such as hypertension or diabetes and did not include any 
patient identified priorities. 
3.7.5 NPs’ and patients’ experiences with the CASP intervention. Analysis of 
both the patient and NP feedback questionnaires revealed that specific components of 
CASP promoted screening, management, and follow-up using a patient-centred approach.  
3.7.5.1 NPs’ experiences. Both the intervention and control group NPs were 
asked about their experiences post-intervention. There were several differences identified 
between the NPs in the intervention group compared to the NPs in control group 
providing usual care. For example, screening according to Choosing Wisely Campaign 
was more important for the NP intervention group (100%) compared to the NP control 
group (66%). Furthermore, in the intervention group, 75% of the NPs often used 
motivational interviewing when communicating CVD screening results compared to 33% 
of the NPs in the control group. In addition, all of the NPs (100%) in the intervention 
group said they participated in individualized goal-setting compared to 66% of the NPs in 




The NPs in the intervention group were also asked for their feedback on CASP in 
the NP Feedback Questionnaires previously discussed. NPs identified several 
components of CASP as being important for promoting CVD screening and management 
such as screening according to Choosing Wisely Campaign; communicating results of 
CVD screening using motivational interviewing with patients; and, participating in 
individualized goal-setting using a patient-centred approach. 
3.7.5.2 Patients’ experiences. According to the patient participants, the Heart 
Health Assessment Pamphlet, My Heart Healthy Plan and the CASP website were 
effective components of the intervention. Following completion of the Heart Health 
Assessment Form, patients learned about their level of CVD risk and eligibility for CVD 
screening. The majority of patients (72%) utilized the CASP website but about 26% of 
patients did not find the website useful or were not familiar with using it to find strategies 
for heart health. All patients who participated in the CASP intervention arm 
recommended that family and friends have CVD screening done in the future. Patients in 
the control group stated that they would be interested in learning more about CVD 
screening and participating in a CVD screening program if it was available. 
3.8 Discussion 
The research problem identified in the literature was the inconsistent utilization of 
CPGs for CVD screening. Screening for risk factors for CVD is known to be sporadic, 
occurring opportunistically rather than systematically and comprehensively. CASP is a 




risk factors, perform physiological measurements, analyze abnormal results and provide 
guidance on management of risks using current evidence. By improving screening, there 
would be improved identification of risk factors by HCPs so that they could be managed 
appropriately. In addition, patient engagement was assessed as this is important for 
ensuring that the patient was at the center of care and the key driver behind the goals 
leading to behaviour change related to modifying risk factors and conditions.  
In this RCT, we tested the effectiveness of CASP utilizing NPs working in 
community practice settings who had access to the target patient population aged 40-74 
years. Patient engagement was achieved with these individuals with whom NPs already 
had a trusted relationship. NPs were able to manage and follow-up with the patients to 
develop personalized goals leading to the successful implementation of CASP. The 
implementation of the CASP intervention was successful to increase comprehensive 
screening, to identify multiple risk factors, to determine the level of CVD risk, and to 
increase patient engagement in setting priorities and individualized goals for heart health. 
The discussion is organized around the key findings related to these outcomes. 
3.8.1 Effect on comprehensiveness of CVD screening. CASP was successful in 
promoting comprehensiveness of CVD screening of patients, with 90% of the patients in 
the intervention group having been screened on 9 or 10 of the components of the CVD 
risk assessment, compared to the control group where 96% of the patients had minimal or 
limited screening. The differences were both statistically significant RR = 43.9, 95% CI 
[13.4, 144.2], p < .0001, adjusted for the effect by NP, and dramatic. The CI was wide 




effect of CASP on comprehensive screening. Because there may be differences in the 
screening practices of the NPs, we used generalized linear modelling to control for the 
effect of the NP and still found a significant effect of CASP on comprehensiveness of 
screening.  
As previously discussed, there are few national screening programs for 
comparison, and they do not focus on comprehensiveness of screening as a measure of 
success. The UK program, for example, measures success in risk factor assessment by the 
proportion of the population who are participating in the National Health Service (NHS) 
Health Check Program or the uptake of the program in different regions. There is 
evidence from a recent quasi-randomized controlled trial with an outcome measure of 
NHS Health Check attendance that showed that attendance rose from 12% to 30% 
between 2011 and 2015 (Kennedy, Su, Pears, Walmsley, & Roderick, 2019). Other 
programs, such as the Million Hearts Initiative (MHI) or CHAP, measured their success 
by the number of patients who had risk factors identified, rather than looking at the 
process of screening. One MHI study utilized a nation-wide improvement program for 
outpatient care that identified patients with risk factors requiring interventions and 
measured success by determining the proportion of patients receiving pharmacotherapy, 
smoking cessation interventions, having controlled hypertension, diabetes mellitus, and 
dyslipidemia (Eapen et al., 2014). The CHAP trial identified CVD risks by giving 
individuals self-assessment forms to complete and conducting automated BP on 
individuals over 65 years and sharing this information with physicians and pharmacists 




based on whether there was a reduction in the number of myocardial infarctions recorded 
at a regional hospital. We feel that looking at comprehensiveness of screening is an 
important outcome measure since CASP was developed to address the issue of sporadic 
screening, not just suboptimal identification of risk factors. 
3.8.2 Identification of multiple CVD risk factors and determining level of 
CVD risk. The CASP program guided the NPs in what risk factors to assess and how to 
screen for them, and facilitated documentation of both what was screened for and what 
was found.  Because of the limited documentation in the charts of the patients in the 
control group, and the limited or minimal screening done on the control patients, it was 
unclear what their actual risks were for CVD.  In contrast, the risk factors of patients in 
the intervention group were clearly identified, with 53% having 4-6 risk factors identified 
and 18% having 7-10 risk factors identified.  Furthermore, the majority of patients in the 
intervention group who had over four risk factors for CVD were at a relatively young age 
between the ages of 55-59 years for both males and females. CASP was therefore 
effective in helping identify patients’ risk factors early so that they could be managed, a 
key step in the prevention of CVD. In this study, females had many risk factors at a 
young age comparable to males at a similar age. It is important for clinicians to consider 
both males and females equally when screening earlier to identify risk factors, and to 
manage both males and females according to current CPGs to reduce the risk of 
developing CVD. 
It is not surprising that CASP was able to effectively identify risk factors since 




as hypertension, type 2 diabetes, chronic kidney disease, and vascular disease (Kelsall, 
Fernando, Gwini, & Sim, 2018; Kennedy, Su, Pears, Walmsley, & Roderick, 2019; 
Lindholt et al., 2019 & Ye et al., 2014), including in higher risk groups. For example, in 
Australia, 500 000 blue collar workers who had health checks completed showed 
statistically higher prevalence ratio PR = 1.19, 95% CI [1.17, 1.20] of type 2 diabetes risk 
and CVD risk and risk factors compared to white collar workers such as managers or 
other professional groups (Kelsall et al., 2018). 
In addition to identifying presence of risk factors, CASP also had significant 
positive effect on the completion of the FRS, which is currently recommended by the 
CCS (2019) and the C-CHANGE guideline (2018) as the most appropriate predictor of 
having a CV event in the next 10 years (CCS, 2019; Tobe et al., 2018). In the 
intervention group, 91% of the patients had the FRS completed compared to only 9% in 
the control group. Identification of a patient’s risk score can be beneficial in two ways. 
First, identification of patients in a higher risk category may prompt NPs to manage these 
patients more assertively and continue to monitor these patients more frequently in effort 
to reduce their CVD risk level. It may also lead to increased action that leads to reduced 
risk.  For example, in a prospective study with a partnership between pharmacists and the 
employee wellness program in British Columbia in 2019, called the Cardiovascular 
Assessment and Medication Management by Pharmacists at the UBC Site (CAMPUUS), 
the identification of high-risk individuals in the work setting was completed. One-on-one 




researchers found that there was 1% reduction in FRS scores in terms of changes in level 
of the employees’ risk in a one year follow-up (Gobis et al., 2019). 
There was an issue with the version of the FRS used in CASP however. With the 
version used, only 8% of the intervention group patients were categorized as being at 
high risk for a CV event in the next ten years, and 10% were at moderate risk.  The 
recalculation of the FRS scores based on the patient data (using an updated FRS tool that 
included assessment of additional factors) showed that the original scores underestimated 
the number of patients at risk. Using the updated FRS, 28% of the intervention group 
patients were categorized as being at high risk for a CV event, and 37% were at moderate 
risk. These proportions were more congruent with the high number of risk factors the 
patients had.  NPs were notified of the recalculation so they could work with their 
patients accordingly. One key lesson learned in this was the importance of the choice of 
risk assessment tools and ensuring use of the most up-to-date version of valid and reliable 
tools appropriate for the population being studied. 
3.8.3 Management of high-risk patients. The comprehensive screening by the 
NPs in the intervention group led to increased recognition of the patients’ multiple risk 
factors, new diagnoses of specific conditions, and determination of the level of CVD risk. 
It was important for the NPs and patients to act on this information so CASP included 
tools and guidance for intervention and risk factor management; this occurred in a 
timelier manner than would have occurred without the screening. The NPs did take and 
document actions relevant for the patient priorities they identified, such as new 




of this study however to evaluate the appropriateness of the management strategies 
implemented by the NPs. A future study can assess the longer term effects of CASP on 
patient behavior and outcomes. 
Other screening programs have found that increased screening led to increased 
use of appropriate medications and increased referrals (Kennedy, Su, Pears, Walmsley, & 
Roderick 2019; Lindholt et al., 2019). There is also evidence of improved patient 
outcomes.  For example, in a six year follow-up matched cohort study in England with 
127 891 NHS Health Check participants and 322 910 controls, there was evidence of 
reductions in risk factor values. Compared with controls, Health Check participants had 
lower BMI, BP levels, and reduced smoking rates of 17% compared to 25% in controls, 
OR = .90, 95% CI [0.87, 0.94], p < .001) (Alageel & Gulliford, 2019).  
In Canada, the CHAP community-based initiative showed statistically significant 
reductions in hospital admissions for myocardial infarctions with a rate ratio = 0.87, 95% 
CI [0.79, 0.97], p = .008 and congestive heart failure rate ratio = 0.90, 95% CI [0.81, 
0.99, p = .029 in the intervention groups communities, but not for stroke rate ratio = 0.99, 
95% CI [0.88, 1.12], p = .89 one year following implementation of CHAP (Kaczorowski 
et al., 2011). Identifying risk factors in a timely manner can have a profound effect on the 
patients’ lives and on the management of these risks by NPs to promote healthy aging. 
3.8.4 Effect on patient engagement, setting priorities, and individualized 
goal-setting with CASP. As HCPs, we have been traditionally taught that as the 




responsible for the actions of the patients in our care. This approach is both inappropriate 
and ineffective in changing behaviour (Rollnick, Miller, & Butler, 2008). Focusing on 
patient-centred care and shared decision-making rather than provider driven priorities, 
and use of motivational interviewing in patient-centred approaches, have been shown to 
enhance behaviour change in individuals (Waldron, van der Weijden, Ludt, Gallacher, & 
Elwyn, 2011; Lundahl et al., 2013). Furthermore, a recent qualitative study in the UK 
promotes the use of a risk report that could be communicated with the patient to support 
risk understanding and promote strategies for risk reduction in the future (Hawking, 
Timmis, Wilkins, Potter, & Robson, 2019). Communication of risk results, discussion 
and sharing of priorities and goals, and use of motivational interviewing therefore were 
all important aspects of CASP. 
The vast majority (92%) of the patients in the intervention group had priorities set 
by the NPs and 80% had patient-identified priorities for improving heart health, with 94% 
of the priorities identified by the NPs being the same as the priorities identified by the 
patients. Articulation of the patient-identified priorities indicates that the NPs were able 
to have that discussion with their patients, take a patient-centred approach, and start to 
engage them in health promotion activities. Investigating the congruence between 
priorities for action following communication of risk assessment results and focusing on 
patient-centered goal-setting related to heart health has not previously been studied to our 
knowledge. A future study can evaluate the effectiveness of this shared priority-setting on 




3.8.5 Strengths of the CASP intervention. The findings have shown that CASP 
was effective in promoting screening, identification of patient risk factors for CVD, 
patient engagement in priority setting, and implementation of risk factor management 
strategies.  NPs and patients gave feedback on the program overall and on its specific 
components.  One of the main strengths of the CASP intervention that likely contributed 
to its effectiveness was that it was designed using evidence from research studies on 
effective interventions that have been used previously to improve adherence to CPGs and 
to promote positive patient outcomes (Shanbhag et al., 2018; Chan et al., 2017; Jeffrey et 
al., 2015; Njie et al., 2015; Unverzagt, Oemler, Braun, & Klement, 2014). Effective 
interventions such as educational strategies, clinical decisions support systems (CDSSs), 
and clinical reminders found in the literature were components of CASP. For example, 
the CASP intervention operationalized the current cardiovascular screening and 
management guideline C-CHANGE (2018) using a CDSS, a novel electronic algorithm. 
CASP provided clinical reminders to identify and document risk factor information in an 
electronic format CVD database that was easily retrievable by practitioners during study 
implementation. Having access to electronic health records and opportunities to 
document patient data has been shown to improve care and patient outcomes (Alageel & 
Gulliford, 2019).  
Another strength of CASP was that it operationalized current CV screening and 
management guidelines (C-CHANGE, 2018) in an electronic format so they were more 
user-friendly for the NPs to perform comprehensive assessments in the clinical setting.  




knowledge user and patient partners. In this mixed methods study, the CASP intervention 
was developed based on the findings of phase 1 with consideration of the barriers, 
facilitators, and strategies for knowledge use and application of the Theoretical Domains 
Framework (TDF) to identify appropriate strategies. In this RCT, phase 2 of the mixed 
methods study, we evaluated the implementation of the C-CHANGE guideline, 
intertwined in the CASP intervention, in daily clinical practice of NPs. In phase 3, the 
integration phase, results from both phase 1 and phase 2 were analyzed to draw 
conclusions about the appropriateness of the various components.  The results from phase 
1 and phase 3 are reported elsewhere. Overall, however, using the mixed methods design 
ensured a systematic and comprehensive approach was taken for development and 
evaluation of the intervention. This was consistent with recommendations of the 
Knowledge to Action (KTA) Framework with the integration of guideline adaptation 
(Harrison et al., 2013; Graham et al., 2006), which was used as a framework for this 
study. 
3.8.6 Limitations of the CASP intervention. There are several limitations to the 
CASP intervention related to time and resources needed for orientation, use of current 
guidelines, and facilitation of CASP and generalizability of results. The time that it takes 
for orientation and integration of CASP components into routine practice may become a 
barrier to implementation in terms of resources in different regional health authorities. 
The CPGs integrated within the CASP intervention are current at the present time, but 
there must be a strategy to ensure that the guidelines remain current in the future within 




remain current and relevant over time. Determination of who could facilitate the 
implementation of CASP is important since researchers were instrumental in orientation 
and support during the CASP intervention, but not having a designated person to 
facilitate implementation remains a potential barrier to use.  
3.8.7 Sustainability of the CASP intervention. Integration of CASP into NP 
practice is potentially feasible across the province of NL. Making the CASP tools, 
website, CVD database, and links to newer and different resources a part of current 
practice for NPs and other HCPs could increase screening and risk factor management in 
this province. Organizational support is critical for change in practice, therefore, having 
buy-in from administration within the regional health authorities is important. Having a 
facilitator to support the implementation of CASP within the organization would assist in 
the sustainability of this intervention. Dissemination of findings to government officials 
to promote province-wide adoption of the CASP intervention would be ideal to 
encourage practitioners and the public to be aware of the importance of CVD screening. 
Finally, public awareness campaigns to encourage asymptomatic patients to access the 
screening program and to know their risks for CVD would be important for sustainability 
of the CASP intervention in the future. 
3.8.8 Strengths and limitations of the study. One main strength of the study was 
that it addressed a gap in the literature related to screening for CVD. This evidence-
informed intervention was successful in promoting comprehensive CVD screening and 
thus adds another tool that can be used by NPs and other practitioners.  Another main 




NPs, for example, were trained in the use of CASP, data collection, and supported by the 
researchers throughout to promote application of CASP and integrity of the data. In 
addition, generalized linear modelling was used to control for the effect of the NP on the 
comprehensiveness of screening. 
Limitations of the study related to the small sample size, choice of risk factors for 
screening, choice of the risk assessment tool used, the short duration of the study, and 
generalizability. There was a small sample size of NPs and patients which limited the 
ability to use regression to control for potential confounders other than the effect of the 
NPs. The main outcome of interest was the comprehensiveness of CVD screening, with 
ten risk components chosen from the C-CHANGE guideline for inclusion in the 
assessment. The question remains about whether we focused on the correct risk factors 
for screening comprehensively. There are other CVD risk factors that may be considered 
more important to use in a definition of comprehensive CVD screening that were not 
included by researchers in this study, but could be assessed in a future study.  In addition, 
the FRS was chosen as the risk assessment tool as it is recommended by the guidelines, 
but the version used underestimated risk for a CV event compared to the updated version. 
There are many global risk assessment tools available that need to be appropriate for the 
population so future implementation of CASP would need to evaluate them and choose 
the best tool or tools. For example, a decision would need to be made to identify the best 
global risk assessment tool to use, taking into consideration that our population studied 
had a large number of First Nations people screened. As previously discussed, the short 




behavior and outcomes. Finally, because this intervention was designed based on input 
from a few patients and professionals in one Canadian province as well as implemented 
by a small number of NPs with only two regions represented in the control group, results 
may not be generalizable to the other populations or health providers. 
3.8.9 Next steps. It is important to share knowledge of successful interventions 
and increased access to other providers to improve patient care and reduce CVD risk. 
Plans will be discussed with the regional health authorities for wider distribution and use 
of CASP, addressing its sustainability and also evaluating its use by other health 
providers. Future research will focus on assessing the risk behavior change of patients 
based on individualized goals and heart health plans developed during this study, and on 
evaluating the impact on patient health outcomes, NP practice, and the healthcare system. 
3.9 Conclusion 
The implementation process of CASP was successful and led to positive 
outcomes in terms of improving uptake of guidelines in clinical practice, identifying 
multiple patient risk factors needing action, and providing opportunities for patient-
centred care and individualized goal-setting to improve heart health. Implementation of 
CASP by NPs and other HCPs could enhance the uptake of the C-CHANGE guideline 
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CHAPTER 4 Recruitment of Healthcare Providers as Participants in Research 
 
The intended audience for the manuscript is novice and experienced researchers 
interested in learning more about how to successfully recruit healthcare providers into 
research studies. 
 
JB conducted the integrated literature review, scanned the abstracts, selected relevant 
journal articles, analyzed results, and wrote the manuscript. DM scanned abstracts, 
reviewed journal articles, guided manuscript outline and writing. DM, CD, and KP 














As researchers we know that recruitment of participants is critical to conducting any type 
of research study. Recruitment of a sufficient number of healthcare providers (HCPs) 
such as nurses and nurse practitioners (NPs) as participants is essential to generate high 
quality research results to address issues that are significant for clinical practice and 
patient care. Often the recruitment process reported in research studies consists of only 
one or two sentences identifying the recruitment strategies used. This very brief 
description of recruiting participants does not capture the reality of the challenges and 
time that it takes to actually recruit an adequate sample. This manuscript describes the 
challenges that we experienced in trying to recruit a sufficient number of HCPs, 
specifically NPs, into a randomized controlled trial. Based on our experience, as well as a 
review of the literature on recruitment of health professionals, we share our 
recommendations for novice and even experienced researchers trying to recruit busy 
professionals as participants.  Key findings were not just about reaching the target 
participants, but actually using strategies to stimulate their interest and persuading them 
to be involved from the beginning. Important things to consider for successful 
recruitment are making an effort to meet with professionals face to face and building 
relationships with administrators and other staff within organizations or agencies. Other 
lessons learned were to ensure to allot extra time for recruitment to allow for 
unanticipated challenges and to utilize multimodal strategies simultaneously to ensure a 
more timely execution of the recruitment process.  





As researchers, we know that recruitment of participants is critical to conducting 
any type of research study. Whether the study design is qualitative, quantitative, or mixed 
methods, it is not possible to implement a study without the involvement of participants 
of the target group. It is critical to be successful in recruiting participants into research 
since having an appropriate sample means that one can reach saturation or obtain a 
variety of different perspectives for a qualitative study (Morse et al., 2015; Thorne, 
2016), or have enough participants to attain sufficient power in a quantitative study 
(Groves et al., 2012). Recruitment of a satisfactory number of healthcare providers 
(HCPs) such as nurses and nurse practitioners (NPs) as participants is essential to 
generate high quality research results to address issues that are significant for clinical 
practice and patient care (Raymond, Profetto-McGrath, Myrick, & Strean, 2018; Rendell, 
Merritt, & Geddes, 2007; Riis, Jensen, Maindal, Bro, & Jensen, 2016). What novice 
researchers and even more experienced researchers may not realize, is how challenging 
this recruitment process can be!  
The recruitment of participants for research studies is often briefly described in 
only one or two sentences in journal articles, which does not reflect the reality of the time 
and effort it actually takes to recruit enough participants to obtain an adequate sample. 
Prior to developing the research proposal for the randomized controlled trial (RCT) that 
was the second phase of a mixed methods study, we had reviewed the literature about 
recruitment strategies and considered our experiences with recruitment in the first phase.  




difficulties and had to add new strategies. We ultimately had a sufficient sample, but did 
not attain the anticipated sample size, and the recruitment process slowed down the 
research. Our goal was to recruit a total of 10 NPs, but it took several months to obtain 
this small sample. Two NPs ultimately did not participate because of the delays in 
starting and changes to their circumstances. Each NP recruited patients; the final sample 
size of patients was sufficient but the research process was slowed because of the 
difficulties with recruitment of NPs.  
It was important for us to learn from our experiences so we returned to the 
literature about recruitment of health professionals and reflected on our planning process 
and strategies used.  In doing so, we realized that we had focused more on reaching our 
target audience of NPs than on strategies to stimulate their interest and persuade them to 
get involved. Recruitment is a complex iterative process that requires multimodal 
strategies (Luck, Chok, & Wilkes, 2017; Riis, Jensen, Maindal, Bro, & Jensen, 2016; 
Broyles, Rodriguez, Price, Bayliss, & Sevick, 2011) aimed at convincing the target 
population to participate. While actually connecting with the potential participants is of 
course essential, researchers also need to use realistic study designs and methods to 
facilitate participation (Signorelli et al., 2017; Williamson et al., 2007) and gain the 
support from healthcare organizations where the target HCPs work (Arends et al., 2014). 
The purpose of this paper is to share specific recruitment strategies found in the 
literature that can be used to recruit health professionals, based on supporting and 
convincing potential participants to participate in a study, and not just reaching them and 




planning to look beyond accessing the target group can help identify key strategies to 
build success and reduce frustration. This is the article that we wished we had available 
and thoroughly read before developing and executing what we thought was a well laid 
out recruitment plan for a dissertation research study. 
4.3 Overview of Our Research Study and Recruitment of Participants 
Our research focused on developing and testing an innovative cardiovascular 
(CV) screening intervention to be used by HCPs to identify CV risk factors and to 
provide early intervention and management of patients in order to reduce CV risk. The 
research design was a multi-phase exploratory mixed methods study with a qualitative 
phase, a quantitative phase, and an integration phase. The recruitment of HCPs was 
critical to both the qualitative phase (phase 1) that informed the intervention 
development, and the quantitative phase (phase 2), the RCT that tested the intervention. 
This paper will focus on the recruitment process used for the NPs in the RCT as that is 
where we faced the most challenges. 
For the RCT, we originally planned four recruitment strategies, three of which 
were implemented simultaneously. The first strategy was to inform the senior leaders 
within health care and regional health authorities (RHAs) about the study. This helped 
with obtaining administrative support and with informing NPs about the study. In one 
RHA, the Director of Nursing assisted in the recruitment of the NPs by providing the 
names of six potentially interested NPs, three of whom agreed to participate in our study. 




and contact information of the NP managers, but not the NPs themselves. The second 
strategy was communicating with the executive board of the provincial NP special 
interest group to send out notifications to the NP members across the province. Since the 
PI was a member of this organization, it was anticipated that this strategy would be 
successful in recruiting a few members to participate in our study, but only two NPs were 
recruited. The third recruitment strategy was snowballing. This process involved asking 
the NPs who had been recruited to speak with their colleagues about also being 
participants in our study. This strategy was successful in recruiting just one NP as a 
participant. The fourth strategy, which was planned but not implemented, involved 
contacting the professional nursing organization to ask if they could assist in the 
recruitment of NPs by sending out a notice about the study by email. But the cost to send 
this email message specifically to NPs was much more than was expected and had not 
been anticipated in the budget. At the time, we did not think the cost of this strategy was 
worth the financial investment. In hindsight, involving the professional organization in 
the recruitment efforts may have further supported our recruitment success.  
In each of these strategies, the NPs were sent a study information sheet that 
explained details of the study, what was expected and why the study was important. We 
had designed the intervention cognizant of their busy work schedules, based on the 
information obtained in phase 1 and after consultation with a knowledge user. HCPs in 
phase 1 had indicated their support for CV screening in general and for the components 
of the intervention specifically, so we expected that they would be interested in the 




province (N=171) received the information about the study, but we are unsure if they 
read it, and they clearly had not been convinced by the information to enrol in the study! 
With limited success after implementing the initial recruitment plan, we added 
additional strategies over a period of four months. Our original recruitment plan was 
focused on bringing awareness of the research study to leaders and potential participants. 
We spent little time thinking through the details of how to convince these busy health 
professionals to participate in our study until after the recruitment process had begun.  
The additional strategies added in the updated recruitment plan were more NP-centred, 
such as checking messaging, sending recruitment materials to assist the NPs to recruit 
their patients, monetary and non-monetary incentives for the NPs, and personalizing 
contact with potential participants. These supplemental strategies required that numerous 
amendments be submitted to the research ethics board, which resulted in delays to study 
implementation and increased workload for the research team, but eventually led to 
attaining the sample of NPs needed. 
4.4 Recruitment of Healthcare Providers into Research Studies 
After reflection and reviewing the literature again, developing a plan for 
recruitment to convince HCPs to participate in research involves thinking through the 
entire study upfront prior to launching into specific recruitment strategies. Designing a 
plan to recruit participants means that researchers have to think through the details of 
how the study will unfold and the implications for the role of the target group 




terms of their interest, time, feasibility, and benefits of being involved, and need to be 
communicated with them in an effective enticing manner. Researchers also need to a plan 
for supporting participants who have been successfully recruited. 
Based on our experience and the literature, we have six main recommendations 
for promoting success in recruiting HCP participants: a) plan study methods to facilitate 
participation; b) articulate clear participant role expectations; c) prepare recruitment 
materials with clear messages to entice participation; d) reach potential participants 
physically and mentally; e) plan strategies for support; and f) build in sufficient time.  For 
each of these recommendations, examples from our experience with recruiting NPs into 
the RCT is highlighted. 
4.4.1 Plan study methods to facilitate participation. As researchers know, the 
design of the study is dependent on the research questions that need to be answered 
(Grove, Burns, & Gray, 2016). Most research questions come from issues identified in 
clinical practice that need to be addressed, or from gaps found in the literature that are 
important to explore. While the need for scientific rigour will direct specific methods, 
one can and should plan interventions and study methods with the participant in mind. 
One has to think ahead about what participants are being asked to do in the research 
study, such as fulfilling specific responsibilities, completing training sessions, or 
changing their daily routine, and build in strategies to make it easier for them.  In our 
study, for example, NPs were required to complete CV screening of patients so we 
developed a computer-based data entry form that both guided them in what and when to 




information from clinical practice guidelines and patient resource material, we created an 
innovative website, clinical decision-making algorithm, and an HCP tool kit. We also 
included webinars, one-on-one training, and support phone calls with the PI to ensure that 
the NPs had the training they needed to implement the intervention and document their 
actions. Training is a key strategy for success of implementation and communication 
about training should be included during recruitment (Alberti & Atkinson, 2017; Veitch, 
Hollins, Worley, & Mitchell, 2001; Williamson et al., 2007). 
One recommendation from the literature was involving HCPs in the recruitment 
plan, which means finding a knowledge user who is a member of the specific target group 
who will eventually benefit from the results of the study (Campbell et al., 2016; Broyles, 
Rodriguez, Price, Bayliss, & Sevick, 2011; Riis, Jensen, Maindal, Bro, & Jensen, 2016; 
Weierbach, Glick, Fletcher, Rowlands, & Lyder, 2010).  For our study, we included a 
knowledge user on our research team to help us understand the reality of clinical routines 
of NPs in community settings in order to be realistic about the participant role during 
study recruitment and implementation. The NP knowledge user was able to review the 
intervention website, the innovative algorithm, and the HCP toolkit for relevance and 
usability, and made recommendations for changes prior to the commencement of our 
study. Utilizing a knowledge user helped to ensure the study components were relevant 
and assisted in the recruitment of NPs. 
4.4.2 Articulate clear role expectations during recruitment. Participants must 
understand what their exact role will be during study implementation, so clear 




2017). The majority of expectations were easy to articulate, as they were related to the 
methods of the intervention (e.g., identify and screen patients) and to the data collection 
(e.g., complete the data collection forms). We also had to comprehend the time demands 
of NP daily practice in order to envision adding realistic tasks to their busy days (Alberti 
& Atkinson, 2017). The participant role must be realistic in terms of the time 
commitment and additional work required to partake in the study (Marks, Wilkes, Blythe, 
& Griffiths, 2017). In our research, even though screening for CVD risk factors was a 
familiar role for NPs in clinical practice, completing the research forms and entering 
information into the study database did create more work in their daily routine. Being 
able to provide a reasonably accurate estimate of the time required to participate in the 
study must be communicated with potential participants during recruitment in order to 
help them understand the commitment. 
It can be difficult to communicate role expectations in written recruitment 
material, as potential participants may have questions that cannot be easily answered in 
an information letter. We therefore submitted an amendment to the ethics board to be 
able to contact NPs directly by phone to talk about the study expectations and to provide 
an opportunity for potential NP participants to ask questions directly to the PI. In doing 
so, NPs interested in participation could obtain a more realistic idea of the time 
commitment required and clarification about the role they would need to play in the 
study.  
4.4.3 Prepare recruitment materials with clear messages to entice 




target population and ones that they should be interested in, and ensure the purpose and 
outcomes of study are important to them (Im et al., 2006; Keating, 2014; Luck, Chok, & 
Wilkes, 2017; Marks, Wilkes, Blythe, & Griffiths, 2017). A knowledge user can verify 
that the study is relevant to potential participants and share insider knowledge that can 
influence the recruitment success (Broyles, Rodriguez, Price, Bayliss, & Sevick, 2011; 
Riis, Jensen, Maindal, Bro, & Jensen 2016; Weierbach, Glick, Fletcher, Rowlands, & 
Lyder, 2010). In our experience, the main research question of the RCT was focused on 
whether the implementation of a newly developed CV risk screening program by NPs 
was effective in promoting comprehensive screening of patients. We knew from phase 1 
that NPs were interested in screening, so the challenge for phase 2 recruitment was in 
ensuring the information shared when inviting participation captured their interest.  
It is important to succinctly share all aspects of the research study that are 
relevant, but not so much as to discourage potential participants with too many details. 
We used our NP knowledge user to help with messaging so that NPs would understand 
the relevance of the main research question and the implications for improving NP 
clinical practice and patient care, as well as key details of what was involved in 
participation. Rather than focusing primarily on the methods of the study, our recruitment 
materials were revised to also promote understanding of the time commitment and the 
benefits of the study for individual participants and overall. 
4.4.4 Reach potential participants physically and mentally. There are two 
aspects of reaching potential participants that need to be considered: connecting with 




with them mentally so they will be interested in participating and persuaded to do so. 
There are a number of strategies available for informing potential participants about a 
study, including sending out emails, using social media, placing posters in strategic 
locations, and attending group meetings (Marks, Wilkes, Blythe, & Griffiths, 2017; Luck, 
Chok, & Wilkes, 2017; Riley, 2016; Johnson et al., 2010). Getting contact information of 
potential participants is a crucial first step, and having key contacts within an 
organization, as we had, can be very helpful. We did not use social media, but in future 
studies we would utilize whatever social media platform is popular with the target group 
(Marks et al., 2017). 
Once contact information is obtained, personalizing all correspondence is a more 
effective strategy than using mass emails or impersonal approaches (McKinn, Bonner, 
Jansen, & McCaffery, 2015). Initially, our email correspondence was not personalized so 
and did not result in successful recruitment. Even though most of the NPs knew the PI 
who was trying to communicate details about the study, requesting busy professionals’ 
assistance through email may result in the delete key being pressed more often than one 
would like. Sending out emails alone was not enough, so we added personalized contact, 
both written and in person by phone or at meetings such as special managers’ meetings. 
One of the key strategies for recruitment identified in the literature related to connecting 
with the target group is taking the time to meet face-to-face with groups or individually 
(Arends et al., 2014; Johnson et al., 2010). Being able to speak with individuals provided 
them with the opportunity to have questions answered and gave us the opportunity to 




In our revised recruitment plan, we added a number of strategies to show our 
appreciation of our participants’ involvement that resulted in increased recruitment 
success. We provided non-monetary incentives such as letters of appreciation that could 
be used towards gaining a leadership premium. Credit hours could also be verified 
towards a continuing competency program for NPs who participated in the research 
study. We also offered a financial token of appreciation to both the NP and patient 
participants to help the recruitment process.  
4.4.5 Plan strategies for support. Having sufficient research funding and 
organizational support are required for conducting research but also has implications for 
recruitment. Obtaining the necessary funding for the study recruitment is critical for 
many reasons. For example, having financial support will enable researchers to travel to 
meet potential participants or to hold recruitment meetings. Providing refreshments at 
such meetings shows that researchers appreciate the time taken to learn about the study 
(Broyles, Rodriguez, Price, Bayliss, & Sevick, 2011). Having research funding also 
enables researchers to provide monetary incentives, which have been shown to be 
effective in engaging health professionals to become involved in research studies (Pit, 
Vo, & Pyakurel, 2014; Treweek et al., 2013). The amount of money being offered to 
participants may also influence recruitment (Ngune, Jiwa, Dadich, Lotriet, & Sriram 
2012; Caldwell, Hamilton, Tan, & Craig, 2010).  The addition of a financial token of 
appreciation for both NPs and patients facilitated recruitment in our study. 
A definitive plan to gain access to the organization and to obtain support from key 




2013). Our recruitment plan involved contacting senior leaders to gain their support and 
permission to contact NPs in their workplaces. Many more hours than expected were 
spent emailing and eventually phoning specific managers in order to get NP work email 
addresses. Having support from administrative staff members proves beneficial and can 
assist in the recruitment of clinicians in the organization (Johnston et al., 2010). In 
addition, keeping staff informed about the study is important since these individuals can 
greatly influence accessibility to administrators and managers as they often act as 
gatekeepers (Johnston et al., 2010). The need to be kind and respectful of their time is 
paramount, as they can make or break success in gaining support from the right people. 
Even though gaining support took time, having help within the organizations where our 
participants were employed was valuable and added credibility to the importance of 
participating in the study when trying to convince the NPs directly during the recruitment 
process.  
Participants need ongoing support once they are in the study (Alberti & Atkinson, 
2018). This is especially true if technology or software will be used during the research 
study. Contacting the Information Technology (IT) department early will ensure efficient 
use of time since computer issues and software glitches are certain to occur.  In our study, 
we made IT support available to address any issues that might occur with the study 
website or database, and the researchers provided encouragement and support on other 
aspects of the study. We let potential participants know of the availability of this support 




4.4.6 Build in sufficient time. Recruitment took much longer than expected 
partially because finding contact information and sending out recruitment materials took 
more time than anticipated, but mostly because the addition of new strategies required 
that amendments be sent to the research ethics board prior to implementation. Five 
amendments related to recruitment of both the NPs and their patients were made to the 
ethics research board: a) changes in recruitment materials; b) use of both non-monetary 
and tokens of appreciation for NPs and patients, c) obtaining permission to ask NP 
managers to relay information about the study to NPs in the same workplace; d) 
contacting the NPs who participated in the first phase of the mixed methods study to 
determine potential interest in participating in the RCT; and e) connecting with NPs by 
phone to speak in a personalized manner and answer study questions directly. The 
process of submitting amendments and waiting for approval required a lot of time and 
effort and resulted in delays. Decisions made by ethics boards and other external agencies 
are not in the researchers’ control, so building in time for delays into the recruitment plan 
will reduce frustration. Adding a research assistant to assist with recruitment and 
employing multiple strategies simultaneously rather than sequentially could also ensure 
more timely execution of the recruitment process. 
4.5 Conclusion 
Recruitment of HCPs, such as NPs and nurses, as participants into research 
studies is important to address clinical problems, but can often be quite challenging. In 
our mixed methods study, we experienced issues in the recruitment of HCPs; especially 




on recruitment of HCPs into research to gain new knowledge and to find effective 
strategies. Key lessons were the need to focus on more than just reaching the target 
audience, but on using strategies to stimulate their interest and persuading them to be 
involved from the beginning. Other things needed to contribute to success are to build 
relationships with administrators and other staff within organizations or agencies and to 
allot extra time in the recruitment plan. This paper might be helpful to novice or even 
experienced researchers who are interested in improving recruitment success when 
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CHAPTER 5 Conclusion 
 
Chapter 5 provides an overview of the mixed methods study and the methodological 
issue of recruitment. This chapter also discusses key findings from the three manuscripts 


















This dissertation research involved a multi-phase exploratory sequential mixed 
methods study that was conducted over a period of two years, from 2016 to 2018, and 
resulted in the development and evaluation of a theory-informed intervention. The 
purpose of this mixed methods study was to address the research problem identified in 
the literature of the inconsistent use of current cardiovascular disease (CVD) screening 
clinical practice guidelines (CPGs) by healthcare providers (HCPs) in clinical practice 
(Unverzagt, Oemler, Braun, & Klement, 2014). In keeping with the philosophy of 
interpretative description and pragmatism, a real-life issue was addressed by developing a 
contextually-relevant theory-informed intervention to increase the uptake of CPGs by 
HCPs. The overarching aim for the study was to determine successful strategies that 
increase utilization of CPGs in daily clinical practice. 
The Knowledge-to-Action (KTA) Framework (Graham et al., 2006), with 
guideline adaptation (Harrison et al., 2013), was used to guide this mixed methods study. 
The initial steps of the KTA Framework focus on identifying the barriers and facilitators 
to knowledge use and tailoring the intervention to the local context. Evaluating the 
implementation of the knowledge use and determining its impact on patients, providers, 
and the system are the final steps of this framework.  
In phase 1 of our research, the barriers, facilitators, and strategies were identified 
according to the KTA Framework and the contextually relevant Cardiovascular 
Assessment Screening Program (CASP) intervention based on current guidelines (C-




informed by focus groups and interviews with patients, providers, and managers from 
October 2016 to May 2017. The various themes that emerged related to the barriers, the 
facilitators, and the strategies for CVD screening were considered in relation to the 
development of the CASP intervention. The Theoretical Domains Framework (TDF), 
along with selected behaviour change techniques, and modes of delivery (Michie et al., 
2013) were used to develop the intervention components of CASP relevant to the local 
context. 
In phases 2 and 3 of our study, we completed the final steps of the KTA cycle. In 
phase 2,  a randomized controlled trial (RCT) was conducted in Newfoundland and 
Labrador (NL) in which four nurse practitioners (NPs) implemented the CASP 
intervention and conducted screening with 68 patients while four NPs provided usual care 
to 99 patients in the control group. The intervention group NPs documented data in the 
study database while the researchers conducted reviews on the control group participants’ 
charts during that same time period. 
Phase 3 involved integration of the results from phases 1 and 2 to answer the 
overarching research question to determine effective strategies to enhance HCPs’ use of 
evidence-based CPGs for CVD screening and management of patients. This integration 
was important to determine what components of the CASP intervention were successful 
to enhance knowledge translation of evidence into practice. 
This chapter summarizes the key findings of the study which were reported in 




reported in Chapter 4.  Recommendations for education, practice, and research are also 
summarized. 
5.2 Key Results: Development of CASP 
The results of the development of CASP from phase 1 with refinements from the 
integration phase 3 were described in detail in the first manuscript (Chapter 2) of this 
dissertation. Phase 1 data analysis revealed different perspectives from various 
professionals and members of the public about the barriers, facilitators, and strategies for 
CVD screening and management in the province of NL. The themes related to barriers 
that emerged were: ambiguity and uncertainty around responsibility for CVD screening; 
lack of knowledge and skills for comprehensive screening using the C-CHANGE 
guideline; questioning the necessity of screening in light of the Choosing Wisely 
Campaign; lack of time and commitment for CVD screening; lack of dedicated resources 
and organizational supports for CVD screening; behaviour change is difficult for patients; 
and (patients’) lack of access to services. Two themes about facilitators for CVD 
screening were related to knowing who and when to screen patients, and secondly, 
utilizing components and tools from previously successful provincial screening initiatives 
for the development of CASP. Potential strategies identified that could be used for CVD 
screening were related to the importance of training of HCPs to ensure consistent 
implementation of CASP, and using public awareness campaigns for patient engagement. 
The CASP intervention was developed based on themes related to the barriers, 
facilitators and strategies for CVD screening, the Theoretical Domains Framework 




modes of delivery of the intervention components. A logic model for CASP was 
developed that was initially based on the literature, and then refined following integration 
of research results. This logic model depicts what the components of CASP and how they 
are related to each other. The CASP logic model has been described in detail in the first 
manuscript (Chapter 2) of this dissertation. CASP contained tools, strategies, and 
resources to be used by NPs to comprehensively screen and manage patients in their 
clinical practices across NL. 
Following the phase 3 integration of the results of phase 2 with phase 1, the 
various components of CASP were confirmed as successful strategies that could be used 
to increase comprehensive CVD screening by HCPs with the people of NL. The 
recommended strategies to enhance cardiovascular screening in NL were the following: 
ongoing support from healthcare organizations, health provider support and education 
and training related to CVD screening, access to current guidelines in an electronic 
format, accurate documentation in an electronic database, and engagement of patients 
throughout the screening process. The evaluation indicated that these components should 
be continued, with refinements made to enhance support from the local environmental 
and cultural context, healthcare organizations and HCPs within these organizations in 
order for the CASP screening intervention to be implemented successfully. A public 
awareness campaign related to the importance of CVD screening would also be important 
to implement to promote or comprehensive screening and individualized goal-setting for 





5.3 Key Results: Evaluation of CASP 
The details of the data analysis and results of phase 2 are described in the second 
manuscript (Chapter 3) of this dissertation. Four key findings from the results of the RCT 
conducted in phase 2 were that CASP was effective for the following: a) promoting 
comprehensive screening by NPs; b) identifying multiple risk factors and determining 
patients’ level of CVD risk; c) identifying NPs’ and patients’ priorities for heart health; 
and d) engaging patients in screening and developing individualized goal-setting for heart 
health. 
The CASP intervention was effective in promoting comprehensive CVD 
screening by NPs in NL. There was a statistically significant difference between 
intervention group NPs doing comprehensive screening (assessing 9-10 components) 
compared to control group NPs with a RR = 43.9, 95% CI [13.4, 144.2], p < .0001 
adjusted for the effect by NP. All of the NPs in the intervention group performed 
moderate or comprehensive screening compared to the control group where the majority 
of NPs performed limited or minimal CVD screening. 
Patients had more risk factors documented by NPs in the intervention group 
compared to the control group. The intervention group patients had a high number of 
CVD risk factors such as premature family history of CVD, smoking, hypertension, 
diabetes, obesity, renal dysfunction, and dyslipidemia. The implementation of the CASP 
intervention by NPs was effective in identifying patients at risk for having a CV event 
within the next 10 years using the Framingham Risk Score (FRS). Ninety-one percent 




a CV event in the next 10 years assessed using the FRS; only 9% (n= 6) of patients in the 
intervention group did not have a FRS recorded. In comparison, the risk for having a CV 
event was largely unknown for 96% (n=92) in the control group because the FRS was 
documented on only seven patients (4%).  
The CASP intervention required NPs to identify priorities for patient management 
based on the results obtained from CVD screening and the current CPGs. Priorities for 
patient management were defined as identifying specific risk factors to be addressed to 
improve heart health. Some examples of NP priorities were the following: reducing salt 
intake, losing weight, controlling glucose level, or increasing physical exercise. There 
was variation in the proportion of patient priorities identified by each NP in the 
intervention group. However, all NPs identified two to three patient priorities at least 
75% of the time. Furthermore, 94% of the priorities for heart health identified by the NPs 
were the same as the priorities identified by the patients. Over three quarters (80%) of the 
patients identified two or more priorities for improving heart health. In comparison, 
patient priorities related to heart health were largely undocumented in the charts of 
patients in the control group. 
CASP was effective in promoting a patient-centred approach to care by engaging 
patients to participate in the screening process with NPs and also in promoting 
individualized goal-setting for actions to improve heart health. Patients used My Heart 
Healthy Plan to determine which goals were going to be focused on with support 
provided by regular follow-up visits with NPs to promote positive behaviour change. 




promoted screening, management, and follow-up, and that CASP had several successful 
components using a patient-centred approach. 
5.4 Methodological Issues: Recruitment Challenges 
The third manuscript (Chapter 4) highlights the lessons learned about moving 
beyond accessing the target population to focusing on six main recommendations for 
recruiting HCPs into research studies. During this mixed methods study, we encountered 
issues in the recruitment of HCPs, occurring mainly when recruiting NPs for the RCT. By 
focusing on this methodological issue experienced during our research study and delving 
deeper into the research literature, we gained insight into effective recruitment strategies 
for HCPs. Six main recommendations for researchers to consider in a recruitment plan 
were discussed in detail in Chapter 4. The emphasis of most of the recommendations 
related to focusing on more than just reaching the target audience and instead on using 
strategies to stimulate their interest and persuading them to be involved, as well as 
obtaining organizational support. Expertise on the topic of recruitment of HCPs was 
gained from reviewing the literature and reflecting on our experience. This knowledge 
can be both shared with novice and experienced researchers and applied in future 
research studies.  
5.5 Strengths and Limitations of This Research Study 
One main strength of the study was that it addressed a gap in the literature related 
to screening for CVD. This evidence-informed intervention was successful in promoting 
CVD screening and thus adds another tool that can be used by NPs and other 




rigour of the data collected. The NPs for example were trained in the use of CASP and 
data collection, and supported by the researchers throughout to promote application of 
CASP and integrity of the data. Also, obtaining patient collaboration and personalized 
goal-setting for heart health emphasized the importance of patient-centred care and could 
potentially lead to behaviour change. Having a facilitator to promote and assist with the 
implementation of CASP throughout the organization is important for sustainability of 
this intervention into the future. 
Limitations of the study related to choice of risk factors for screening, choice of 
the risk assessment tool used, the short duration of the study, and generalizability. The 
main outcome of interest was the comprehensiveness of CVD screening, with ten factors 
chosen from the C-CHANGE guideline for inclusion in the assessment. The question 
remains whether we focused on the correct risk components for screening 
comprehensively. There are other CVD risk factors that were not included by researchers 
in this study that may be considered more important to use in a definition of 
comprehensive CVD screening; these could be assessed in a future study.  In addition, the 
FRS was chosen as the risk assessment tool as it is recommended by the guidelines, but 
the version used underestimated risk for a CV event compared to the updated version. 
There are many global risk assessment tools available that need to be appropriate for the 
population so future implementation of CASP would need to evaluate them and choose 
the best tool or tools. The short duration of the study precluded assessing the impact of 
the intervention on patient behavior and outcomes. Finally, because this intervention was 




and implemented by a small number of NPs, results may not be generalizable to the other 
populations or health providers. 
5.6 Recommendations for Education 
There are opportunities to enhance the education of HCPs, especially for NPs and 
nurses, in relation to CVD health promotion. Focusing on CVD prevention and health 
promotion to enhance competencies, knowledge, and skills may lead to improved patient 
outcomes individually and at the population level. If NPs and nurses could take a 
leadership role in providing effective preventative care, they need to know how to 
evaluate. NPs and nurses need to know how to evaluate and implement evidence-
informed care in relation to CVD prevention. The educational resources developed for 
this research study focused on providing evidence-based knowledge and skills for 
identifying risk factors using valid and reliable instruments. Performing focused history 
and physical examination for CVD was required during the implementation of CASP. 
NPs were given clear direction on calculating global risk scores and heart age for 
individuals and for determining the patients’ level of CVD risk.  
Resources were also made available to enhance the knowledge level and to assist 
NPs with counselling of patients to assess readiness for change and to help patients set 
realistic goals for heart health. Improving the knowledge level of advanced practice 
nurses such as NPs, may also lead to the mentoring of nurses and other health 
professionals to become more competent in assessing readiness for change and self-




5.7 Recommendations for Practice 
In congruence with the initial phases of the KTA Framework, gathering input 
from a variety of patients, providers, and administrators in phase 1 of this study was 
instrumental for ensuring that the development of an evidence-based intervention was 
relevant to clinical practice within the local context. Promoting the CASP intervention in 
daily clinical practice can be effective in increasing comprehensive CVD screening and 
identifying priorities for action to reduce CVD risk and promote healthy aging. Even 
though NPs and patients were used in the testing of this intervention during the RCT, the 
intention of this research intervention was to involve other members of the 
interprofessional team. Having an electronic intervention that can be integrated within the 
current HealtheNL provincial health record would be valuable tool to be used within 
regional health authorities and clinical practice of NPs, nurses, physicians and others 
across NL. Gaining organizational support and promoting a public awareness campaign 
around the importance of CVD screening and about the NP’s role in CVD screening that 
may lead to the sustainability of the CASP intervention in the future. This program is 
generic and, therefore, is appropriate for men as well as women. NPs can address the 
issues unique to women by tailoring the program. The public awareness campaign can 
also focus women’s heart health to ensure the message about identifying risk for CVD 
early is communicated. 
5.8 Recommendations for Research 
There are research opportunities in utilizing interprofessional teams and different 




adapt the current CASP intervention to be used with different HCPs in the 
interprofessional team such as physicians, dietitians, and community health nurses 
working in community or other settings. Details of how the intervention could be 
specifically tailored to meet the unique needs of vulnerable populations who could 
benefit from evidenced-informed guidelines could address health inequities across the 
province. Even areas that are very remote and isolated could likely benefit from the 
CASP intervention implementation and enhanced interactions and collaboration between 
the providers and patients; this could be evaluated in a future study. Implementing CASP 
with patients who already have established CVD would also be important to screen and 
manage multiple CVD risk factors simultaneously to improve quality of life. Obtaining a 
larger sample size in future research could address the generalizability of the results so 
that other regions could utilize this intervention in the future. Finally, the full impact of 
the CASP intervention on patients, providers, and the healthcare system could be 
evaluated in future research by examining longer term behaviour change and patient 
outcomes. 
5.9 Conclusion 
This mixed methods study is important and contributes to the existing literature. 
Utilizing mixed methods research to develop an intervention is well documented in the 
literature (van Beljouw et al., 2014; Straus, Moore, Uka, Marquez, & Gulmezoglu, 2013). 
Ensuring that the intervention is contextually relevant is important and has been shown to 




on the comprehensiveness of CVD screening and simplifying complex CPGs is unique 
and adds new knowledge to the knowledge translation literature. 
This mixed methods study adds knowledge to the nursing literature contributing 
to the nursing metaparadigm of environment, nurse, person, and health. This study 
considered the influences of the environmental context in the development of the CASP 
intervention and in determining successful strategies for the intervention implementation. 
This study provides evidence of an effective intervention that can be utilized by NPs and 
other HCPs in clinical practice. This study also considered the value of engaging patients 
and knowledge users (NPs) throughout the research process in the design and 
implementation of the intervention and the importance of person-centred care. Finally, 
this study contributes to the nursing literature in promoting strategies aimed at reducing 
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Knowledge to Action (KTA) Framework 
 
Knowledge to Action (KTA) Framework (Graham, Logan, Harrison 2006) with 

















































The Screening intervention: 
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RE: "Exploring strategies to facilitate screening for cardiovascular disease to 
promote healthy aging."   
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APPENDIX D: Research Documents for Chapter 2 
 
• Research Study Information Letter 
• Promoting Heart Health Screening Study Recruitment Poster 
• Focus Group/Individual Interview Questions for Health 
Professionals 
• Focus Group/Individual Interview Questions for the Public 
• Interview Questions Health Administrators/Managers 

















Research Study  
Information Letter 
 
TITLE: Exploring strategies to facilitate screening for cardiovascular disease to promote 
healthy aging.   
 
INVESTIGATOR(S): Jill Bruneau 
CO-INVESTIGATORS: Donna Moralejo, Catherine Donovan, Karen Parsons  
 
SPONSORS: Newfoundland and Labrador Centre for Applied Health Research & 
ARNNL.  
 
You have been invited to take part in a research study.  Taking part in this study is 
voluntary.  It is up to you to decide whether to be in the study or not.  You can 
decide not to take part in the study.  If you decide to take part, you are free to leave 
at any time. This will not affect your usual health care or employment status, as 
applicable. 
 
Before you decide, you need to understand what the study is for, what risks you 
might take and what benefits you might receive.  This information letter explains 
the study.   
 
Please read this carefully. Take as much time as you like. If you like, take it home to 
think about for a while. Mark anything you do not understand, or want explained 
better. After you have read it, please ask questions about anything that is not clear. 
 
The researchers will: 
 
 discuss the study with you 
 answer your questions 
 keep confidential any information which could identify you personally 
 be available during the study to deal with problems and answer questions 
1. Introduction/Background: 
 
Cardiovascular disease (CVD), such as heart disease and stroke, are the leading 
cause of death in Canada and is the second leading cause of death in the province of 
Newfoundland and Labrador (NL). Having heart disease or a stroke may also result 
in long hospital stays, costly medications, and special heart procedures. Screening for 
heart disease early can lead to healthier lives for people as they age. In NL, screening 




years. It is possible to develop or adapt a screening intervention program based on 
what others have done, but it is not known if such a program would meet our needs 
here in NL. If we explore different perspectives of health professionals and adults to 
meet our needs, we can develop a relevant program. 
 
2. Purpose of study: 
 
To obtain different perspectives on the barriers, facilitators, and strategies associated 
with systematic screening for heart disease in NL. 
 
3. Description of the study procedures: 
 
You will be asked to participate in an individual interview or a focus group to discuss 
your perspective on a program to increase screening for cardiovascular disease 
(CVD) in NL.  You will be asked to discuss your opinion about the barriers and 
facilitators associated with screening for CVD.  You will also be asked to look at a 
preliminary screening program to see if it is relevant for adults in NL..  These 
interviews can take place in person or by phone.  The focus groups and interviews 
will be recorded on a digital recorder. They will be at a time and place that is 
convenient for you.   
 
4.    Length of time: 
 
You will be asked to participate in one focus group or interview over the next six 
weeks at a place of your convenience.  Each interview or focus group will last 60-90 
minutes. 
 
5.    Possible risks and discomforts: 
 
It is possible that participating in the focus group or an interview or looking at the 
screening program may cause some emotional upset.  You can leave the focus group 
or stop the interview at any time.  If participating in this focus group or interview is 
upsetting to you, we recommend that you discuss your concerns with your healthcare 
provider (general practitioner or nurse practitioner). If you would like, we will give 
you information for the 24 hour mental health crisis line.  
 
6.    Benefits: 
 
It is not known whether this study will benefit you.  
 
7.    Liability statement: 
 
Signing this form gives us your consent to be in this study.  It tells us that you 




do not give up your legal rights.  Researchers or agencies involved in this research 
study still have their legal and professional responsibilities. 
 
8.    What about my privacy and confidentiality?  
 
Protecting your privacy is an important part of this study. Every effort to protect 
your privacy will be made. However it cannot be guaranteed. For example, we may 
be required by law to allow access to research records.  
Other people taking part in the focus group may know your name and hear your 
comments. All members of the focus group will be reminded to:  
 respect the privacy of each member of the group  
 treat all information shared with the group as confidential 
 
        Access to records 
The members of the research team will see study records that identify you by name. 
Other people may need to look at your study records that identify you by name. This 
might include the research ethics board. You may ask to see the list of these people. 
They can look at your records only when supervised by a member of the research 
team.  
 
Use of your study information 
The research team will collect and use only the information they need for this 
research study.        
 
This information will include your:  
 age 
 sex 
 information from study interviews and focus groups 
 
Your name and contact information will be kept secure by the research team in 
Newfoundland and Labrador.  It will not be shared with others without your 
permission. Your name will not appear in any report or article published as a result 
of this study. 
 
Information collected for this study will be kept for five years. 
If you decide to withdraw from the study, the information collected up to that time 
will continue to be used by the research team.  It may not be removed. This 
information will only be used for the purposes of this study.  
 
Information collected and used by the research team will be stored at the MUN 
School of Nursing, Education Building, 5th floor in a secured area only accessible to 
faculty and staff. Files will be kept on an encrypted hard drive and locked filing 
cabinet with only one key that will be kept by Jill Bruneau, the person responsible 





Your access to records 
You may ask the researcher to see the information that has been collected about 
you.   
 
9.    Questions or problems: 
 
If you have any questions about taking part in this study, you can meet with the 





Or you can talk to someone who is not involved with the study at all, but can advise 
you on your rights as a participant in a research study.  This person can be reached 
through: 
                  
Ethics Office at 709-777-6974 
      Email at info@hrea.ca 
 
This study has been reviewed and given ethics approval by the Newfoundland and 



















Would you like to be a part of improving 
screening rates for heart health in 
Newfoundland and Labrador? 
Are you between 40-74 years old? 
You may qualify to participate in our study. 
We are looking for volunteers to participate in a 
focus group to learn more about how to improve 
heart health screening for people in Newfoundland 
and Labrador. 
To hear more about this study or to ask if you can take part, 
please contact a member of our research team: Jill Bruneau at 
777-8153, jill.bruneau@mun.ca        
Eligible participants will be reimbursed for out of pocket expenses.  
 




Focus Group/Individual Interview Questions 
(Members of the health professional groups) 
Opening script: Thank you for agreeing to participate in this [focus group/interview] 
today. We really appreciate your time and interest in the topic of screening for heart 
disease in NL. We do ask that you keep our discussion confidential so please do not to 
discuss what we have talked about with friends, family, or coworkers outside this room. 
You do not have to respond to any questions that you are not comfortable to answer. 
Your comments will not be linked to in any way to your name or no one will be able to 
identify you in any way. Thank you again for your participation. So, today’s discussion is 
about ways to increase screening for cardiovascular disease in NL. There are three main 
steps in the screening process. We are going to talk about each of these and then have a 
general discussion. Step 1 is identifying patients to screen. Step 2 is actually carrying out 
the screening process. Step 3 is about acting on the screening test results.  
 
[Prompt: Step 1. Identification of patients to screen] 
 
First, we are going to talk about ways that we can identify people who need to be 
screened. 
  
1. Do you routinely screen patients for CVD? If no, whose responsibility is it? 
What is the best way to identify people to screen for CVD? 
2. How do you usually identify people to screen for CVD? 
a. Prompt: Do you review patient’s charts, current patient rosters, or do 
you have clinical reminder systems (electronic or paper-based) that 
flag charts according to the patient’s age? Do you receive referrals 
from other professionals to screen patients? 
b. What works for you? 
c. Does it work well? 
d. What are some issues related to screening for CVD? 
e. Are there lessons to be learned from screening for other conditions? 
 
3. Is knowing who to screen a problem?  
a. When do you specifically screen men? Women? Children? 
4. What kind of organizational supports would help you with screening patients 
for CVD? (For example: more time, EHR, incentives, policy to make it a 
priority, etc). 
  
[Prompt: Step 2. Screening patients] 
Now we are going to talk about actually screening the patients by taking measurements 




using other tools to screen (such as CPGs, Framingham global risk assessment) and 
discuss some of the barriers or issues that may be occurring. Now let’s talk about 
screening. 
5. We have a preliminary program developed based on the C-CHANGE 
guideline. Would you be comfortable with using C-CHANGE? What kind of 
access do you need to find the C-CHANGE guideline? Would this table help 
you? [show C-CHANGE table] 
 
6. What CPGs do you use for screening adults in your practice? What guidelines 
would be useful to access to help you know what to screen for and when? 
 
We also suggest that you use a global CV risk tool 
7. What tools (global risk assessments) do you use to screen for CVD risk 
factors in your clinical practice?  
a. Is there any concerns with using the Framingham Risk Tool?  
b. Do you use another tool?  
c. How do you use this tool? 
d. Would you be comfortable to change your approach?  
e. Do you use the online calculator?  
f. Do you calculate the “Heart Score”? 
Part of the screening process involves doing physical measurements 
8. What physical measurements do you perform when screening patients?  
a. Body mass index 
b. Weight measurement 
c. Height measurement 
d. Waist circumference measurement 
e. Blood pressure measurement 
f. What do you use as measurement tools?  
g. Do you take blood samples in the clinic? 
h. Do you normally take these physical measurements?  
i. Are there barriers or issues associated with taking physical 
measurements? 
 
9. Would you use the proposed screening intervention in your clinical practice? 
Why or why not? (Show one page explanation of proposed screening 
intervention). 
a. What would you need to convince you or to help you implement this 
screening initiative? 
b. What suggestions do you have to improve this proposed screening 
intervention? 
 





[Prompt: Step 3. Acting on the results of screening] 
Next, we want to know what sort of actions are required after completing the screening 
process. 
11. Where do you document your findings related to screening patients? 
a. Do you use the electronic health record (EHR)? 
b. Does the EHR work for you? 
c. Is it easy to find information for follow-up after screening patients? 
d. What system do you use? 
 
12. After screening patients, how do you follow-up on the results of testing and 
screening? What do you need to be able to follow-up on screening results 
(tools and resources)? Do you set up appointments or phone patients when 
results come back? Do you send referrals to other practitioners? Do you do 
patient education yourself? 
Part of following up on screening results is asking patients to change behaviour or to 
follow advice. 
13. Are you familiar with motivational interviewing? Behavioural change 
counselling (Ask, Advise, Assist)? How do you ensure that you are providing 
patient-centred care? 
 
14. Do you have any suggestions for patient engagement for following through 
with your suggestions after being screened? Is there something that needs to 
be included 
     in the preliminary program to help with patient engagement? 
 
 [Prompt: General questions about screening] 
 
Now we would like your opinion on some more general questions related to screening. 
15. What are some barriers to implementing a screening intervention? What 
suggestions do you have to address them? 
16. What are some facilitators to implementing a screening intervention? 
 
17. Are there any other strategies to increase CVD screening? 
 
18. How important would training be for this intervention? Would you want to 
have tools or would you like to have training related to this screening 
intervention?  
 






Focus Group/ Individual Interview Questions 
(Members of the general public) 
Opening script: Thank you for agreeing to participate in this [focus group/interview] 
today. We really appreciate your time and interest in the topic of screening for heart 
disease in NL. If you haven’t given me your signed consent form, you can give it to me 
now.  We do ask that you keep our discussion confidential so please do not to discuss 
what we have talked about with friends, family, or coworkers outside this room. You do 
not have to respond to any questions that you are not comfortable to answer. Your 
comments will not be linked to in any way to your name or no one will be able to identify 
you in any way.  
[Prompt: Identification of patients to be screened] 
First of all, we would like your advice on how to best contact you to get you involved in 
screening for heart disease. 
1. Would you like to participate in a screening program to assess your risk for heart 
disease or stroke? Why or why not? 
 
2. What is the best way to get you involved in screening? Invitations to be sent via 
regular mail, email, or a telephone call from your HCP? 
 
3. When do you think it is the best time for you to be screened for heart disease? 
What age? 
 
[Prompt: Screening process] 
 
Now, we are going to talk about the screening process itself and what that means. 
 
4. What concerns do you have about the actual screening tests (such as getting your 
BP taken, physical measurements like your height, weight, or having a blood test 
done)? 
 
5. Are you interested in knowing about your overall risk for developing heart 
disease?  
6. What are some barriers (or things that make it difficult) to participate in a 
screening program?  
 










[Prompt: Acting on screening test results]  
 
After the screening tests are completed, your healthcare provider wants to share the 
results of these tests or measurements with you and make some recommendations. 
 
9. Would you follow recommendations (or advice) from a healthcare provider that 
could possibly reduce your risk of developing CVD in the future?  
 
10. What makes it difficult to follow the advice given to you by a healthcare 
provider? 
11. What makes it easier to follow the advice given to you by a healthcare provider?  
a. Would printed materials be helpful?  
b. Website resources? 
c. Would a dietician be helpful to make changes to your diet? 
d. Counselling by your healthcare provider? 
e. Group support to make necessary changes? 
 
A screening program is being developed and we need your advice on whether or not you 
think it will work or what changes should be made before using it 
. 
[Prompt: Proposed screening intervention] 
12. Would you participate in this screening program? Why or why not? 














Opening script: Thank you for agreeing to participate in this interview today. We really 
appreciate your time and interest in the topic of screening for heart disease in NL. If you 
haven’t given me your signed consent form, you can give it to me now. We do ask that 
you keep our discussion confidential so please do not to discuss what we have talked 
about with friends, family, or coworkers outside this room. Thank you again for your 
participation today. So, today’s topic is about ways to increase screening for heart 
disease in NL. 
[Prompt: Support for health professionals to do screening for CVD] 
First of all, we would like your opinion on what can be done to support NPs or others to 
screen for CVD in their clinical practice.  
1. What are your thoughts about NPs doing systematic CVD screening? Why? 
 
2. If it can be supported, what can be done from an organizational support point of 
view? 
a. Prompt: Organizational support according to the literature means 
providing time, resources, EHR, relief from other responsibilities, etc. 
 
b. What needs to be done to ensure that it can be implemented in terms of 
other responsibilities currently performed by HCPs? 
[Prompt: Proposed screening intervention] 
Now, we would like your opinion on a provisional or tentative screening initiative that 
has been developed. These are the elements of the program and how they are related. 
(Show one page of proposed screening intervention and explain it). 
3. Are you willing to support this provisional CVD screening intervention and 
encourage NPs to implement it? Why or why not? Do you think that it would be 
useful for other HCPs? 
 
4. From your perspective, what suggestions do you have for improvements or 
effective strategies for the successful implementation of this screening 
intervention? 
 








Proposed CVD Screening Intervention 
Three main parts of the screening 
intervention: 
Tools for implementation 




 Review current patient lists to find 
individuals aged 40-74 years,  
 Use clinical reminder systems in 
electronic or paper-based charts to cue 
screening when a patient turns 40 or 50 
years of age. 
 Get referrals from other HCPs to screen 
specific patients. 
2. Screening of patients 
 
 
 Perform physical measurements (weight, 
height, BMI, waist circumference, BP)  
 Use screening tools like the global risk CV 
assessment (Framingham, Score-
Canada). 
 Ask patients to complete self-
assessment. 
 If abnormal results from screening tests, 
refer to specialist, start new medications, 
or book follow-up appointment. 
 Document findings in electronic health 
record if available or in paper file. 
3. Follow-up & risk management of 
patients 

















 Use tools for management the C-




 Table from C-CHANGE in Appendix 1 
 Online risk assessment tools 
 Communication of risk to patient 
including risk score, “cardiovascular age” 
score, BP results, blood test results, BMI, 
WC. 
 Make referrals to other specialists and 
team members,  
 Order additional tests, 
 Counsel on behavior change using 
motivational interviewing  
 Prescribing recommended medications 
 Schedule follow-up appointments. 
 Individualized goal setting using patient-













APPENDIX E: Cardiovascular Assessment Screening Program (CASP) 
Components 
 
• CASP Components 
• CASP Educational Resources (Online Educational Module) 
• CASP Measurement Tools and Resources (examples) 
• Healthcare Providers’ Toolkit Contents 
• My Heart Healthy Plan 
• CASP Website 














































































MY HEART HEALTHY PLAN 
October 2017 
Your plan may go perfectly or it may not, which is normal when people try new things. 
My action plan is: (Example: Go for a 30 minute walk on Monday, Wednesday and Friday morning at 9am) 
 
______________________________________________________________________________________ 
My goal is: (Example: Make walking a part of my life at least three days of the week) 
 
______________________________________________________________________________________ 
Choose how to check-in. Use the questions on the other side as a guide: 
A. Do-it-yourself check-in: 
Make an appointment with yourself to look at how it went 
B. Check-in with someone else: 
 You can check in with someone else. They can: 
 Help you find new ideas 
 Just listen or offer support 
 Not give advice 
 Let you decide what will work for you 
 
My plan to check-in:  
To support myself to complete and learn from my plan I will check in with:  
A. Myself. I will sit down on the __________________ at_________________ and 
____________________________________________________________.  
B. Someone else. We will check in by __________________ (phone, text, in person.) on the 
________________________________ at ______________________. 
 
It’s about learning:  
Your plan may go perfectly or not; there will still be things to learn. You may learn:  
- What you like and what you don’t  
- What makes sense for you and what does not! 
 
A check-in 
helps you learn 
what worked, 
what didn’t 
and what you 





Check-in Question Guide 
Remember, checking on the plan isn’t about finding success or failure, it’s about learning. You 
didn’t fail if you learned something! If your plan went well, celebrate! 
The Question My Experience 
 















Next I want to: 
If you are going to make another plan, write 
it here! 
My new plan: 
 
 










What would make you more confident? 
 
 
Re-write your plan if needed. 
 
 
Adapted and Used with permission from: Centre for Collaboration, Motivation and Innovation 
www.centrecmi.ca and Patients as Partners at the BC Ministry of Health in the development of 



















































APPENDIX F: Research Documents for Chapter 3 
 
• Request Letter to Access Health Records of Control Group Participants 
• Request Letter for NLCHI to Develop CVD Database 
• Confirmation Document from NLCHI for CVD Database Development 
• Recruitment Email for Healthcare Leaders 
• Recruitment Letter for Nurse Practitioners 
• Research Study Information Sheet 
• Initial Recruitment Email for NP Managers to Assist the Recruitment of 
Nurse Practitioners 
• Follow-up Email Request for NP Managers for Recruitment of NPs 
• Follow-up Telephone Script for NP managers for Recruitment of NPs 
• NP Informed Consent Form (Intervention and Control) 
• Patient Recruitment Poster for NP Clinics 
• Heart Health Assessment Pamphlet for Patient Participants 
• Patient Informed Consent Form (Intervention) 
• Patient Informed Consent Form (Control) 
• NP Profile Questionnaire (Intervention and Control) 
• Eligibility for Heart Health Screening Form (Part A) 
• Decision to Screen Form (Part B) 
• Tracking Form for Heart Health Screening (Intervention) 
• Cardiovascular Screening Checklist (Intervention group) 
• Record of Potential Participants (Control) 
• Chart Review Form (Control) 
• NP Feedback Questionnaire (Intervention) 
• NP Feedback Questionnaire (Control) 
• Patient Feedback Questionnaire (Intervention) 







Request Letter to Access Health Records of Control Group Participants 
 
    
June 20th, 2017 
To whom it may concern, 
I am a PhD student at Memorial University of Newfoundland School of Nursing and I am 
writing to request access to health records as part of the ethical protocol for the purposes 
of a research study that is a randomized controlled trial (RCT) entitled: “Implementing 
and testing a cardiovascular assessment screening program to promote healthy 
aging.” We are interested in finding out whether or not the implementation of the 
screening program by NPs (intervention group) will be effective in improving 
comprehensive screening of people (40-74 years) in Newfoundland and Labrador (NL) 
compared to usual care provided to patients by NPs (control group).  
This study has received ethics approval from the HREA and RPAC as well as other 
regional health authorities across NL. This study is anticipated to take place between 
September, 2017 and December, 2017. 
We are requesting access to health records within your regional health authority for 
purposes of a retrospective chart review on patient charts in the NP control group who 
have consented to participate in the study. On specific dates agreed upon by the NP 
clinics and the researchers, the office clerks will pull patient charts, the researcher will 
read through the charts and record information on a chart review form into a secure 
database of an encrypted laptop. Please see Chart Review Form attached. 
If you have any questions or require further clarification, please contact the principal 
investigator, Jill Bruneau, at jb4276@mun.ca 
Thank you for your time in considering this request. 
 
Sincerely, 
Jill Bruneau PhD(c) NP 
Doctoral student 






Request Letter for NLCHI to Develop CVD Database 
    
June 20th, 2017 
Ms. Michele Butler 
Information Request Coordinator 
Newfoundland and Labrador Centre for Health Information (NLCHI) 
Health Analytics and Evaluation Services 
70 O’Leary Avenue, St. John’s, NL   A1B 2C7 
 
Dear Ms. Butler, 
I am a PhD student at Memorial University of Newfoundland School of Nursing 
conducting a randomized controlled trial (RCT), entitled: “Implementing and testing a 
cardiovascular assessment screening program (CASP) to promote healthy aging.” 
We are interested in finding out whether or not the implementation of the screening 
program by nurse practitioners (NPs) (intervention group) will be effective in improving 
comprehensive screening of people aged 40-74 years in Newfoundland and Labrador 
(NL) compared to usual care provided to patients by NPs (control group). This study is 
evaluating the effectiveness of CASP. 
We are requesting that NLCHI develop an Access Database for the intervention arm of 
this study. This Access Database will be used by the NPs to enter patient data during the 
implementation of this RCT. Once data collection is completed, the Access Database files 
will be sent securely by the NPs to NLCHI. In addition to the requests to develop the 
Access Database and to receive the Access Database files from the NPs, we are also 
requesting that NLCHI de-identify the data and then send the de-identified data to me, the 
principal investigator. 
This study has received ethics approval from the HREA and RPAC as well as other 
regional health authorities across NL. This study is anticipated to take place between 
September, 2017 and December, 2017. 
If you have any questions or require further clarification, please contact me at 
jb4276@mun.ca 
Thank you for your time in considering this request.  
Jill Bruneau  















Recruitment Email for Healthcare Leaders 
July 2, 2017 
 
Dear [healthcare leader], 
I am writing to tell you to about a research study that we are about to start in 
Newfoundland and Labrador (NL). As a [healthcare leader], you should be aware of such 
initiatives and I am also asking for your assistance in informing other senior 
administrators about the study. One strategy for recruitment of nurse practitioners (NPs) 
to the study will be through nursing leaders. 
I have attached an information sheet about this research study which is titled 
“Implementing and Testing a Cardiovascular Screening Program (CASP) to Promote 
Healthy Aging:” In brief, it is a randomized controlled trial with NPs to evaluate the 
effectiveness of a new CV screening intervention in promoting screening for 
cardiovascular disease (CVD).  CASP was developed following consultations with NPs 
and other key stakeholders, and consists of tools NPs can use to facilitate comprehensive 
screening and follow-up actions that are consistent with current clinical practice 
guidelines and the Choose Wisely NL recommendations.  Screening and associated 
interventions are part of the mandate of NP practice, so additional resources are not 
required. However, participation in the short data collection period (4-6 weeks) will result 
in more time spent on screening activities than might have otherwise occurred.  
The research project has received ethical approval from HREA and from RPAC and 
equivalent committees in each RHA. We have received a letter of support from the 
Department of Health and Community Services that confirms that this research study 
aligns with many of the provincial strategic goals to promote healthy aging in our 
communities. 
Would you please inform other [CEOs and other leaders] by forwarding this email and 
attached Research Study Information Sheet to other leaders within the regional health 
authorities? I will follow up with the directors to request their assistance with recruitment 
of NPs. 
If you have any questions, please let me know by contacting me at jb4276@mun.ca.  




Jill Bruneau NP PhD(c) 
Doctoral student 




Recruitment Email for Nurse Practitioners 
 
July 2nd, 2017    
Dear nurse practitioners,   
You are invited to participate in a research study being conducted as part of my PhD 
dissertation focused in cardiovascular health promotion. Other research committee 
members are Dr. Donna Moralejo, Dr. Catherine Donovan, Dr. Karen Parsons, a nurse 
practitioner working in a primary healthcare setting as well as patient partners from both 
rural and urban centres. Phase 1 of this study has already taken place and has informed 
the development of the cardiovascular screening program to be relevant to nurse 
practitioners in Newfoundland and Labrador.  
Phase 2 of this study is entitled: “Implementing and testing a cardiovascular 
assessment screening program (CASP) to promote healthy aging.” We are interested 
in finding out whether or not the implementation of the screening program by nurse 
practitioners will be effective to improve comprehensive screening of people aged 40-74 
years in NL. We are also interested in learning about the factors that influence patients’ 
and nurse practitioners’ participation in program implementation. If you choose to 
participate, you will be randomly selected to be in either the intervention group or the 
control group. The intervention group will receive training on program materials to 
implement the program. The control group will be provided with program materials at a 
different time.  
All of the information collected will be kept completely confidential. Results of the study 
will be shared with all NPs as well as participating patients if requested. Participation in 
this study is completely voluntary. A letter of support has been given to researchers by 
the Department of Health and Community Services. This study has been given ethics 
approval by the NL Health Research Ethics Board (HREB) and the Regional Health 
Authorities (RHAs) across NL. 
If you are interested in participating in this study or if you have any questions before 
making your decision, please email me at jb4276@mun.ca. 
Sincerely, 
Jill Bruneau 
Jill Bruneau PhD(c) NP  
Doctoral student 





Research Study Information Sheet (for Nurse Practitioners) 
Why is this research study important? 
Cardiovascular disease (CVD), such as heart disease and stroke, is the leading cause of 
death in Canada and the second leading cause of death in Newfoundland and Labrador 
(NL). Having heart disease or a stroke may also result in long hospital stays, costly 
medications, and special heart procedures. Screening and early intervention for heart 
disease and stroke can lead to healthier lives for people as they age. In NL, screening for 
heart disease or stroke is not always consistently done for individuals aged 40-74 years. 
The Cardiovascular Assessment Screening Program (CASP) was developed for this study 
following discussions with health professionals and patients. The purpose of CASP is to 
identify high risk people and recommend management of risk factors according to current 
guidelines. 
 
What is the purpose of this research study? 
To evaluate the effectiveness of CASP.  
 
What will happen during the study and who will be involved? 
This study is a randomized controlled trial (RCT). Nurse practitioners (NPs) across NL 
who agree to participate will be randomly assigned to one of the two groups: the 
intervention or the control. The NPs in the intervention group will be asked to recruit, 
from their practice, about 30 individuals, aged 40-74 who have no established heart 
disease. The NPs will use the CASP tools to screen the individuals, recommend follow-
up actions, as well as document actions and results. The control group will recruit 30 
eligible patients and carry on with regular practice. The charts of the control group 
patients will be reviewed by the researchers. At the end of the study, the CASP tools will 
be given to NPs in the control group. To acknowledge the time and effort required to 
participate in this study, NPs will be given a VISA gift card of $100.00. 
 
How long will it take for this research study to be completed? 
NPs in the intervention group will be expected to screen individuals over two visits. The 
initial assessment may take up to 30 minutes. The second visit appointment may take up 
to 40 minutes. The NPs in the control group will carry on with usual care; identifying 
patients and completing documentation will take five minutes per patient. For each NP, 
data collection will take 4-6 weeks and will be completed once 30 patients have been 
identified for the study. The researcher will review the charts of eligible patients in the 
control group. 
 
What are the benefits of doing this research study? 
Evaluating and refining CASP can result in comprehensive and consistent screening by 
NPs with appropriate follow-up actions in patient-oriented research. Implementation of 




and a valuable toolkit for CVD screening will be available to other healthcare providers 
in NL. 
More information? Please contact Jill Bruneau NP PhD(c), Principal Investigator, 











































Initial Recruitment Email for NP Managers 
 
July 2, 2017 
 
Dear [NP managers], 
I am writing to invite you to assist in recruitment of participants for a research study 
entitled: “Implementing and testing a cardiovascular assessment screening program 
(CASP) to promote healthy aging.” We are interested in evaluating the implementation a 
heart health screening program by nurse practitioners for adults aged 40-74 years across 
Newfoundland and Labrador. Results of this study are intended to increase systematic 
screening in NL and to promote healthy aging in this province. 
Would you please assist in recruitment of nurse practitioners as participants of this 
research study within the regional health authorities? If yes, I am asking you to forward 
the recruitment letter and Research Study Information Sheet attached to this email and 
then potential participants can contact me directly if they are interested in participating in 
the study. 
Thank you for considering this request to assist in recruitment of participants for this 




Jill Bruneau NP PhD(c) 
Doctoral student 








Follow-up Email Request for NP Managers for Recruitment of NPs 
 
November 10, 2017 
Dear [name of NP manager], 
I am writing to request your support in recruiting of nurse practitioners (NPs) in 
your region for a nursing research study that will evaluate the effectiveness of a 
Cardiovascular Assessment Screening Program (CASP).  
The NP participants should be currently working in a community or an outpatient setting 
and have access to a patient population between the ages of 40-74 years without 
diagnosed cardiovascular disease. The NPs in the intervention group (10) will be given 
resources to assist them in the screening and management of patients (a toolkit including 
a newly designed website with resources for both NPs and patients). They should be able 
to do at least one follow-up visit with each patient. The NPs in the control group (10) will 
continue with usual practice, but will be given access to these resources following study 
completion.  The study is funded by NL SUPPORT and has received ethics approval. 
The NPs may be interested in participating in this research for many reasons, in addition 
to promoting healthy aging. The educational training associated with this study can be 
used towards formal hours for the Association of Registered Nurses of Newfoundland 
and Labrador (ARNNL) Continuing Competency Program. Also, the NPs participating in 
this research can gain points towards the Registered Nurses Union of Newfoundland and 
Labrador Leadership Premium by attending the training sessions and webinars. As well, 
to acknowledge the time and effort to recruit, screen, and manage the patient participants, 
a $100.00 Visa gift card will be given to each NP who completes this study. 
Would you be able to approach NPs and ask them if I could contact them directly to 
explain about participation in this study? If NPs are interested, could you please give 
me their contact information? I will contact you by phone about this and any other 
suggestions you may have about promoting participation in this  research. In the 
meantime, if you have any questions, please call me at 709-777-7258 or email me at 
jill.bruneau@mun.ca. 
Thank you for your support in the recruitment of NPs for this study.   
Sincerely, 
Jill Bruneau NP PhD(c) 
Doctoral student 




Follow-up Telephone Script for NP Managers 
Hello [manager’s name], 
My name is Jill Bruneau and I am a doctoral student from Memorial University School of 
Nursing conducting a research study on heart health screening that will begin this 
September, 2017. I am calling to see if you had received an email two weeks ago asking 
for your assistance in recruiting nurse practitioners for this study. 
1. Did you receive this email? (Yes or No)  
a. If No, I can resend this email today. We are trying to recruit NPs in your 
organization for this study. Would you be willing to forward this email 
with the NP recruitment letter and Research Study Information Sheet to 
NPs in your region? (yes or no) 
i. If yes, do you have any further questions? Thank you again for 
your time and assistance in helping to recruit NPs for this study 
ii. If no, do you have any further questions about this study? 
 
b. If Yes, did you have an opportunity to forward the NP recruitment letter 
and Research Study Information Sheet to the NPs in your region? (yes or 
no). 
i. If yes, do you have any questions? Thank you again for your time 
and assistance in helping to recruit NPs for this study. 
ii. If no, do you have any questions? Would you be willing to forward 
this email with the NP recruitment letter and Research Study 
Information Sheet to NPs in your region? 
 


















Consent to Take Part in Research (NPs) 
 
  
TITLE: Implementing and testing a cardiovascular assessment screening program 
(CASP) to promote healthy aging.    
 
INVESTIGATOR(S): Jill Bruneau 
SUPERVISOR: Donna Moralejo 
CO-INVESTIGATORS: Catherine Donovan and Karen Parsons 
 
  
You have been invited to take part in a research study.  Taking part in this study is 
voluntary.  It is up to you to decide whether to be in the study or not.  You can decide not 
to take part in the study.  If you decide to take part, you are free to leave at any time.  
This will not affect your employment in a regional health authority.  
 
Before you decide, you need to understand what the study is for, what risks you might 
take and what benefits you might receive.  This consent form explains the study.   
 
Please read this carefully. Take as much time as you like. If you like, take it home to think 
about for a while. Mark anything you do not understand, or want explained better. After 
you have read it, please ask questions about anything that is not clear. 
 
The researchers will: 
 
 discuss the study with you 
 answer your questions 
 keep confidential any information which could identify you personally 
 be available during the study to deal with problems and answer questions 
 
4. Introduction/Background: 
Cardiovascular disease (CVD), such as heart disease and stroke, are the leading 
cause of death in Canada and is the second leading cause of death in the province of 
Newfoundland and Labrador (NL). Having heart disease or a stroke may also result 
in long hospital stays, costly medications, and special heart procedures. Screening for 
heart disease early can lead to healthier lives for people as they age. In NL, screening 
for heart disease or stroke is not always consistently done for individuals aged 40-74 
years. A screening program was developed for this study following discussions with 




evaluating this newly developed program with nurse practitioners and patients across 
Newfoundland and Labrador (NL) to promote healthy aging in this province.  
 
 
2.    Purpose of study: 
To evaluate the effectiveness of a new heart health screening program called the 
Cardiovascular Assessment Screening Program (CASP). 
 
3.    Description of the study procedures: 
NPs across NL who agree to participate in this randomized controlled trial (RCT) 
will be randomly assigned to one of the two groups: the intervention group or the 
control group. The NPs in the intervention group will be asked to recruit, from their 
practice, about 30 individuals, aged 40-74 who have no established heart disease. 
The NPs will use the CASP tools to screen the individuals, recommend follow-up 
actions, as well as document actions and results. The control group will carry on with 
usual practice. Their charts will be reviewed by the researchers once recruitment has 
been completed. At the end of the study, the CASP tools will be given to NPs in the 
control group. The NPs in both the intervention and the control groups will be asked 
to complete questionnaires at the beginning and the end of the study.  
 
4.    Length of time: 
 
NPs in the intervention group will be expected to screen approximately 30 
individuals at the clinic where they are employed over a time period of 4-6 weeks. 
The initial assessment may take up to 30 minutes. The second visit appointment may 
take up to 40 minutes to complete. 
The NPs in the control group will carry on with usual care and identify 30 patients 
for participation. Once 30 patients have been identified to participate in the study, 
then data collection for the control group will be completed. The principal 
investigator will review the charts of the eligible patients in the control group. 
 
5.    Possible risks and discomforts: 
 
There are no potential risks to participate in this study. There may be extra time 
associated with implementing the intervention as a NP providing care to patients.  
 
6.    Benefits: 
 
It is not known whether this study will benefit you. To acknowledge the time and 









Signing this form gives us your consent to be in this study.  It tells us that you 
understand the information about the research study.  When you sign this form, you 
do not give up your legal rights.  Researchers or agencies involved in this research 





8.    What about my privacy and confidentiality?  
 
Protecting your privacy is an important part of this study. Every effort to protect 
your privacy will be made. However it cannot be guaranteed. For example we may 
be required by law to allow access to research records.  
 
        When you sign this consent form you give us permission to  
 Collect information from you 
 Share information with the people conducting the study 
 Share information with the people responsible for protecting your safety        
Access to records 
The members of the research team will see health and study records that identify you 
by name. 
Other people may need to look at the study records that identify you by name. This 
might include the research ethics board. You may ask to see the list of these people. 
They can look at your records only when supervised by a member of the research 
team.  
 
Use of your study information 
The research team will collect and use only the information they need for this 
research study.        
 
This information will include your  
 age 
 sex 
 number of years working as an NP  
 information from study questionnaires 
 
Your name and contact information will be kept secure by the research team in 
Newfoundland and Labrador.  It will not be shared with others without your 
permission. Your name will not appear in any report or article published as a result 
of this study. 
 





If you decide to withdraw from the study, the information collected up to that time 
will continue to be used by the research team.  It may not be removed. This 
information will only be used for the purposes of this study.  
 
After your part in this study ends we may also contact you at a later date in the future 
if further information if needed. You can contact the principal investigator (PI) to 
obtain a copy of the study summary and recommendations. The PI plans to do a 
follow-up study related to this topic in the future that would be approved by the 
research ethics board.  
 
Information collected and used by the research team will be stored at MUN School 
of Nursing, Education Building, Room 5004, on the St. John’s campus in a locked 
filing cabinet. Jill Bruneau is the person responsible for keeping it secure. 
Information on computers that are password protected and encrypted hard drives. 
 
Your access to records 
You may ask the researcher to see the information that has been collected about 
you.   
 
9.    Questions or problems: 
 
If you have any questions about taking part in this study, you can meet with the PI 
who is in charge of the study.  That person is:  
 
Jill Bruneau at 709-777-7258 
Or you can speak to my supervisor: Dr. Donna Moralejo 709-864-3603 
 
Or you can talk to someone who is not involved with the study at all, but can advise 
you on your rights as a participant in a research study.  This person can be reached 
through: 
                  
Ethics Office at 709-777-6974 
      Email at info@hrea.ca 
 
This study has been reviewed and given ethics approval by the Newfoundland and 






























TITLE: Implementing and testing a cardiovascular assessment screening program 
(CASP) to promote healthy aging.    
 
INVESTIGATOR(S): Jill Bruneau 
SUPERVISOR: Dr. Donna Moralejo 
CO-INVESTIGATORS: Dr. Catherine Donovan and Dr. Karen Parsons 
  
You have been invited to take part in a research study.  Taking part in this study is 
voluntary.  It is up to you to decide whether to be in the study or not.  You can decide not 
to take part in the study.  If you decide to take part, you are free to leave at any time.  
This will not affect your health care. 
 
Before you decide, you need to understand what the study is for, what risks you might 
take and what benefits you might receive.  This consent form explains the study.   
 
Please read this carefully. Take as much time as you like. If you like, take it home to think 
about for a while. Mark anything you do not understand, or want explained better. After 
you have read it, please ask questions about anything that is not clear. 
 
The researchers will: 
 
 discuss the study with you 
 answer your questions 
 keep confidential any information which could identify you personally 
 be available during the study to deal with problems and answer questions 
 
2. Introduction/Background: 
Heart disease and stroke is the leading cause of death in Canada and is the second 
leading cause of death in the province of Newfoundland and Labrador (NL). Having 
heart disease or a stroke may also result in long hospital stays as well as costly drugs 
and tests. Screening for heart disease earlier can lead to healthier lives for people as 
they age. A recent study explored different perspectives of health providers and 







2.    Purpose of study: 
To evaluate the effectiveness of a new heart health screening program called the 
Cardiovascular Assessment Screening Program (CASP). 
 
3.    Description of the study procedures: 
There are two different groups of participants in this study, the intervention group 
and the control group. You will be asked to participate in one of these groups. 
Patients in the intervention group may be asked to do the following: 
1. Fill out a questionnaire about your family history of heart disease, risk factors, 
medical conditions, and medications that you are taking 
2. Answer questions about your heart health with a nurse practitioner (NP). 
3. Have a physical exam to check your heart and blood vessels. 
4. Give a blood sample of about 12ml (3 tubes) and a urine sample of about 30 ml at 
your nearest agency or hospital. 
5. Have another appointment with the nurse practitioner to get the results of blood 
tests/procedures. 
6. Provide feedback about your experience in this study by completing a 
questionnaire that will be given to you by the nurse practitioner to be mailed back 
to the researchers. 
7. Allow us to review your health record 
 
4.    Length of time: 
 
You may be expected to come to the clinic for another appointment with the nurse 
practitioner over the next month. The first appointment may take about 30 minutes. The 
second appointment may take up to 40 minutes to complete. You will decide with the NP 
whether other visits are required. 
 
5.    Possible risks and discomforts: 
 
Possible risks of being in the study are physical in terms of having a blood test done 
since you may bleed or have a bruise. You may also become upset from learning 
about a new health issue that requires further tests or treatment. If you become upset, 
the NP will talk with you, or we will arrange time to speak with a counsellor.   
 
6.    Benefits: 
 
It is not known whether this study will benefit you.  
 
7.    Liability statement: 
 
Signing this form gives us your consent to be in this study.  It tells us that you 




do not give up your legal rights.  Researchers or agencies involved in this research 
study still have their legal and professional responsibilities. 
8.    What about my privacy and confidentiality?  
 
Protecting your privacy is an important part of this study. Every effort to protect 
your privacy will be made. However it cannot be guaranteed. For example we may 
be required by law to allow access to research records. A copy of this consent will be 
put in your health record.   
 
        When you sign this consent form you give us permission to  
 Collect information from you 
 Collect information from your health record  
 Share information with the people conducting the study 
 Share information with the people responsible for protecting your safety        
 
Access to records 
The members of the research team will see health and study records that identify you 
by name. Other people may need to look at your health records and the study records 
that identify you by name. This might include the research ethics board. You may 
ask to see the list of these people. They can look at your records only 
when supervised by a member of the research team.  
 
Use of your study information 
The research team will collect and use only the information they need for this 
research study.        
 
This information will include your  
 age 
 sex 
 family history  
 medical conditions 
 medications 
 the results of tests and procedures during the study 
 information from questionnaires 
 
Your health information will be kept secure by the research team in Newfoundland 
and Labrador.  It will not be shared with others without your permission. Your name 
will not appear in any report or article published as a result of this study. 
 
Information collected for this study will be kept for five years. 
 
If you decide to withdraw from the study, the information collected up to that time 




discarded once the tests are completed. It may not be removed. This information will 
only be used for the purposes of this study.  
 
After your part in this study ends, we may continue to review your health records to 
check that the information we collected is correct. We may need to review your 
record at a later date in the future if further information if needed. You can contact 
the principal investigator (PI) to obtain a copy of the study summary and 
recommendations. We would like to follow your progress after this study and may 
need to contact you at a later date if you agree to participate. The PI plans to do a 
follow-up study related to this topic in the future that would be approved by the 
research ethics board.  
 
Information collected and used by the research team will be stored in a locked file at 
the Memorial University School of Nursing, Education Building, Room 5004, St. 
John’s, NL. Jill Bruneau is the person responsible for keeping it secure.  
 
Your access to records 
You may ask the researcher to see the information that has been collected about 
you.   
 
9.    Questions or problems: 
 
If you have any questions about taking part in this study, you can meet with the 
investigator who is in charge of the study.  That person is:  
 
Jill Bruneau 709-864-3623 
Or you can speak to my supervisor(s): Dr. Donna Moralejo 709-864-3603 
 
Or you can talk to someone who is not involved with the study at all, but can advise you 
on your rights as a participant in a research study.  This person can be reached through: 
                  
Ethics Office at 709-777-6974 
      Email at info@hrea.ca 
 
This study has been reviewed and given ethics approval by the Newfoundland and 













Patient Consent to Take Part in Research 
(Control) 
 TITLE: Implementing and testing a cardiovascular assessment screening program 
(CASP) to promote healthy aging.    
 
INVESTIGATOR(S): Jill Bruneau 
SUPERVISOR: Dr. Donna Moralejo 
CO-INVESTIGATORS: Dr. Catherine Donovan and Dr. Karen Parsons 
  
You have been invited to take part in a research study.  Taking part in this study is 
voluntary.  It is up to you to decide whether to be in the study or not.  You can decide not 
to take part in the study.  If you decide to take part, you are free to leave at any time.  
This will not affect your health care. 
 
Before you decide, you need to understand what the study is for, what risks you might 
take and what benefits you might receive.  This consent form explains the study.   
 
Please read this carefully. Take as much time as you like. If you like, take it home to think 
about for a while. Mark anything you do not understand or want explained better. After 
you have read it, please ask questions about anything that is not clear. 
 
The researchers will: 
 
 discuss the study with you 
 answer your questions 
 keep confidential any information which could identify you personally 
 be available during the study to deal with problems and answer questions 
 
5. Introduction/Background: 
Heart disease and stroke is the leading cause of death in Canada and is the second 
leading cause of death in the province of Newfoundland and Labrador (NL). Having 
heart disease or a stroke may also result in long hospital stays as well as costly drugs 
and tests. Screening for heart disease earlier can lead to healthier lives for people as 




patients to develop a heart health screening program for NL to promote healthy 
aging.  
 
2.    Purpose of study: 
To evaluate the effectiveness of a new heart health screening program called the 
Cardiovascular Assessment Screening Program (CASP). 
 
3.    Description of the study procedures: 
There are two different groups of participants in this study, the intervention group 
and the control group. The intervention group will have patients of NPs who are 
evaluating CASP and, therefore, will be asked questions, will have a physical exam, 
and will require blood work to be taken. The control group will have patients of NPs 
who will provide usual care and the health records will be reviewed. At the end of 
the study, the CASP tools and resources will be given to NPs in the control group. 
You are being asked to participate in the control group. We will be reviewing your 
health record for information about heart health and your visit to the NP. You will 
also be asked to complete a brief patient feedback questionnaire about your thoughts 
on heart health screening. You will be given a small token of appreciation of a 
$10.00 gift card by the nurse practitioner  
 
4.    Length of time: 
 
You will decide with the NP whether other visits are required. 
 
5.    Possible risks and discomforts: 
 
There are no known risks of participating in this study. 
 
6.    Benefits: 
 
It is not known whether this study will benefit you.  
 
7.    Liability statement: 
 
Signing this form gives us your consent to be in this study.  It tells us that you 
understand the information about the research study.  When you sign this form, you 
do not give up your legal rights.  Researchers or agencies involved in this research 
study still have their legal and professional responsibilities. 
8.    What about my privacy and confidentiality?  
 
Protecting your privacy is an important part of this study. Every effort to protect 




be required by law to allow access to research records. A copy of this consent will be 
put in your health record.   
 
        When you sign this consent form you give us permission to  
 Collect information from you 
 Collect information from your health record  
 Share information with the people conducting the study 
 Share information with the people responsible for protecting your safety        
 
Access to records 
The members of the research team will see health and study records that identify you 
by name. Other people may need to look at your health records and the study records 
that identify you by name. This might include the research ethics board. You may 
ask to see the list of these people. They can look at your records only 
when supervised by a member of the research team.  
 
Use of your study information 
The research team will collect and use only the information they need for this 
research study.        
 
This information will include your  
 age 
 sex 
 family history  
 medical conditions 
 medications 
 the results of tests and procedures during the study 
 information from study questionnaires 
 
Your health information will be kept secure by the research team in Newfoundland 
and Labrador.  It will not be shared with others without your permission. Your name 
will not appear in any report or article published as a result of this study. 
 
Information collected for this study will be kept for five years. 
 
If you decide to withdraw from the study, the information collected up to that time 
will continue to be used by the research team.  It may not be removed. This 
information will only be used for the purposes of this study.  
 
After your part in this study ends, we may continue to review your health records to 
check that the information we collected is correct. We may need to review your 
record at a later date in the future if further information if needed. You can contact 




recommendations. We would like to follow your progress after this study and may 
need to contact you later if you agree to participate. The PI plans to do a follow-up 




Information collected and used by the research team will be stored in a locked file at 
the Memorial University School of Nursing, Education Building, Room 5004, St. 
John’s, NL. Jill Bruneau is the person responsible for keeping it secure.  
 
Your access to records 
You may ask the researcher to see the information that has been collected about 
you.   
 
9.    Questions or problems: 
 
If you have any questions about taking part in this study, you can meet with the 
principal investigator who is in charge of the study.  That person is:  
 
Jill Bruneau 709-777-7258 
Or you can speak to my supervisor(s): Dr. Donna Moralejo 709-864-3603 
 
Or you can talk to someone who is not involved with the study at all but can advise you 
on your rights as a participant in a research study.  This person can be reached through: 
                  
Ethics Office at 709-777-6974 
      Email at info@hrea.ca 
 
This study has been reviewed and given ethics approval by the Newfoundland and 
























 Question 1 2 3 4 5 
1. It is important to screen for 
cardiovascular disease 
(CVD) in adults 40-74 years 
in NL. 
 
     
2. It is important for NPs to 
know about clinical 
practice guidelines (CPGs) 
for CVD screening in 
primary care settings. 
 
     
3. It is difficult is it to find 
Canadian CPGs that are 
focused on CVD 
prevention. 
 
     
4. CVD screening is important 
to my clinical practice 
setting. 
 
     
5. CVD screening is a priority 
for the regional health 
authority where I work. 
 
     
6. CVD screening in 
accordance with the NL 
Choosing Wisely Campaign 
is important. 
 
     
7. It is difficult to identify 
patients who need to be 
screened for CVD. 
 
     
8. It is difficult to find time to 
screen patients for CVD. 
 
     
9. It is easy to do CVD 
screening in daily clinical 
practice. 
 




10. My patients collaborate 
with me to make decisions 
about improving heart 
health. 
 
     
11. I can easily access CPGs for 
following up on the results 
of screening for CVD. 
 
     
12. It is important to 
communicate results of 
screening tests to my 
patients. 
 
     
13. I communicate using 
motivational interviewing 




     
14. I participate in 
individualized goal-setting 
with my patients in daily 
clinical practice. 
 
     
15. My patients are interested 
in changing unhealthy 
behaviours. 
 
     
16. I participate in patient-
centred care in daily clinical 
practice. 
 
     
17. I believe that screening 
improves heart health. 
 
     
18. I would like resources to 
help me screen patients for 
CVD. 
 
     
19. I use a computer every day 
to enter patient data. 
 
     
20. I email or text my patients 
information. 














21. I send referrals to 
interprofessional team to 
optimize patient care.  
     
22. I use e-consult to contact 
specialist physicians to 
optimize patient care. 
 
     
       
21. I am: Male 
 
Female    












23. I have had experience 














24. I attend conferences 













Eligibility for Heart Health Screening Form (Part A) 
 Identify age-eligible patients     Code: 
 
Name of clinic________________________________________ 
 
1. The patient is between 40-74 years old     Yes   No 
 
2. The patient was given Heart Health Assessment Pamphlet  Yes   No 
 




 Date completed________________________________ 









Decision to Screen Form (Part B) 
 Decision to screen patient     Code: 
Name of clinic________________________________ 
 
The patient will have heart health screening      Yes   No 
If going to be screened, why? 
Reasons:  
□ Initiated by patient 
□ Initiated by NP 
□ Patient has one or more risk factors for CVD 
(Dyslipidemia, hypertension, family history, stress, overweight or obesity, sleep 
apnea, excess alcohol use, smoking, or unhealthy diet) 




If not going to be screened, why? 
Reasons:  
□ Diagnosed cardiovascular disease (Angina, MI, Arrhythmia, CHF) 
□ Diagnosed cerebrovascular disease (previous TIA or CVA) 
□ Not interested in being screened at all 
□ Not interested in being screened today so another appointment has been arranged 
□ Recently screened (past three months) 
□ Other reasons: 
 Initials________ 





 Tracking Form for Heart Health Screening (Intervention) 
On this form, record the date, the number of patients who are between the ages of 40-74 
years, and the number of Eligibility for Heart Health Screening Form As that you 
completed. At the end of each day, compare your clinic census with the patient’s names 
and ages to ensure that you have captured all of the patients who are eligible to have heart 
health screening done.  
Please place completed forms in the research study envelope located in a secure area in 
your manager’s office. The research study envelope will be picked up at the end of the 
data collection period. If you have any questions about completing this form, please 
contact Jill Bruneau at jb4276@mun.ca. Thank you! 
Tracking form       Code: 
Date Number of 40-74 year old 
patients 









































Cardiovascular Screening Checklist (Intervention group) 
Complete this form for patients who between the ages of 40-74 years and who have consented 
to participate in the Cardiovascular Assessment Screening Program.  
 Patient data       Code: 
Visit 1        Date:_____________ 
Demographic data: 
□ Gender 
o Male______   
o Female________ 
 
□ Age ________years 
 
□ Marital status 
o Married 





□ Sources of support (check all that apply) 
o Spouse/partner________ 
o Family_______ 
o Support group members________ 
o Coworkers__________ 
o Friends__________ 




□ Level of education 
o Less than high school 
o High school diploma 
o Undergraduate degree 
o Master’s degree or higher 
 






□ Complete the following: 
1. Focused cardiovascular health history 
□ Family history premature coronary artery disease (CAD) (father <55 years 
or mother <65 years when diagnosed) 
□ CV risk conditions (check all that apply) 
o Diabetes  
o Hypertension 
o Abdominal obesity 
o Inflammatory conditions (systemic lupus erythematosus, 
rheumatoid or psoriatic arthritis, ankylosing spondylitis, IBD) 
o COPD 
o CKD 
o Chronic HIV infection 
o Abdominal aneurysm 
o Erectile dysfunction 
o Obstructive sleep apnea 
o Eating disorders 
o Depression and other psychiatric disorders 
o Street drug use 
o For women only (polycystic ovary syndrome, history of delivery of 
macrosomic infant, oral contraceptives, hormone replacement 
therapy) 
□ CV risk factors (check all that apply) 
o Dyslipidemia 
o Psychological stress 









2. Complete the following physiological measurements: 
o Height_______(cm) 
o Weight_______(cm) 
o Calculate BMI (use online chart)__________________ 
o Waist circumference measurement (see diagram and use Heart & 
Stroke Measuring Tape) ___________cm 
o Check BP using automated device (provided)______/______mmHg 
o Low range (below 90/60mmHg)  
o Normal range (<130/80 mmHg (diabetes) or <140/90 
mmHg) 
o High range (>130/80 mmHg (diabetes) or > 140/90 mmHg) 
o Heart rate__________ (apical) 
o Auscultate heart sounds & record any abnormalities (S3, S4, 
murmurs, arrhythmias) ___________________ 
o Auscultate vascular bruits & location (eg. carotid, 
femoral)_____________ 
3. At the end of Visit 1 
o Give bloodwork requisition to patient (CBC, electrolytes, LFTs, 
fasting lipid profile, fasting blood glucose, A1C, TSH, ACR, eGFR) 
o Arrange for a follow-up appointment 
 
Pre-Visit 2 
 Review patient’s blood work results and highlight abnormalities to communicate 
with patient during Visit 2 
 
  Access Framingham Score online calculator and calculate CVD risk 
https://www.cvdriskchecksecure.com/FraminghamRiskScore.aspx 
   Level of CVD risk identified for patient (global risk) 
o Low risk (<10% risk of having a CV event in next 10 years)  
o Moderate risk (10-20% risk of having a CV event in next 10 years) 





  Determine “heart age” using online calculator from the Framingham Heart 
Study (https://www.cdc.gov/vitalsigns/cardiovasculardisease/heartage.html)  
o Actual chronological age ______years 
o Calculated heart age________ years 
 
   Priority areas identified by NP 
   1. 
   2. 
   3. 
Follow-up Patient-Centred Priority Areas 
Visit 2          Date: 
______________ 




























   Referrals to interprofessional team: 
□ Physician_______________________(date) 




□ Public Health Nurse/ Community Health Nurse______________(date) 
□ Diabetes team______________(date) 
   Further testing required 
□ Check BP with every visit (if appropriate) 
□ 12 lead ECG (only if indicated such as arrhythmias, proteinuria, reduced 
pulses, or vascular bruits and consistent with Choosing Wisely NL) 
□ Echocardiogram (if abnormal heart sounds present but not previously 
documented, apical pulse displaced, ventricular arrhythmias) 
□ If FBG 5.6-6.0 (plus > one risk factor), A1C 5.5-5.9% OR FBG 6.1-6.9 and 
A1C 6-6.4%,  then order 2 hour PG in 75g OGTT test  
□ Other __________________________________________________ 




□ Stress reduction strategies__________________(sleep 7-9 
hours)________ 
□ Alcohol use < 1-2 drinks/day or < 9 drinks/week for women, <14 
drinks/week for men 
□ Tobacco use (cessation) ______________________ 
□ Exercise (150 min/week vigorous moderate 
intensity)_________________ 
□ Sodium intake (<2000mg of sodium/5g of 
salt/day)______________________ 
□ Nutritionally balanced diet (low saturated fat, high fibre intake, whole 
grain cereals, low glycemic index foods, more fruits and vegetables, lean 
meats or alternatives (peas, beans and lentils), polyunsaturated and 
monounsaturated oils, Omega 3 fatty acids, avoid trans fats 
__________________________ 
□ Obesity (non-judgmental approach, consult RD for counseling, if BMI > 





  Counselling on behavior change 
□ Use motivational interviewing___________________ 
□ Self-management______________________________ 
  Did you access any of the following resources or recommend any of these 
resources for this patient? (Check all that apply) 
□ Heart Health Screening Website/App 
□ Smoker’s Help Line www.smokershelp.net 
□ Carrot Reward Program https://www.carrotrewards.ca/en/ 
□ NL Health Eating Resource www.healthyeatingnl.ca/about  
□ Heart & Stroke Foundation www.heartandstroke.ca 
□ Dietitians of Canada www.dietitians.ca 
□ Canadian Diabetes Association www.diabetes.ca 
□ Health Canada www.hc-sc.gc.ca 
□ Hypertension Canada www.hypertension.ca 




□ Canadian Mental Health Association www.cmha.ca 
□ C-CHANGE Guideline www.preventioninhand.com 
   Did you prescribe any of the following medications? 
□ None 
□ Beta blocker 
□ Calcium channel blocker 
□ Ace inhibitor or ARB 
□ Diuretic 
□ Statin (LDL < 2.0 or 50% reduction with treatment) 
□ Antiplatelet (only if chronic stable angina, remote PCI,  or CABG) 
□ Oral hypoglycemic agents or insulin 
□ Other___________________________________________________ 
   Follow-up appointments scheduled? 
□ Appointment date____________________________(date) 


















Record of Potential Participants (Control) 
On this form, record the date that your patients were seen in the clinic. Indicate whether 
your patient is between 40-74 years of age and whether he/she has diagnosed CVD 
(coronary heart disease, peripheral vascular disease, abdominal aortic aneurysm). Then, 
record whether the patient is eligible to participate in the research study. If patient is 
eligible and has provided consent to participate in the study, record the patient’s MCP 
number. Please place completed forms in the research study envelope located in a secure 
area in your manager’s office. The research study envelope will be picked up by the 
researcher. If you have any questions about completing this form, please contact Jill 
Bruneau at jb4276@mun.ca. Thank you! 





74 years old 




(Yes or No) 
Patient is eligible 
to participate in 
the study  
(Yes or No) 
Patient MCP #  
(Record MCP# only 
after patient has 
consented to 




    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 




Chart Review Form (Control) 
 Patient information      Code: 
         
 Date:_____________  
1. Demographic data  
□ Gender 
o Male______   
o Female________ 
 
□ Age ________years 
 
□ Marital status 
o Married 





□ Sources of support (check all that apply) 
o Spouse/partner________ 
o Family_______ 
o Support group members________ 
o Coworkers__________ 
o Friends__________ 




□ Level of education 
o Less than high school 
o High school diploma 
o Undergraduate degree 






 Patient assessment       










3. Was the patient’s blood pressure checked?     Yes   No 
  If yes, what was the reading? 
 
 
4. Were blood tests ordered by the NP?     Yes   No 






5. Was the Framingham Risk Score calculated?    Yes   No  




6. Were any patient priority areas identified by the NP?   Yes   No  







 Follow-up      
 
7. Were further tests ordered by the NP?     Yes   No  





8. Were any referrals made to other healthcare providers?   Yes   No  
If yes, what referrals were made? 
 
9. Were recommendations made by the NP?     Yes   No 
 If yes, list recommendations.  
 
10. Were any new medications prescribe?      Yes   No  
 If yes, what was prescribed? 
 












Nurse Practitioner Feedback Questionnaire (Intervention) 
For questions 1-19, please mark an X in the appropriate space to indicate whether or not 
you Strongly Agree, Agree, Disagree, or Strongly Disagree with the following 
statements. If you have not used these tools or resources, please indicate by placing an X 
in the column Not Applicable. For questions 20-37, please make your comments in the 
space provided. Thank you. 
  Strongly 
Disagree 




 Question 1 2 3 4 5 
1. It is important 
to screen for 
cardiovascular 
disease (CVD) 
in adults 40-74 
years in NL. 
 
     
2. It is important 







in primary care 
settings. 
 
     
3. It is difficult is 
it to find 
Canadian 





     
4. CVD screening 








  Strongly 
Disagree 





5. CVD screening 




where I work. 
 
     
6. CVD screening 
in accordance 






     
7. It is difficult to 
identify 
patients who 




     
8. It is difficult to 




     
9. It is easy to do 
CVD screening 
in daily clinical 
practice. 
 
     
10. My patients 
collaborate 










  Strongly 
Disagree 




11. I can easily 
access CPGs 
for following 





     





to my patients. 
 
     










     








     






     
16. I participate in 
patient-centred 
care in daily 




  Strongly 
Disagree 












     
18. I would like 
resources to 




     






     
20. My Healthy 
Heart Plan was 
useful to focus 




     
21. I will discuss 
My Healthy 
Heart Plan with 




     












  Strongly 
Disagree 





23. Did you find 
the training 
process prior to 
implementation 
helpful? Why 
or why not? 
 
     








     








     











     











  Strongly 
Disagree 









or why not? 
28. What was the 





     
29. What was the 
most difficult 





     







     
31. Do you feel 
that there is 
benefit for the 






     
32. Do you believe 
that screening 
improves heart 
health? Why or 
why not? 
     
33. Is it easier to 
screen patients 




  Strongly 
Disagree 


















or why not? 
     









Please explain.  
     







or why not? 
 







Nurse Practitioner Feedback Questionnaire (Control) 
For questions 1-3, please mark an X in the appropriate space to indicate whether or not 
you Strongly Agree, Agree, Disagree, or Strongly Disagree with the following 
statements. If you have not used these tools or resources, please indicate by placing an X 
in the column Not Used. For questions 4-14, please make your comments in the space 
provided. Thank you. 
 
   Strongly 
Disagree 




  Question 1 2 3 4 5 




in adults 40-74 
years in NL. 
 
     
2.  It is important 









     
3.  It is difficult is it 
to find Canadian 
CPGs that are 
focused on CVD 
prevention. 
 
     
4.  CVD screening 




     
5.  CVD screening 
is a priority for 
the regional 




   Strongly 
Disagree 





where I work. 
 
6.  CVD screening 
in accordance 





     
7.  It is difficult to 
identify patients 




     
8.  It is difficult to 




     
9.  It is easy to do 
CVD screening 
in daily clinical 
practice. 
 
     
10.  My patients 
collaborate with 





     
11.  I can easily 
access CPGs for 
following up on 








   Strongly 
Disagree 




12.  It is important to 
communicate 
results of 
screening tests to 
my patients. 
 
     




when helping a 




     
14.  I participate in 
individualized 
goal-setting with 




     






     
16.  I participate in 
patient-centred 
care in daily 
clinical practice. 
 
     





     
18.  I would like 
resources to help 
me screen 




   Strongly 
Disagree 







19.  The Record of 
Potential 
Participant Form 
was useful tool 
to gather 
information 
about the patient. 
     
20.  The researchers 
were able to 
answer questions 
that I had about 
the study. 
 
     
21.  I usually speak 





     
22.  Do your patients 
collaborate with 





     
23.  Would you be 
interested in 
resources to help 
you screen 
patients for 
CVD? Why or 
why not? 
     










   Strongly 
Disagree 









helpful? Why or 
why not? 
 
     
26.  What type of 
support do you 





     







     
28.  What was the 
easiest part of 
being involved 
with the study? 
 
     
29.  What was the 
most difficult 




     





     
31.  Do you believe 
that screening 
improves heart 




   Strongly 
Disagree 




health? Why or 
why not 




participate in a 
screening 
program? Why 
or why not? 
 
























Patient Feedback Questionnaire (Intervention) 
For questions 1-11, please mark an X in the appropriate space to indicate whether or not 
you Strongly Agree, Agree, Disagree, or Strongly Disagree with the following 
statements. If you have not used these resources or does not apply to your circumstances, 
please indicate by placing an X in the column Not Applicable. For questions 12-13, 
please make comments in the space provided. Thank you. 
  Strongly 
Agree 




 Question 1 2 3 4 5 
1. The Heart Health 
Assessment 
Pamphlet was 
easy to complete. 
     




about my risk 
factors for heart 
disease and stroke 
     




me feel anxious. 
 
     




easy to do. 
     
5. The nurse 
practitioner spoke 
to me about my 
risk factors for 
heart disease and 
stroke. 
     




how to lower my 
risk for heart 




  Strongly 
Agree 











     
8. I will talk with the 
nurse practitioner 
about My Healthy 
Heart Plan at my 
next visit. 
     
9. My Healthy Heart 
Plan helped me to 
focus on what I 
needed to do. 
     
10. The information 
on the Heart 
Health Screening 
Website was 
helpful to me. 
     
11. I would 
recommend my 
family and friends 
have this type of 
screening done.  
If yes, go to 
question 12.  
If no, go to 
question 13. 
 
     
















Patient Feedback Questionnaire (Control) 
For questions 1-11, please mark an X in the appropriate space to indicate whether or not 
you Strongly Agree, Agree, Disagree, or Strongly Disagree with the following 
statements. If this does not apply to your circumstances, please indicate by placing an X 
in the column Not Applicable. 
 Strongly 
Agree 




Question 1 2 3 4 5 
The nurse 
practitioner 
spoke to me 
about my risk 
factors for heart 
disease and 
stroke. 
     
The nurse 
practitioner 
gave me helpful 
information 
about how to 




     






     
I am interested 
in participating 
in a heart health 
screening 
program. 
     
I am interested 




heart health.  
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THE END 
 
 
 
 
